<SEC-DOCUMENT>0001193125-12-067741.txt : 20120217
<SEC-HEADER>0001193125-12-067741.hdr.sgml : 20120217
<ACCEPTANCE-DATETIME>20120217171705
ACCESSION NUMBER:		0001193125-12-067741
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20120217
DATE AS OF CHANGE:		20120217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-167025
		FILM NUMBER:		12623809

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d303715d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-167025 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus Supplement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(To Prospectus
dated May&nbsp;28, 2010) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g29a33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$10,000,000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a Controlled Equity
Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> sales agreement with Cantor
Fitzgerald&nbsp;&amp; Co. relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell from time to time through Cantor
Fitzgerald&nbsp;&amp; Co., acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $10&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>Under the terms of the sales agreement, we may also sell our common stock to Cantor Fitzgerald&nbsp;&amp; Co., as principal for its own account, at a price negotiated at the time of sale. <I>If we
sell shares to Cantor Fitzgerald&nbsp;&amp; Co. in this manner, we will enter into a separate agreement setting forth the terms of such transaction, and we will describe the agreement in a separate prospectus supplement or pricing supplement.
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;GALE.&#148; The closing sale price of our
common stock on The NASDAQ Capital Market on February&nbsp;16, 2012 was $0.94. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of our common stock, if any, under this
prospectus supplement and the accompanying prospectus may be made in sales deemed to be &#147;at-the-market&#148; equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or
through The NASDAQ Capital Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or any other method permitted by law. Cantor Fitzgerald&nbsp;&amp; Co. will act as sales agent on a best-efforts basis. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cantor Fitzgerald&nbsp;&amp; Co. will be entitled to compensation at a fixed commission rate of 3.0% of the
gross sales price per share sold. In connection with the sale of the common stock on our behalf, Cantor Fitzgerald&nbsp;&amp; Co. may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended, and the
compensation of Cantor Fitzgerald&nbsp;&amp; Co. may be deemed to be underwriting commissions or discounts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of
February&nbsp;16, 2012, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $59,171,970, based on 47,524,094 outstanding shares of common stock, of which approximately 46,961,881 shares were held by
non-affiliates, and a price of $1.26 per share, which was the closing sale price of our common stock on The NASDAQ Capital Market on February&nbsp;6, 2012. As of the date of this prospectus supplement, we have offered and sold securities having an
aggregate market value of $455,000 pursuant to General Instruction I.B.6. of Form S-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investing in our common stock involves a high degree of risk. Before making an investment decision, you should read the discussion of
material risks under the heading &#147;Risk Factors&#148; beginning on page&nbsp;S-8 of this prospectus supplement and the risk factors described in the other documents incorporated by reference herein. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g68n37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of this prospectus supplement is February 17, 2012. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="index"></A>TABLE OF CONTENTS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="4"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_2">ABOUT THIS PROSPECTUS SUPPLEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_3">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_4">SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_5">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_6">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_7">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_8">PRICE RANGE OF OUR COMMON STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_9">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_11">DESCRIPTION OF COMMON STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_10">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_12">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_13">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_14">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_15">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS DATED MAY 28, 2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_20">ABOUT THIS PROSPECTUS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_21">THE COMPANY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_22">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_23">FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_24">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_25">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_26">DESCRIPTION OF COMMON STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_27">DESCRIPTION OF PREFERRED STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_28">DESCRIPTION OF WARRANTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_29">DESCRIPTION OF DEBT SECURITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_30">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_31">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_32">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suptoc303715_33">INCORPORATION OF DOCUMENTS BY REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_2"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document is part of the registration statement on Form&nbsp;S-3 (File No.&nbsp;333-167025), or the &#147;<B>registration
statement</B>,&#148; that we filed with the Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) using a &#147;shelf&#148; registration process to register sales of our common stock, among other of our securities, under the Securities Act
of 1933, as amended, or the &#147;<B>Securities Act</B>.&#148; This document consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering.
The second part is the accompanying prospectus filed with the SEC as part of the registration statement, including the documents incorporated by reference, that gives more general information, some of which may not apply to this offering. Generally,
when we refer only to the &#147;<B>prospectus</B>,&#148; we are referring to both parts combined. This prospectus supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement or the accompanying prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If information in this prospectus supplement is inconsistent with
the accompanying prospectus or with any document incorporated by reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying
prospectus and the documents incorporated into each by reference include important information about us, the securities being offered and other information you should know before investing in our securities. You should also read and consider
information in the documents to which we have referred you in the section of this prospectus supplement and the accompanying prospectus entitled &#147;Where You Can Find More Information.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should rely only on this prospectus supplement, the accompanying prospectus and the information incorporated or deemed to be
incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide you with information that is in addition to or different from that contained or incorporated by reference in this
prospectus supplement and the accompanying prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus supplement, the accompanying prospectus and any related free writing prospectus do
not constitute an offer to sell or the solicitation of an offer to buy securities, nor do this prospectus supplement, the accompanying prospectus and any related free writing prospectus constitute an offer to sell or the solicitation of an offer to
buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained or incorporated by reference in this prospectus supplement or the
accompanying prospectus is accurate as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as the case may be, or in the case of the documents incorporated by reference, the date of such documents
regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to
any document that is incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the
parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
September&nbsp;26, 2011, we changed the name of our company from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. In this prospectus supplement, we sometimes refer to Galena Biopharma, Inc. as &#147;<B>Galena</B>&#148; and to our
wholly-owned subsidiary, Apthera, Inc., as &#147;<B>Apthera</B>.&#148; On September&nbsp;26, 2011, we also announced the contribution of our historical RNAi assets to a new subsidiary formed by us for this purpose and the proposed partial spin-off
of the subsidiary referred to under &#147;Summary - Recent Developments&#148; beginning on page&nbsp;S-3 of this prospectus supplement. Our new subsidiary, which assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in our
name, is referred to in this prospectus supplement as &#147;<B>RXi</B>.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Unless the context otherwise indicates, references in this prospectus supplement to the &#147;<B>company</B>,&#148; &#147;<B>we</B>,&#148; &#147;<B>us</B>&#148; or &#147;<B>our</B>&#148; refer
(i)&nbsp;to Galena, Apthera and our new RXi subsidiary, collectively, prior to the proposed partial spin-off of RXi; and (ii)&nbsp;to only Galena and Apthera, together, after the partial spin-off of RXi. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_3"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated herein
by reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause
our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of
financing needs, revenue, expenses, earnings or losses from operations, or other financial items; any statements of the plans, strategies and objectives of management for future operations, including the future of RXi; any statements concerning
product research, development and commercialization plans and timelines; any statements regarding safety and efficacy of product candidates; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing.
In addition, forward-looking statements may contain the words &#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will be,&#148; &#147;will
continue,&#148; &#147;will result,&#148; &#147;seek,&#148; &#147;could,&#148; &#147;may,&#148; &#147;might,&#148; or any variations of such words or other words with similar meanings. All forward-looking statements attributable to us or to persons
acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in the &#147;Risk Factors&#148; section and elsewhere in this prospectus supplement and set forth in our Form 10-K for the year
ended December&nbsp;31, 2010 and our Forms&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2011,&nbsp;June&nbsp;30, 2011 and September&nbsp;30, 2011, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this prospectus supplement, the accompanying prospectus and the documents that we
reference in this prospectus supplement and the accompanying prospectus with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we do not undertake any obligation to update or
revise any forward-looking statements contained in this prospectus and any supplements to this prospectus, whether as a result of new information, future events or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_4"></A>SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights selected information appearing elsewhere in this prospectus supplement or in
the accompanying prospectus or incorporated by reference in this prospectus supplement and the accompanying prospectus and does not contain all of the information that may be important to you or that you should consider before investing in our
common stock. This prospectus supplement and the accompanying prospectus include or incorporate by reference information about the securities we are offering, as well as information regarding our business and detailed financial data. Before making
an investment decision, you should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein in their entirety, including &#147;Risk Factors&#148; beginning on page&nbsp;S-8 of this prospectus
supplement. </I></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:1%;margin-right:1%" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Company </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background on the Company and Changes in Strategic Focus </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena is a biotechnology company focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using targeted biotherapeutics. Galena is pursuing the development of novel cancer therapeutics using peptide-based immunotherapy products, including our main product candidate, NeuVax (E75), for the
treatment of various cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax is a peptide-based immunotherapy intended to reduce the
recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin&reg;; Genentech/Roche). On January&nbsp;20, 2012, we initiated our PRESENT trial for NeuVax&#153; (E75 peptide plus
GM-CSF) vaccine in low-to-intermediate HER2-positive breast cancer patients (often referred to as HER2 negative) in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The PRESENT (<U>P</U>revention of
<U>R</U>ecurrence in <U>E</U>arly-<U>S</U>tage, Node-Positive Breast Cancer with Low to Intermediate HER2 <U>E</U>xpression with <U>N</U>euVax <U>T</U>reatment) study is a randomized, multicenter, multinational clinical trial that will enroll
approximately 700 breast cancer patients. The trial design has been updated to include current National Comprehensive Cancer Network (&#147;<B>NCCN</B>&#148;) guidelines and has received Special Protocol Assessment, or &#147;<B>SPA</B>,&#148;
concurrence from the U.S. Food and Drug Administration, or &#147;<B>FDA</B>.&#148; Based on a previous Phase 2 trial of NeuVax that achieved its primary endpoint of disease-free survival, or &#147;<B>DFS</B>,&#148; the FDA has agreed in the SPA that
the design and planned analysis of the Phase 3 PRESENT study is adequately designed to provide the necessary data that, depending upon the outcome, could support a regulatory submission for marketing approval. We previously reported a Phase 2 trial
in which none of the Phase 3 targeted low-to-intermediate, node-positive patients treated with the optimal regimen had experienced a relapse after 36 months of treatment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">More recently, on February&nbsp;14, 2012, we announced the start of a Phase&nbsp;2 trial comparing NeuVax
in combination with trastuzamab (Herceptin&reg;) versus trastuzamab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. We previously reported a pilot Phase 2 trial of sequential therapy with trastuzumab followed by
HER2 vaccination in the adjuvant setting. Of 62 patients who received standard-of-care trastuzumab, the 32 who received no NeuVax vaccine experienced a 12.5% breast cancer recurrence rate (4/32), which is comparable to reported rates of similarly
staged and treated patients. In contrast, none of the 30 patients who received the NeuVax vaccine following trastuzumab therapy experience a recurrence. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our second product candidate, Folate Binding Protein-E39 (FBP), is a targeted vaccine aimed at preventing
the recurrence of ovarian, endometrial, and breast cancers. We expect to start two Phase 1/2 trials of FBP for one or more of these indications in the first quarter of 2012. FBP, which has very limited tissue distribution and expression in
non-malignant tissue, consists of the E39 peptide derived from the folate binding protein and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired Apthera and our NeuVax product candidate in April 2011. Prior to that time, we
were engaged primarily in conducting discovery research and pre-clinical development activities based on RNA interference, or </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
&#147;<B>RNAi</B>,&#148; a naturally occurring cellular mechanism that has the potential to effectively and selectively interfere with, or &#147;silence,&#148; expression of targeted
disease-associated genes. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic direction by giving us access to a late-stage product candidate, NeuVax. In connection with our acquisition of
Apthera, we reduced the scope of our RNAi activities to focus primarily on RXi-109, our lead RNAi-product, while maintaining our key development alliances and core RNAi discovery and development capability. Following the Apthera acquisition, our
board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to our later-stage oncology drug programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As referred to below under &#147;Recent Developments,&#148; on September&nbsp;24, 2011, we contributed to
a new wholly-owned subsidiary formed by us for this purpose substantially all of our RNAi-related technologies and assets and entered into a number of agreements relating to RXi&#146;s ongoing business and operations. Our new subsidiary, which
assumed the RXi name, will focus solely on developing and commercializing therapeutic products based on RNAi technologies for the treatment of human diseases, including fibrotic disease, with financing provided by institutional investors in RXi. In
the agreements, we have agreed, among other things, to undertake to distribute to our stockholders a portion of our shares of common stock of RXi, which we sometimes refer to as the &#147;<B>partial spin-off</B>&#148; of RXi. See &#147;Recent
Developments,&#148; below, for information on the status of the partial spin-off of RXi, and &#147;RXi&#146;s RNAi Program,&#148; below, for a summary of RXi&#146;s current research and development activities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Oncology Therapeutic Programs </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The chart below summarizes the current status of our oncology drug development programs, with the dark
shading indicating completed stages of development and the light shading indicating development activities we intend to prioritize in the near-term: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g82s35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing a pipeline of immunotherapy product candidates for
the treatment of various cancers based on the E75 peptide, the most advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast
cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). We recently initiated our Phase 3 PRESENT clinical trial of NeuVax for the
prevention of breast cancer recurrence in early-stage low-to-intermediate HER2-positive breast cancer patients. For the results of a single trial to support registration for an indication, the results of the trial must be internally consistent,
clinically meaningful, and statistically very persuasive. Specifically, FDA has indicated that, in general, the results from two Phase 3 studies would </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be required to support approval, and it would accept a single pivotal study in support of approval only if results show a highly statistically significant effect on a clinical meaningful endpoint
such as overall survival that is internally consistent across relevant subgroups, and that the results of the single pivotal trial must be sufficiently robust and so compelling that it would be unethical to repeat the study. The results from one
study, if not highly statistically significant, are unlikely to be considered sufficiently persuasive to meet regulatory requirements. Therefore, the results of the recently initiated Phase 3 PRESENT clinical trial of NeuVax must satisfy FDA
requirements for a single trial, or an additional Phase 3 trial will be required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax is
an immunotherapy that stimulates the immune system to actively seek out and selectively kill cancer cells. NeuVax directs &#147;killer&#148; T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial
tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of two components: a HER2/neu-derived peptide called E75 and the immune adjuvant GM-CSF. E75 is a nine-amino acid sequence that is immunogenic (produces
an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax has been shown to be most effective in patients with low-to-intermediate HER2/neu expressors with
HLA type A2+ or A3+. We believe that approximately 25,000-40,000 of the approximately 200,000 women diagnosed with breast cancer in the United States each year meet these criteria. We believe that NeuVax&#146;s specificity provides for a highly
targeted therapy to prevent breast cancer recurrence for a selected subset of breast cancer patients and we believe it will increase the chance of a successful treatment outcome for these patients. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also developing novel applications for NeuVax based on preclinical studies and pilot Phase 2
clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin&#153;; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein.
Based on these results, a randomized, multicenter Phase 2 trial with 300 patients will compare NeuVax with trastuzumab versus trastuzumab alone. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also are pursuing additional therapeutic indications for NeuVax that are currently in Phase 1/2
clinical trials. Under our investigational new drug application, or &#147;<B>IND</B>,&#148; open protocols for the treatment of prostate cancer, ovarian cancer and bladder cancer exist for patient populations with the same general criteria for
eligibility as in breast cancer (<I>i.e.</I>, early-stage disease and adjuvant treatment setting after surgery with immunologic competence). We may also explore whether NeuVax provides clinical benefits in other areas, such as a prophylactic vaccine
against breast cancer occurrence in healthy women with a high likelihood for developing breast cancer based on genetic assays or biomarkers and a strong positive familial history of breast cancer. We also may investigate the use of NeuVax in
combination with other therapies with a view to leveraging NeuVax&#146;s attractive safety profile and targeted mechanism of action. Clinical trials conducted on NeuVax have provided proof-of-principle data in early-stage node-negative breast
cancer, although such data is preliminary and not statistically significant, since the trials were not designed to provide statistically significant efficacy data. Both the early-stage node-negative breast cancer indication and the high-risk patient
indication are longer-term areas of interest that we currently expect to explore only with support from corporate partners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Developments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26,
2011, we changed the name of our company from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. in connection with our planned separation into two companies: (i)&nbsp;Galena, which will operate as a late-stage oncology drug development
company; and (ii)&nbsp;RXi, which will continue to develop novel RNAi-based therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the
change in our name to Galena. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, we entered into a securities
purchase agreement with RXi and two investors, pursuant to which the investors agreed to purchase a total of $9,500,000 of preferred stock of RXi at the closing of the partial spin-off of RXi and to make bridge loans of up to $1,500,000 to RXi to
fund its operations between signing and closing. The </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
outstanding principal and accrued interest from the bridge loans will be converted into RXi preferred stock at the closing of the partial spin-off of RXi and will represent a portion of the
$9,500,000 total investment, which is sometimes referred to in this prospectus supplement the &#147;<B>RXi financing.</B>&#148; The RXi financing and the partial spin-off of RXi are subject to customary closing conditions, and there is no assurance
that the RXi financing and the partial spin-off of RXi will be completed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
September&nbsp;24, 2011, we contributed to RXi substantially all of our RNAi-related technologies and assets and entered into a number of agreements relating to the financing and other aspects of RXi&#146;s ongoing business and operations. RXi will
focus on developing and commercializing therapeutic products based on RNAi technologies for the treatment of human diseases, including its lead anti-scarring and anti-fibrosis product candidate, RXi-109, with initial financing to be provided by the
investors. In these agreements, we have committed, among other things, to undertake to distribute to our stockholders a portion of the RXi common stock held by Galena, which we refer to in this prospectus supplement as the &#147;<B>partial spin-off
of RXi</B>.&#148; We sometimes refer to the shares of common stock of RXi to be distributed to our stockholders as the &#147;<B>spin-off shares</B>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, RXi&#146;s activities have consisted of completing its organizational activities, acquiring our
RNAi-related assets and entering into the agreements described in detail in our Current Reports on Form 8-K filed with the SEC on September&nbsp;26, 2011 and September&nbsp;27, 2011, respectively. These Current Reports also include as exhibits the
principal agreements described in the Current Reports. We also describe in these Current Reports changes in the employment arrangements with our former Chief Scientific Officer and former Vice President of Pharmaceutical Development related to
RXi&#146;s activities. See &#147;Incorporation of Information by Reference&#148; in this prospectus supplement for information on how to obtain our Current Reports, which you should read in their entirety. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have been sued in connection with the contribution and spin-off transactions by some of the holders of
our outstanding warrants. See &#147;Risk Factors - Risks Relating to Our Financial Position and Capital Requirements - <I>We have been sued by some of our warrant holders, and we could be found liable to repurchase their warrants</I>&#148; on page
S-19 of this prospectus supplement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi&#146;s RNAi Program </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi-109, RXi&#146;s first RNAi product candidate, is a dermal anti-scarring therapy that targets
connective tissue growth factor, or &#147;<B>CTGF</B>,&#148; and that may inhibit connective tissue formation in human fibrotic disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Data obtained from pre-clinical studies of RXi&#146;s sd-rxRNA compounds in preliminary pre-clinical models using local administration to the skin have shown robust delivery and effective target gene
silencing. RXi has targeted filing an IND application and commencing clinical trials of RXi-109 in 2012. If clinical studies of RXi-109 produce successful results in anti-scarring, we understand that RXi may explore opportunities in other
dermatology applications and other anti-fibrotic indications, possibly including pulmonary fibrosis, liver fibrosis, acute spinal cord injury, ocular scarring and restenosis. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Condition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had cash and cash equivalents of approximately $11.5&nbsp;million as of December&nbsp;31, 2011. We
believe that our existing cash and cash equivalents and the proceeds from this offering should be sufficient to fund our operations through at least 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not generated revenue to date and may not generate product revenue in the foreseeable future, if
ever. We expect to incur significant operating losses as we advance our product candidates through the drug development and regulatory process. In connection with the Phase&nbsp;3 PRESENT clinical trial of NeuVax, we expect that our expenses will
increase significantly from historic levels for the foreseeable future. In addition to increasing research and development expenses, we expect general and administrative costs to increase as we add personnel. We will need to generate significant
revenues to achieve profitability and might never do so. In the absence of product revenues, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development payments and payments
received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or
terminate our operations, or to seek to merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:1%;margin-right:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate
Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on
April&nbsp;3, 2006 and changed our name to RXi Pharmaceuticals Corporation on November&nbsp;28, 2006. On September&nbsp;26, 2011, we changed the name of our company from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc., as described under
&#147;Recent Developments&#148; above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:1%;margin-right:1%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal executive offices are located at 310 N.
State Street, Suite 208, Lake Oswego, Oregon 97034, and our phone number is (855)&nbsp;855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into this prospectus supplement or the accompanying
prospectus, and you should not consider such information part of this prospectus supplement or the accompanying prospectus. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Offering </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us pursuant to this prospectus supplement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares having an aggregate offering price of up to $10&nbsp;million.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manner of offering</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;At-the-market&#148; offering that may be made from time to time through our agent, Cantor Fitzgerald &amp; Co. See &#147;Plan of Distribution&#148; on page
S-35</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including the Phase&nbsp;3 PRESENT study and other clinical trials of
our lead product candidate, NeuVax. See &#147;Use of Proceeds&#148; on page S-33.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NASDAQ Capital Market symbol</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALE</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page S-8 of this prospectus supplement, as well as the other information
included in or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of risks you should consider carefully before making an investment decision.</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_5"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the
risks described below, together with all of the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, including from our most recent Annual Report on Form&nbsp;10-K and subsequent Quarterly
Reports on Form&nbsp;10-Q. Some of these factors relate principally to our business and the industry in which we operate. Other factors relate principally to your investment in our common stock. The risks and uncertainties described below are not
the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely affect our business and operations. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>If any of the matters included in the following risks were to occur, our business, financial condition, results of operations, cash
flows or prospects could be materially and adversely affected. In such case, you may lose all or part of your investment. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks
Relating to Our Business and Industry </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We recently changed our strategic focus, and the anticipated benefits of our new strategic
focus may not be realized. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may have difficulty evaluating our business, because we acquired Apthera only in the
past year and are undertaking to partially spin off RXi. Following the partial spin-off, our financial statements will no longer reflect the consolidated financial condition and results of operations of RXi, and we will account for our partial
ownership of RXi based on the equity method of accounting. For these reasons, the historical consolidated financial information included in our annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent quarterly reports on
Form 10-Q do not necessarily reflect the financial condition, results of operations or cash flows that we will achieve in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, we contributed to RXi substantially all of our RNAi-related technologies and assets and entered into a number of agreements in contemplation of the partial spin-off of RXi. RXi
will focus solely on developing and commercializing therapeutic products based on our RNAi technologies for the treatment of human diseases, including fibrotic disease. There is no assurance, however, that the partial spin-off of RXi will be
completed or that RXi will be able to succeed as a stand-alone company. There also is no assurance that we will be successful in implementing our new focus as an oncology product development pipeline company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are largely dependent on the success of our leading drug candidate, which may not receive regulatory approval or be successfully commercialized.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business prospects depend heavily on successfully developing and commercializing our lead product candidate,
NeuVax. On May&nbsp;8, 2009, we submitted an SPA for a Phase 3 clinical trial for NeuVax, but did not include required chemistry, manufacturing, and controls (&#147;<B>CMC</B>&#148;) information. In July 2009, FDA placed our IND application for a
Phase 3 trial for NeuVax on partial clinical hold pending submission of the missing CMC information. We submitted the CMC information August&nbsp;8, 2011, and the FDA removed the partial clinical hold on September&nbsp;7, 2011, allowing us to
proceed with the Phase 3 clinical trial. The FDA has agreed in the SPA for our Phase 3 PRESENT clinical trial of NeuVax that the design, resulting data, and planned analyses of the Phase 3 study support an acceptable regulatory submission for
marketing approval.<B> </B>There is no assurance, however, that the Phase&nbsp;3 study will be successful, that a single Phase&nbsp;3 trial will support marketing approval, or that we will be able to obtain marketing approval for NeuVax or any other
product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently generate no revenue from sales, and we may never be able to develop marketable products.
Before they can be marketed, our products in development must be approved by the FDA or similar foreign governmental agencies. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
outcome. Before obtaining regulatory approval for the sale of any drug candidate, we must conduct extensive pre-clinical tests and clinical trials to demonstrate the safety and efficacy in humans
of our product candidates. Although NeuVax has demonstrated safety during Phase&nbsp;1 and Phase&nbsp;2 clinical trials, further testing in our Phase 3 trial may undermine those determinations or unexpected side effects may arise. A failure of any
pre-clinical study or clinical trial can occur at any stage of testing. The results of pre-clinical and initial clinical testing of these products may not necessarily indicate the results that will be obtained from later or more extensive testing.
It also is possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A number of different factors could prevent us from obtaining regulatory approval or commercializing our product candidates on a timely basis, or
at all. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, the FDA or other applicable regulatory authorities or an institutional review board, or
&#147;<B>IRB</B>,&#148; which is an independent committee under the oversight of the United States Department of Health and Human Services, or &#147;HHS,&#148; that has been formally registered with HHS and functions to approve, monitor and review
biomedical and behavioral research involving humans, may suspend clinical trials of a drug candidate at any time for various reasons, including if we or they believe the subjects or patients participating in such trials are being exposed to
unacceptable health risks. Among other reasons, adverse side effects of a drug candidate on subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve
a particular drug candidate for any or all indications of use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials of a new drug candidate require the enrollment
of a sufficient number of patients, including patients who are suffering from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in
patient enrollment can result in increased costs and longer development times. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials also require the review and
oversight of IRBs, which approve and continually review clinical investigations and protect the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical
trials, and the FDA may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB review and approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, cancer vaccines are a relatively new form of therapeutic and a very limited number of such products have received regulatory approval. Therefore, the FDA or other regulatory authority may
apply standards for approval of a new cancer vaccine that is different from past experience. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerous factors could affect
the timing, cost or outcome of our drug development efforts, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in enrolling patients in our Phase&nbsp;3 PRESENT study in conformity with required protocols or projected timelines or in our
other NeuVax clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conditions imposed on us by the FDA, including the possibility that that the FDA would require an additional Phase&nbsp;3 trial of NeuVax, or
comparable foreign authorities regarding the scope or design of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human
biological systems in unforeseen, ineffective or harmful ways, and the possibility that our previous Phase&nbsp;II trials were not indicative of our drug candidates&#146; performance in larger patient populations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected
characteristics; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of our clinical trials may be greater than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to
generate statistically significant data confirming the efficacy of the product being tested; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results obtained by other companies developing similar drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">modification of the drug during testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the FDA&#146;s requirements for our testing during the course of that testing; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reallocation of our limited financial and other resources to other clinical programs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that none of the product candidates that we develop will obtain the appropriate regulatory approvals necessary for us to
begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. The time required to obtain FDA and other approvals is unpredictable but often can take
years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could
delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenue from the particular drug candidate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing
authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of local regulations in
foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will
rely upon third parties for the manufacture of our clinical product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have the facilities or
expertise to manufacture supplies of any of our potential product candidates for clinical trials. Accordingly, we will be dependent upon contract manufacturers for these supplies. There can be no
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
assurance that we will be able to secure needed supply arrangements on attractive terms, or at all. Our failure to secure these arrangements as needed could have a materially adverse effect on
our ability to complete the development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our current plans call for the manufacture of our compounds by contract manufacturers offering research grade, Good Laboratory grade and Good Manufacturing Practices grade materials for preclinical
studies (e.g., toxicology studies) and for clinical use. Certain of our product candidates are complex molecules requiring many synthesis steps, which may lead to challenges with purification and scale-up. These challenges could result in increased
costs and delays in manufacturing. NeuVax contains GM-CSF, a compound produced by Genzyme. If Genzyme were to discontinue supplying GM-CSF, we may experience delays in securing a replacement supplier. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize some or all of
our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to depend on collaborators, partners, licensees, clinical research organizations
and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to
successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements
will depend on, among other things, potential partners&#146; evaluation of the superiority of our technology over competing technologies and the quality of the pre-clinical and clinical data that we have generated, and the perceived risks specific
to developing our product candidates. In addition, we reduced the scale of our RNAi operations in connection with the partial spin-off of RXi, which could affect our ability to maintain or enter into new alliances. If we are unable to obtain or
maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Under certain license agreements that we have already entered into, we have minimum
dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to maintain certain licenses. If we fail to meet this requirement under any of our licenses
that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under such agreement, which may result in the loss of the technology licensed. We cannot necessarily control the amount or timing of
resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements
in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill their obligations to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, we may receive notices from third parties from time to time alleging that our technology or product candidates infringes the intellectual property rights of those third parties. Any assertion
by third parties that our activities or product candidates infringe upon their intellectual property rights may adversely affect our ability to secure strategic partners or licensees for our technology or product candidates or our ability to secure
or maintain manufacturers for our compounds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing
regulatory review. If we fail to comply with ongoing regulatory requirements, we could lose our approvals to market drugs and our business would be materially adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following regulatory approval of any drugs we may develop, we will remain subject to continuing regulatory review, including the review
of adverse drug experiences and clinical results that are reported after our drug products are made available to patients. This would include results from any post marketing tests or vigilance required as a condition of approval. The manufacturer
and manufacturing facilities we use to make any of our drug products will also be subject to periodic review and inspection by the FDA. The discovery of any new or previously unknown problems with the product, manufacturer or facility may result in
restrictions on the drug or manufacturer or facility, including withdrawal of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the drug from the market. We would continue to be subject to the FDA requirements governing the labeling, packaging, storage, advertising, promotion, recordkeeping, and submission of safety and
other post-market information for all of our product candidates, even those that the FDA had approved. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory
approval, product recalls and seizures, operating restrictions and other adverse consequences. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we receive regulatory approval
to market our product candidates, our product candidates may not be accepted commercially, which may prevent us from becoming profitable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NeuVax and our other cancer-targeted product candidates may not achieve market acceptance. Factors that we believe will materially affect market acceptance of our product candidates include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safety, efficacy and ease of administration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advantages of our product candidates over those of our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">willingness of patients to accept relatively new therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">success of our physician education programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of government and third-party payor reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pricing of our products, particularly as compared to alternative treatments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of effective alternative treatments and the relative risks and/or benefits of the treatments. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will be subject to competition and may not be able to compete successfully. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biotechnology industry, including the cancer therapy vaccines market, is intensely competitive and involves a high degree of risk. We
compete with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the United States and worldwide are numerous and include pharmaceutical and biotechnology companies,
educational institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize
products that compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. We may be unable to effectively develop our technology or any other applications on a
cost effective basis or otherwise. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us
in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. Our collaborators or we will face competition with respect to product efficacy and safety, ease of use
and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including potentially dominant patent
positions of others. An inability to successfully complete our product development could lead to us having limited prospects for establishing market share or generating revenues from our technology. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-term
disease free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (Herceptin&reg;) may be given to patients with tumors
with high expression of HER2 (IHC 3+). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of cancer vaccines in development for breast cancer, including but not
limited to Lapuleucel-T (Dendreon), AE-37 (Antigen Express) and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, there is no guarantee that any of the these compounds will not in the future be
indicated for treatment of low to intermediate HER 2 breast cancer patients and become directly competitive with NeuVax. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are
dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently are dependent on licenses from third parties for technologies relating to our product candidates. Our current licenses
impose, and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with respect to any of these technologies is terminated for any
reason, the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing technology. The costs of obtaining new licenses are high.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to protect our intellectual property rights licensed from others parties, our intellectual property rights may be
inadequate to prevent third parties from using our technologies or developing competing products, and we may need to license additional intellectual property from others. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our licenses, we also rely on copyright and trademark protection, trade secrets, know-how, continuing technological
innovation and licensing opportunities. In an effort to maintain the confidentiality and ownership of our trade secrets and proprietary information, we require our employees, consultants, advisors and others to whom we disclose confidential
information to execute confidentiality and proprietary information agreements. However, it is possible that these agreements may be breached, invalidated or rendered unenforceable, and if so, there may not be an adequate corrective remedy available.
Furthermore, like many companies in our industry, we may from time to time hire scientific personnel formerly employed by other companies involved in one or more areas similar to the activities we conduct. In some situations, our confidentiality and
proprietary information agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisors have prior employment or consulting relationships. Although we require our employees and consultants
to maintain the confidentiality of all confidential information of previous employers, we may be subject to allegations of trade secret misappropriation or other similar claims as a result of our employees&#146; or consultants&#146; prior
affiliations. Finally, others may independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets. Our failure to protect our proprietary information and techniques may inhibit or
limit our ability to exclude certain competitors from the market and execute our business strategies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our success depends upon our
ability to obtain and maintain intellectual property protection for our products and technologies. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will
depend on our ability to obtain and maintain adequate protection of our intellectual property covering our product candidates and technologies. The ultimate degree of patent protection that will be afforded to biotechnology products and processes,
including ours, in the United States and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. There is no certainty that our existing
patents, or patent applications if obtained, will afford us substantial protection or commercial benefit. Similarly, there is no assurance that our pending patent applications or patent applications licensed from third parties will ultimately be
granted as patents or that those patents that have been issued or are issued in the future will stand if they are challenged in court. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a risk that the products incorporating our peptide-based immunotherapy technology
or otherwise marketed by us might infringe the patent, trademark or other intellectual property rights of third parties, and there may be patent or other intellectual property rights belonging to others that require us to alter our products, pay
licensing fees or cease certain activities. For example, in June 2010, we received a letter from Alnylam Pharmaceuticals, Inc. claiming that we require access to Alnylam&#146;s patent and patent applications and demanding that we stop engaging in
unspecified alleged infringing activities unless we obtain a license from Alnylam. If our products infringe patent or other intellectual property rights of others, the owners of those rights could bring legal actions against us claiming damages and
seeking to enjoin manufacture, use, marketing and sales of the affected products. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture
or market the affected products. We may not prevail in any action brought against us, and any license required under any rights that we infringe may not be available on acceptable terms or at all. Others may attempt to invalidate our intellectual
property rights or those of our licensors. Even if our rights, or those of our licensors, are not directly challenged, disputes among third parties could lead to the weakening or invalidation of our intellectual property rights. Any attempt by third
parties to undermine or invalidate our intellectual property rights could be costly to defend, require significant time and attention of our management and have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain regulatory exclusivity for NeuVax, our business would be adversely affected and such exclusivity may not provide
sufficient protection to prevent competitors from entering our markets. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because our intellectual property rights to
the composition of matter of NeuVax expire prior to commercialization, we expect to rely substantially on data exclusivity provided under the Federal Food, Drug, and Cosmetic Act and similar laws in other countries and, to a lesser extent, on orphan
drug designation, if granted for NeuVax. We are preparing to apply for Orphan Drug status for NeuVax that, if granted, could provide seven years or ten years of data exclusivity in the United States or the European Union, respectively. However,
there is no assurance that the FDA or the European Medicines Agency, or &#147;<B>EMEA</B>,&#148; will approve our Orphan Drug Application. While we also anticipate that NeuVax will qualify for 12 years of data exclusivity, or the inability of
another company to use our clinical data to support their application for regulatory approval, under the Patient Protection and Affordable Care Act; there can be no assurance that the 12 years of exclusivity provided for under the Patient Protection
and Affordable Care Act will remain law, or that NeuVax will meet the qualifications of a &#147;biological product&#148; to receive the specified period of exclusivity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While the orphan drug designation for NeuVax, if granted, will provide seven years of market exclusivity in the United States, we will not be able to exclude other companies from manufacturing and/or
selling E75 beyond that timeframe. Even if we have orphan drug designation for a particular drug indication, we cannot guarantee that another company also holding orphan drug designation will not receive FDA approval for the same indication before
we do. If that were to happen, our applications for that indication may not be approved until the competing company&#146;s seven-year period of exclusivity expired. Even if we are the first to obtain FDA approval for an orphan drug indication, there
are circumstances under which a competing product may be approved for the same indication during our seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to the orphan product. Further, the
seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same compound for other indications or the use of other types of drugs for the same use as the orphan drug. In addition, data exclusivity does not prevent
another company from completing its own clinical trials with NeuVax and obtaining regulatory approval for the same indication for which NeuVax may be approved. Consequently, we may not be able to prevent competitors from entering the market prior to
the end of any applicable data exclusivity period. If we are not able to prevent competitors from entering the market with a similar product to NeuVax, our ability to achieve profits from sales of NeuVax will be dramatically limited. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to potential liabilities from clinical testing and future product liability claims.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our future products are alleged to be defective, they may expose us to claims for personal injury by
patients in clinical trials of our products. If our products are approved by the FDA, users may claim that such products caused unintended adverse effects. We will seek to obtain clinical trial insurance for clinical trials that we conduct, as well
as liability insurance for any products that we market. There can be no assurance that we will be able to obtain insurance in the amounts we seek, or at all. We anticipate that licensees who develop our products will carry liability insurance
covering the clinical testing and marketing of those products. There is no assurance, however, that any insurance maintained by us or our licensees will prove adequate in the event of a claim against us. Even if claims asserted against us are
unsuccessful, they may divert management&#146;s attention from our operations and we may have to incur substantial costs to defend such claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives,
which could have a material adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to sell our products primarily to hospitals,
oncologists and clinics which receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid and other domestic and international government programs, private insurance plans and
managed care programs. Most third-party payors may deny reimbursement if they determine that a medical product was not used in accordance with cost-effective treatment methods, as determined by the third-party payor, was used for an unapproved
indication or if they believe the cost of the product outweighs its benefits. Third-party payors also may refuse to reimburse for experimental procedures and devices. Furthermore, because our programs are still in development, we are unable at this
time to determine their cost-effectiveness and the level or method of reimbursement for them. Increasingly, the third-party payors who reimburse patients are requiring that drug companies provide them with predetermined discounts from list prices,
and are challenging the prices charged for medical products. If the price we are able to charge for any products we develop is inadequate in light of our development and other costs, our profitability could be adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently expect that any drugs we develop may need to be administered under the supervision of a physician. Under currently
applicable law, drugs that are not usually self-administered may be eligible for coverage by the Medicare program if: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are &#147;incidental&#148; to a physician&#146;s services; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are &#147;reasonable and necessary&#148; for the diagnosis or treatment of the illness or injury for which they are administered according to
accepted standard of medical practice; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are not excluded as immunizations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they have been approved by the FDA. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Insurers may refuse to provide insurance coverage for newly approved drugs, or insurance coverage may be delayed or be more limited than the purpose for which the drugs are approved by the FDA. Moreover,
eligibility for insurance coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable,
may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by
mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United
States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and
private payors for new drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to develop products, and our overall financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, third-party payors are increasingly attempting to contain health care costs by
limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the
demand for and price levels of our products. If our customers are not reimbursed for our products, they may reduce or discontinue purchases of our products, which could have a material adverse effect on our business, financial condition and results
of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive health care reform legislation, which was recently adopted by Congress and was subsequently
signed into law, could adversely affect our business and financial condition. Among other provisions, the legislation provides that a &#147;biosimilar&#148; product may be approved by the FDA on the basis of analytical tests and certain clinical
studies demonstrating that such product is highly similar to an existing, approved product and that switching between an existing product and the biosimilar product will not result in diminished safety or efficacy. This abbreviated regulatory
approval process may result in increased competition if we are able to bring a product to market. The legislation also includes more stringent compliance programs for companies in various sectors of the life sciences industry with which we may need
to comply and enhanced penalties for non-compliance with the new health care regulations. Complying with new regulations may divert management resources, and inadvertent failure to comply with new regulations may result in penalties being imposed on
us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some states and localities have established drug importation programs for their citizens, and federal drug import
legislation has been introduced in Congress. The Medicare Prescription Drug Plan legislation, which became law in December 2003, required the Secretary of Health and Human Services to promulgate regulations for drug reimportation from Canada into
the United States under some circumstances, including when the drugs are sold at a lower price than in the United States. The Secretary, however, retained the discretion not to implement a drug reimportation plan if he finds that the benefits do not
outweigh the costs, and has so far declined to approve a reimportation plan. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing
the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our new management team is not effective or if we fail to attract, hire and retain qualified personnel, we may not be able to design, develop, market or sell our products or successfully manage
our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business prospects are dependent on our management team. The loss of Dr.&nbsp;Ahn, our President
and Chief Executive Officer, or our other executive officers, or our inability to identify, attract, retain and integrate additional qualified key personnel, could make it difficult for us to manage our business successfully and achieve our business
objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competition for skilled research, product development, regulatory and technical personnel also is intense, and we
may not be able to recruit and retain the personnel we need. The loss of the services of any key research, product development, regulatory, and technical personnel, or our inability to hire new personnel with the requisite skills, could restrict our
ability to develop our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We use biological and hazardous materials, and we may be liable for any contamination or
injury we cause. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development activities involve the controlled use of potentially harmful biological
materials as well as hazardous materials, chemicals and various radioactive compounds. We cannot completely eliminate the risk of accidental contamination or injury; we may be liable for any damages that result, and any liability could exceed our
resources. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous environmental, health and workplace safety laws and
regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to
injuries to our employees resulting from the use of these materials. State laws mandate the limits of our workers&#146; compensation insurance, and our workers&#146; compensation liability is capped at these state-mandated limits. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations
affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any of these laws or regulations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating To Our Financial Position and Capital Requirements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able
to obtain sufficient financing, and may not be able to develop our product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our existing
cash and cash equivalents and the proceeds from this offering should be sufficient to fund our operations through at least 2012. In the future, we will be dependent on obtaining further financing from third parties in order to maintain our
operations and to meet our financial obligations. We cannot assure that additional debt or equity or other funding to maintain our operations and to meet our obligations to our licensors will be available to us in the future on acceptable terms, or
at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations, or to seek to merge with or to be acquired by another company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that we will need to raise substantial amounts of money to fund a variety of future activities integral to the development
of our business, which may include but are not limited to the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to conduct our Phase 3 PRESENT clinical trial of NeuVax and Phase 2 trial of NeuVax in combination with Herceptin&reg; and our other planned NeuVax
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to obtain regulatory approval for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to file and prosecute patent applications and to defend and assess patents to protect our technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to retain qualified employees, particularly in light of intense competition for qualified scientists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to manufacture products ourselves or through third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to market our products, either through building our own sales and distribution capabilities or relying on third parties; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to acquire new technologies, licenses, products or companies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot assure you that any financing needed for the development of our business will be available to us on acceptable terms or at all.
If we cannot obtain additional financing in the future, our operations may be restricted and we may ultimately be unable to continue to develop and potentially commercialize our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability, and may
lead to uncertainty about or as to our ability to continue as a going concern. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantial funds were expended to
develop our technologies and product candidates, and additional substantial funds will be required for further pre-clinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for
commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate enough
revenue, even if we are able to commercialize any of our product candidates, to become profitable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that we are unable to achieve or sustain profitability or to secure additional
financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing
their entire investment. There is no guaranty that we will become profitable or secure additional financing. Our financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we
were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or other events will
all affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our stockholders or may otherwise
adversely affect our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we raise funds through the issuance of debt or equity, any debt securities or preferred
stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining
to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute your ownership in us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms of debt securities may also impose restrictions on our operations, which may include limiting our ability to incur additional
indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy
such covenants may be affected by events outside of our control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may have difficulty evaluating our business, because we
have a limited history and our historical financial information may not be representative of our future results. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have limited
operating experience and may not be able to effectively operate. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a development-stage company with limited
operating history conducting oncology drug programs. We will focus on developing and, if we obtain regulatory approval, commercializing our product candidates, and there is no assurance that we will be successful. There is no assurance that we will
be able to manage our business effectively, or that we will be able to identify, hire and retain any needed additional management or scientific personnel to develop and implement our product development plans, obtain third-party contracts or any
needed financing or achieve our other business objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to comply with our reporting and other requirements under
federal securities laws. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a publicly traded company, we are subject to the reporting requirements of the Securities
Exchange Act of 1934, as amended, or the &#147;<B>Exchange Act,</B>&#148; and the Sarbanes-Oxley Act of 2002, or the &#147;<B>Sarbanes-Oxley Act</B>.&#148; In addition, the Exchange Act requires that we file annual, quarterly and current reports.
Our failure to prepare and disclose this information in a timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. The Sarbanes-Oxley Act requires that we, among
other things, establish and maintain effective internal controls and procedures for financial reporting. From time to time we evaluate our existing internal controls in light of the standards adopted by the Public Company Accounting Oversight Board.
It is possible that we or our independent registered public accounting firm may identify significant deficiencies or material weaknesses in our internal control over financial reporting in the future. Any failure or difficulties in implementing and
maintaining these controls could cause us to fail to meet the periodic reporting obligations or result in material misstatements in our financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404 of the Sarbanes-Oxley Act requires annual management assessments of the
effectiveness of our internal control over financial reporting. Our failure to satisfy the requirements of Section&nbsp;404 on a timely basis could result in the loss of investor confidence in the reliability of our financial statements, which in
turn could have a material adverse effect on our business and our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We recently reported a material weakness in the
effectiveness of our internal controls over financial reporting, and if we cannot provide reliable financial and other information, investors may lose confidence in our SEC reports. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011, our management identified a material weakness in the effectiveness of our internal control over financial reporting
related to our accounting for certain outstanding stock options and warrants. As a result, we restated our unaudited condensed consolidated financial statements as of June&nbsp;30, 2011. Based on this evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures, and because of the error described above, our management concluded that our disclosure controls and procedures over our accounting for stock options modified and for warrants potentially
settleable in cash were not effective as of the end of the quarter ended June&nbsp;30, 2011. Disclosure controls and procedures generally include controls and procedures designed to ensure that information required to be disclosed by us in the
reports we file with the SEC is recorded, processed, summarized and reported accurately and within the time periods specified in the SEC&#146;s rules and forms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective internal controls over financial reporting and disclosure controls and procedures are necessary for us to provide reliable financial and other reports and effectively prevent fraud. If we cannot
provide reliable financial or SEC reports or prevent fraud, investors may lose confidence in our SEC reports, our operating results and the trading price of our common stock could suffer materially and we may become subject to litigation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have been sued by some of our warrant holders, and we could be found liable to repurchase their warrants. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;21, 2011, Hudson Bay Master Fund, Ltd. (&#147;<B>Hudson Bay</B>&#148;) filed a Complaint against us in the United States
District Court for the Southern District of New York (the &#147;<B>Court</B>&#148;), captioned <U>Hudson Bay Master Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)</U>, alleging that our plan to partially spin off RXi and related actions
taken by us in preparation for the spin-off gives Hudson Bay the right to require us to repurchase for approximately $1.4&nbsp;million warrants acquired by Hudson Bay in our April 2011 underwritten public offering. Hudson Bay also seeks related
declaratory and injunctive relief. On January&nbsp;12, 2012, three other warrant holders affiliated with each other filed a Complaint in the Court, captioned <U>Tenor Opportunity Fund, Ltd., Aria Opportunity Fund, Ltd., and Parsoon Opportunity Fund,
Ltd. v. Galena Biopharma, Inc., 12 CIV 0260</U>, and on January&nbsp;20, 2012 and February&nbsp;2, 2012, respectively, two other warrant holders filed their own Complaints in the Court, captioned <U>Cranshire Capital Master Fund, Ltd. v. Galena
Biopharma, Inc., 12 CIV 0493</U> and <U>Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc., 12&nbsp;CIV&nbsp;0839</U>, respectively. In these latest Complaints, which are substantially identical to the previous Complaints filed in the Court, the
various warrant holders claim that our planned spin-off of RXi and related actions give them the right to require us to repurchase for a total of approximately $3.8&nbsp;million our outstanding warrants held by them. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that we have valid defenses to the claims made in the foregoing Complaints, and intend to defend the claims vigorously. We
cannot predict the outcome of these claims, however, and if the plaintiffs were to prevail, we could become liable to the plaintiffs to repurchase their warrants. We have not set aside any reserves or other funds for this purpose. If we were to
become liable to repurchase the plaintiffs&#146; warrants, we may not have on hand sufficient funds to satisfy the liability and to meet our other obligations as they come due, raising doubt as to our ability to continue as a going concern.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Ownership of Our Common Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our common stock may be delisted from The NASDAQ Capital Market, which would adversely affect the price and liquidity of our common stock.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is currently listed on The NASDAQ Capital Market. On November&nbsp;14, 2011, we were notified by The
NASDAQ Capital Market that during the previous 30 consecutive business days the closing bid price of our common stock had been below the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Capital Market. The notice states that
we will have 180 calendar days, or until May&nbsp;14, 2012, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price of our common stock must close at $1.00 per share or above for a minimum of 10 consecutive
business days any time before May&nbsp;14, 2012. The notice also states that, in the event we do not regain compliance by May&nbsp;14, 2012, we may be eligible for additional time. To qualify, we will be required to meet the continued listing
requirements for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the bid price requirement, and will need to provide written notice to NASDAQ of our intention to cure
the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If we meet these requirements, we will be granted an additional 180 calendar days from May&nbsp;14, 2012 to avoid delisting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should we fail to comply with the minimum bid price requirement or any of the other continued listing requirements, our common stock may
be delisted from The NASDAQ Capital Market. If our common stock is delisted, it could reduce the price of our common stock and the levels of liquidity available to our stockholders. In addition, the delisting of our common stock could materially
adversely affect our access to the capital markets, and any limitation on liquidity or reduction in the price of our common stock could materially adversely affect our ability to raise capital on terms acceptable to us or at all. Delisting from The
NASDAQ Capital Market could also result in other negative implications, including the potential loss of confidence by suppliers, customers and employees, the loss of institutional investor interest and fewer business development opportunities.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The market price and trading volume of our common stock may be volatile. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market price of our common stock could fluctuate significantly for many reasons, including the following factors: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of regulatory developments or technological innovations by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of business or strategic transactions such as our planned partial spin-off of RXi and related transactions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in our relationship with our licensors and other strategic partners; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our quarterly operating results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments in patent or other technology ownership rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern regarding the safety of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stock
holders; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">government regulation of drug pricing; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, factors beyond our control may also have an impact on the price of our stock. For example, to the extent that other large
companies within our industry experience declines in their stock price, our stock price may decline as well. In addition, when the market price of a company&#146;s common stock drops significantly, stockholders often institute securities class
action lawsuits against the company. A lawsuit against us could cause us to incur substantial costs and could divert the time and attention of our management and other resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover provisions of our certificate of incorporation and by-laws and provisions of Delaware law could delay or prevent a change of control that you may favor. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-takeover provisions of our certificate of incorporation and by-laws and provisions of Delaware law may discourage, delay or prevent
a merger or other change of control that stockholders may consider favorable, or may impede the ability of the holders of our common stock to change our management. These provisions of our certificate of incorporation and by-laws, among other
things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">divide our board of directors into three classes, with members of each class to be elected for staggered three-year terms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit the right of stockholders to remove directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">authorize our board of directors to issue preferred stock in one or more series, without stockholder approval. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire,
or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation such as our company shall not engage in any business combination with that corporation, including by merger, consolidation or
acquisitions of additional shares for a three-year period following the date on which that person or its affiliate crosses the 15% stock ownership threshold. Section&nbsp;203 could operate to delay or prevent a change of control of our company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may acquire other businesses, including businesses in which our directors or officers may have an interest, or form joint ventures
that may be unsuccessful and could adversely dilute your ownership of our company. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our business strategy,
we may pursue acquisitions of other complementary businesses and assets and may also may pursue strategic alliances. We have limited experience in acquiring other companies and in forming such alliances. Apthera was our first acquisition. Mark J.
Ahn, Ph.D., our President and Chief Executive Officer, served as a director of Apthera and Sanford J. Hillsberg, our Chairman of the Board, was a substantial stockholder of Apthera at the time of the acquisition and had interests in the Apthera
acquisition that were different from the interests of our stockholders, generally. We may not be able to successfully integrate any acquisitions into our existing business, and we could assume unknown or contingent liabilities or become subject to
possible stockholder claims in connection with any related-party or third-party acquisitions or other transactions. We also could experience adverse effects on our reported results of operations from acquisition-related charges, amortization of
acquired technology and other intangibles and impairment charges relating to write-offs of goodwill and other intangible assets from time to time following the acquisition of Apthera or other acquisitions. Integration of an acquired company requires
management resources that otherwise would be available for ongoing development of our existing business. We may not realize the anticipated benefits of any acquisition, technology license or strategic alliance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To finance future acquisitions, we may choose to issue shares of our common stock as
consideration, which would dilute your ownership interest in us. Alternatively, it may be necessary for us to raise additional funds through public or private financings. Additional funds may not be available on terms that are favorable to us and,
in the case of equity financings, may result in dilution to our stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to this Offering </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management will have broad discretion as to the use of the net proceeds of this offering. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently anticipate using the net proceeds from the sale of our common stock offered by us hereunder for working capital and other
general corporate purposes, including the Phase 3 PRESENT study and our other NeuVax clinical trials. However, we have not reserved or allocated specific amounts for these purposes and we cannot specify with certainty how we will use the net
proceeds. Accordingly, our management will have considerable discretion in the application of the net proceeds and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
The net proceeds may be used for corporate purposes that do not increase our operating results or market value. Until the net proceeds are used, they may be placed in investments that do not produce income or that lose value. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investors in this offering will experience immediate and substantial dilution because the public offering price is much higher than the book value
of our common stock. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you purchase shares of common stock in this offering, you will suffer immediate and
substantial dilution because we have a net tangible deficit. See &#147;Dilution&#148; on page&nbsp;S-33 of this prospectus supplement for more information about the dilution you will incur in this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of
our common stock. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantial issuances or sales of our common stock, including shares issued upon exercise of our
outstanding options, in the public market, or the perception by the market that these issuances or sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital. As of February 16, 2012,
we had 47,524,094 shares of common stock issued and outstanding. Substantially all of these shares are available for public sale, subject in some cases to volume and other limitations or delivery of a prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of January&nbsp;31, 2012, we had reserved for issuance up to 7,252,562 shares of our common stock issuable upon the exercise of
outstanding stock options at a weighted-average exercise price of $2.67 per share. Subject to applicable vesting requirements, upon exercise of these options, the underlying shares may be resold into the public market. In the case of outstanding
options that have exercise prices that are below the market price of our common stock from time to time, investors would experience dilution. We cannot predict if future issuances or sales of our common stock, or the availability of our common stock
for issuance or sale, will harm the market price of our common stock or our ability to raise capital by offering equity securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our
outstanding warrants may result in dilution to our stockholders. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our outstanding April 2011 warrants and March 2011
warrants to purchase a total of 11,814,444 shares of common stock at a current exercise price of $0.65 per share contain so-called full-ratchet anti-dilution provisions that will be triggered </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
upon an issuance by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some exceptions. We expect that the
distribution to Galena stockholders of the spin-off shares will result in a downward adjustment to the exercise price of our outstanding April 2011 and March 2011 warrants, as well as some of our other outstanding warrants that are subject to
so-called weighted-average anti-dilution adjustments. Although the actual adjustments have not been determined, we do not expect them to materially affect the current exercise prices of our outstanding warrants. It is possible that one or more
warrant holders might object to our determination of applicable anti-dilution adjustments, which possibility may be increased by the pendency of the lawsuits filed by some warrant holders as described above under &#147;Risks Relating to Our
Financial Position and Capital Requirements &#150; <I>We have been sued by some of our warrant holders, and we could be found liable to repurchase their warrants</I>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of these warrants on a full-ratchet basis, which would have a
dilutive effect on our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may issue preferred stock in the future, and the terms of the preferred stock may reduce the
value of our common stock. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are authorized to issue up to 5,000,000 shares of preferred stock in one or more
series. Our board of directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue preferred stock, it could affect your rights or reduce the market value of our outstanding common
stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to
merge with or sell our assets to a third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have never declared or paid dividends on our capital stock and we do not anticipate
paying dividends in the foreseeable future. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business requires significant funding. We currently plan to invest
all available funds and future earnings in the development and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, capital appreciation, if any, of our common stock will
be our stockholders&#146; sole source of potential gain for the foreseeable future. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated With the Partial Spin-Off of RXi
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of risks associated with the partial spin-off of RXi, including the following: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The partial spin-off may be delayed or may not be completed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has not yet fixed a record date for determining our stockholders who will be entitled to receive the spin-off shares, and, even if declared, the partial spin-off of RXi and the
closing of the transactions under our securities purchase agreement with RXi and the investors in RXi will be subject to certain customary closing conditions. There is no assurance, therefore, that the partial spin-off of RXi will be completed.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will no longer control RXi. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently own all of the outstanding shares of common stock of RXi. Upon completion of the RXi financing and the partial spin-off of RXi, assuming they are completed, we will own only approximately 4%
of the as-converted common stock of RXi and our stockholders will own in the aggregate approximately 8% of the as-converted common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will have no management rights in RXi, and the officers, directors and other RXi stockholders may
have interests that are different from ours. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we will own approximately 4% of RXi&#146;s outstanding common
stock upon completion of the spin-off of RXi, we will have no control over its management or operations. RXi will have its own board of directors and management, who will be responsible for the affairs and policies of RXi and its development plans.
Mark J. Ahn, Ph.D., our President and Chief Executive Officer, will resign as a director of RXi in conjunction with the partial spin-off of RXi, and neither we nor our stockholders will have any right to designate or elect Dr.&nbsp;Ahn or other
individual as a director of RXi or any other management rights in RXi. The directors, management and other stockholders of RXi may have interests that are different from ours, and RXi may engage in actions in connection with its business and
operations that we believe are not in our best interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have agreed to guarantee the bridge loan to RXi, and even if the spin-off
of RXi is not completed we will lose control of RXi </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the securities purchase agreement among RXi, the
investors in RXi and us, the investors have provided a bridge loan to RXi by purchasing $500,000 of RXi convertible notes and have agreed, in the investors&#146; discretion, to purchase up to an additional $1&nbsp;million of RXi convertible notes
prior to the closing. The RXi convertible notes accrue interest at a rate of 7%&nbsp;per annum (or 18%&nbsp;per annum in the case of an event of default) and mature on March 5, 2012, or earlier in the case of an event of default. The obligations due
under the RXi convertible notes are secured by a first-priority blanket lien on the assets of RXi and are guaranteed by us. Additionally, we have pledged all of our shares of RXi common stock to further guarantee the timely payment of the amounts
due under the RXi convertible notes, if not converted into RXi preferred stock at the closing of the transactions under the securities purchase agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the closing of the transactions under the securities purchase agreement has not occurred by the March 5, 2012 extended maturity date of the RXi convertible notes, the permanent financing and the
partial spin-off of RXi will not occur, and one-half of the outstanding principal of and accrued interest on the RXi convertible notes held by the investors will be converted into shares of RXi common stock equal to 51% of the shares of outstanding
common stock of RXi immediately upon such conversion. RXi will be obliged to repay the balance of the principal of and accrued interest on the RXi convertible notes held by the investors, and we have agreed in the securities purchase agreement to
guarantee RXi&#146;s repayment of the RXi convertible notes to the extent they are not converted. In this event, we will own 44% of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone private company under the
investors&#146; control, with its own management and with whatever funding and other financial resources that may be available to it. Neither the investors in RXi nor Galena will be obliged to provide any funding to RXi in this event, and there is
no guarantee that funding will be available to RXi on acceptable terms, or at all. If RXi fails to obtain additional funding in this event, it would be forced to scale back or terminate its operations, or to seek to merge with or to be acquired by
another company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We retain little discretion over the use of RXi&#146;s funds. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed in securities purchase agreement to use the proceeds of the RXi convertible notes and the funds contributed to RXi by us
in accordance with budgets agreed or to be agreed upon by the investors and us. We retain no discretion over the use of these funds, and these funds will not be available to us for use in Galena&#146;s business or operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated With Our Ownership Interest in RXi </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the partial spin-off is completed, or if it is not completed and we become a minority stockholder of RXi, the value of our ownership
interest in RXi and of the spin-off shares to be received by our stockholders will depend on RXi&#146;s success in developing and commercializing products developed based upon its RNAi technologies, which activities are subject to significant risks
and uncertainties, including the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be dependent on the success of its leading drug candidate, which may not receive
regulatory approval or be successfully commercialized. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi-109, RXi&#146;s first RNAi-based product candidate,
targets connective tissue growth factor, or &#147;<B>CTGF</B>,&#148; and may have a variety of medical applications. RXi is planning to file an IND application with the FDA and begin Phase&nbsp;1/2 clinical trials in 2012 for RXi-109. The FDA,
however, may deny RXi&#146;s application or require additional information before approving the application, and such information may be costly to provide. There is no assurance that RXi will be able to successfully develop RXi-109 or any other
product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi currently generates no revenue from sales, and may never be able to develop marketable products. The
FDA or similar foreign governmental agencies must approve RXi&#146;s products in development before they can be marketed. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before
obtaining regulatory approval for the sale of any drug candidate, RXi must conduct extensive pre-clinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. RXi has not shown safety or efficacy in
humans for any RNAi-based product candidates, including RXi-109. A failure of any pre-clinical study or clinical trial can occur at any stage of testing. The results of pre-clinical and initial clinical testing of these products may not necessarily
indicate the results that will be obtained from later or more extensive testing. It is also possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A number of different factors could prevent RXi from obtaining regulatory approval or commercializing its product candidates on a timely basis, or
at all. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi, the FDA or other applicable regulatory authorities, or an IRB may suspend clinical trials of a drug
candidate at any time for various reasons, including if RXi or they believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a drug candidate on
subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications of use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials of a new drug candidate require the enrollment of a sufficient number of patients, including patients who are suffering
from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in increased costs and longer development times.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials also require the review and oversight of IRBs, which approve and continually review clinical investigations
and protect the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived
from a clinical investigation not subject to initial and continuing IRB review and approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerous factors could affect the
timing, cost or outcome of RXi&#146;s drug development efforts, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in filing the initial drug application for RXi-109 or other product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulty in securing centers to conduct trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of RXi&#146;s clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulty in enrolling patients in conformity with required protocols or projected timelines; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party contractors failing to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi&#146;s drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with
human biological systems in unforeseen, ineffective or harmful ways; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to suspend or terminate clinical trials if the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient or inadequate supply or quality of RXi&#146;s drug candidates or other necessary materials necessary to conduct our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected
characteristics; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of RXi&#146;s clinical trials may be greater than it anticipates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative or inconclusive results from RXi&#146;s clinical trials or the clinical trials of others for similar drug candidates or inability to generate
statistically significant data confirming the efficacy of the product being tested; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the FDA&#146;s requirements for testing during the course of that testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reallocation of RXi&#146;s limited financial and other resources to other clinical programs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results obtained by other companies developing similar drugs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that none of the product candidates that RXi may develop will obtain the appropriate regulatory approvals necessary to
begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which RXi may market the product. The time required to obtain FDA and other approvals is unpredictable, but often can take
years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis RXi performs of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could
delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on RXi&#146;s ability to generate revenue from the particular drug candidate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi also is subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing
authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of local regulations in
foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The approach RXi is taking to discover and develop novel therapeutics using RNAi is unproven and may
never lead to marketable products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RNA interference is a relatively new scientific discovery. RXi&#146;s RNAi
technologies have not yet been clinically tested, nor are we aware of any clinical trials for efficacy having been completed by third parties involving these technologies. To date, no company has received regulatory approval to market therapeutics
utilizing RNAi, and a number of clinical trials of RNAi technologies by other companies have been unsuccessful. The scientific evidence to support the feasibility of developing drugs based on these discoveries is both preliminary and limited. To
successfully develop RNAi-based products, RXi must solve a number of issues, including stabilizing the RNAi material and delivering it into target cells in the human body. RXi may spend large amounts of money trying to solve these issues and never
succeed in doing so. In addition, any compounds that RXi develops may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen,
ineffective or even harmful ways. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The FDA could impose a unique regulatory regime for RNAi therapeutics. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The substances RXi intends to develop may represent a new class of drug, and the FDA has not yet established any definitive policies,
practices or guidelines in relation to these drugs. While we expect any product candidates that RXi develops will be regulated as a new drug under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them or other products RXi
may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that RXi may submit. Moreover, the FDA may respond to these submissions by
defining requirements that RXi may not have anticipated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The FDA approval process may be delayed for any drugs RXi develops that
require the use of specialized drug delivery devices or vehicles. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some drug candidates that RXi develops may need to
be administered using specialized vehicles, such as an implantable pump that deliver RNAi therapeutics directly to diseased parts of the body. The drug delivery vehicles that RXi expects to utilize to deliver its drug candidates have not been
approved by the FDA or other regulatory agencies. In addition, the FDA may regulate the product as a combination product of a drug and a device or require additional approvals or clearances for the modified delivery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If specialized delivery vehicle is owned by another company, RXi would need that company&#146;s cooperation to implement the necessary
changes to the vehicle, or its labeling, and to obtain any additional approvals or clearances. Any delays in finding suitable drug delivery vehicles to administer RNAi therapeutics directly to diseased parts of the body could negatively affect our
ability to successfully develop our RNAi therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if RXi receives regulatory approval to market its product candidates, its
product candidates may not be accepted commercially, which may prevent RXi from becoming profitable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RNAi product
candidates that RXi is developing are based on new technologies and therapeutic approaches. RNAi products may be more expensive to manufacture than traditional small molecule drugs, which may make them more costly than competing small molecule
drugs. Additionally, for various applications, RNAi products are likely to require injection or implantation and to not readily cross the so-called blood brain barrier, which will make them less convenient to administer than drugs administered
orally. Key participants in the pharmaceutical marketplace, such as physicians, medical professionals working in large reference laboratories, public health laboratories and hospitals, third-party payors and consumers may not accept products
intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for RXi to convince the medical community and third-party payors to accept and use RXi&#146;s products, or to provide favorable reimbursement. If
medical professionals working with large reference laboratories, public health laboratories and hospitals choose not to adopt and use RXi&#146;s RNAi technology, its products may not achieve broader market acceptance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other factors that we believe will materially affect market acceptance of RNAi product
candidates include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of RXi&#146;s receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safety, efficacy and ease of administration of RXi&#146;s product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advantages of RXi&#146;s product candidates over those of RXi&#146;s competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">willingness of patients to accept relatively new therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">success of RXi&#146;s physician education programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of government and third party payor reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pricing of RXi&#146;s products, particularly as compared to alternative treatments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of effective alternative treatments and the relative risks and/or benefits of the treatments. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be subject to competition and may not be able to compete successfully. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe numerous companies are investigating or plan to investigate a variety of proposed anti-scarring therapies in clinical trials.
The companies include large and small pharmaceutical, chemical and biotechnology companies, as well as universities, government agencies and other private and public research organizations. Such companies include Renovo Group plc, CoDa Therapeutics,
Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc.,
Healthpoint Biotherapeutics and Pharmaxon. In particular, Excaliard Pharmaceuticals, Inc., which has been acquired by Pfizer, Inc., has successfully advanced an anti-CTGF antisense oligonucleotide through several Phase&nbsp;1 and Phase&nbsp;2
trials, demonstrating improved scar outcome over placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe other companies working in the RNAi area, generally,
include Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira
Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris, as well as a number of large pharmaceutical companies. Many other companies are pursuing non-RNAi-based therapies for one or more fibrotic disease
indications, including ocular scarring or other indications that RXi may seek to pursue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of RXi&#146;s competitors have
substantially greater research and development capabilities and financial, scientific, technical, manufacturing, marketing, distribution and other resources than RXi, and RXi may not be able to successfully compete with them. In addition, even if
RXi is successful in developing its product candidates, in order to compete successfully RXi may need to be first to market or to demonstrate that its RNAi-based products are superior to therapies based on different technologies. A number of
RXi&#146;s competitors have already commenced clinical testing of RNAi product candidates and may be more advanced than RXi is in the process of developing products. If RXi is not first to market or are unable to demonstrate superiority, any
products for which RXi is able to obtain approval may not be successful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be dependent on technologies it licenses, and if it
loses the right to license such technologies or fails to license new technologies in the future, its ability to develop new products would be harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Many patents in the RNAi field have already been exclusively licensed to third parties, including RXi&#146;s competitors. If any of RXi&#146;s existing licenses are terminated, the development of the
products contemplated by the licenses could be delayed or terminated and RXi may not be able to negotiate additional licenses on acceptable terms, if at all, which would have a material adverse effect on RXi&#146;s business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may be unable to protect its intellectual property rights licensed from others parties, its
intellectual property rights may be inadequate to prevent third parties from using its technologies or developing competing products, and RXi may need to license additional intellectual property from others. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therapeutic applications of gene silencing technologies, delivery methods and other technologies that RXi licenses from third parties are
claimed in a number of pending patent applications, but there is no assurance that these applications will result in any issued patents or that those patents would withstand possible legal challenges or protect RXi&#146;s technologies from
competition. The United States Patent and Trademark Office and patent granting authorities in other countries have upheld stringent standards for the RNAi patents that have been prosecuted so far. Consequently, pending patents that RXi has licensed
or owns may continue to experience long and difficult prosecution challenges and may ultimately issue with much narrower claims than those in the pending applications. Third parties may hold or seek to obtain additional patents that could make it
more difficult or impossible for RXi to develop products based on RNAi technology without obtaining a license to such patents, which licenses may not be available to RXi on attractive terms, or at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, others may challenge the patents or patent applications that RXi currently licenses or may license in the future or that RXi
owns and, as a result, these patents could be narrowed, invalidated or rendered unenforceable, which would negatively affect RXi&#146;s ability to exclude others from using RNAi technologies described in these patents. There can be no assurance that
these patent or other pending applications or issued patents RXi licenses or owns will withstand possible legal challenges. Moreover, the laws of some foreign countries may not protect RXi&#146;s proprietary rights to the same extent as the laws of
the United States. Any patents issued to RXi or its licensors may not provide RXi with any competitive advantages, and there can be no assurance that the patents of others will not have an adverse effect on RXi&#146;s ability to do business or to
continue to use its technologies freely. RXi&#146;s efforts to enforce and maintain its intellectual property rights may not be successful and may result in substantial costs and diversion of management time. Even if RXi&#146;s rights are valid,
enforceable and broad in scope, competitors may develop products based on technology that is not covered by RXi&#146;s licenses or patents or patent application that it owns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010, we received a letter from Alnylam Pharmaceuticals, Inc. claiming that we require access to Alnylam&#146;s patent and patent applications and demanding that we stop engaging in unspecified
alleged infringing activities unless we obtain a license from Alnylam. We understand that other companies working in the RNAi area have received similar letters from Alnylam. Although we believe that RXi&#146;s current and planned activities do not
infringe any valid patent rights of Alnylam, there is no assurance that RXi will not need to alter its development candidates or products or obtain a license to Alnylam&#146;s rights to avoid any such infringement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no guarantee that future licenses will be available from third parties for RXi&#146;s product candidates on satisfactory terms,
or at all. To the extent that RXi is required and is able to obtain multiple licenses from third parties to develop or commercialize a product candidate, the aggregate licensing fees and milestones and royalty payments made to these parties may
materially reduce RXi&#146;s economic returns or cause RXi to abandon development or commercialization of a product candidate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi&#146;s success depends upon its ability to obtain and maintain intellectual property protection for its products and technologies.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applications based on RNAi technologies claim many different methods, compositions and processes relating to the
discovery, development, delivery and commercialization of RNAi therapeutics. Because this field is so new, very few of these patent applications have been fully processed by government patent offices around the world, and there is a great deal of
uncertainty about which patents will issue, when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference and opposition proceedings in various patent offices, relating to
patent rights in the RNAi field and that RXi may be a party to such proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will rely upon third parties for the manufacture of its clinical product candidates.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi does not have the facilities or expertise to manufacture supplies of any of its potential product candidates for
clinical trials. Accordingly, RXi will be dependent upon contract manufacturers for these supplies. RXi currently obtains supplies for RXi-109 from a single supplier, Agilent Technologies, Nucleic Acid Solutions Division. If for any reason RXi is
unable to obtain RXi-109 from this supplier, it would have to seek to obtain it from another major digonucleotide manufacturer. There is no assurance that RXi will be able to timely secure needed supply arrangements on satisfactory terms, or at all.
RXi&#146;s failure to secure these arrangements as needed could have a material adverse effect on its ability to complete the development of its product candidates or, if RXi obtains regulatory approval for its product candidates, to commercialize
them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially
commercialize some or all of its product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that RXi will be dependent upon collaborators,
partners, licensees, clinical research organizations and other third parties to support its discovery efforts, to formulate product candidates, to manufacture its product candidates and to conduct clinical trials for some or all of its product
candidates. We cannot guarantee that RXi will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all.
RXi&#146;s ability to successfully negotiate such agreements will depend on, among other things, potential partners&#146; evaluation of the superiority of RXi&#146;s technology over competing technologies, the quality of the preclinical and clinical
data that RXi has generated and the perceived risks specific to developing its product candidates. If RXi is unable to obtain or maintain these agreements, it may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals
for or commercialize its product candidates. RXi cannot necessarily control the amount or timing of resources that its contract partners will devote to RXi&#146;s research and development programs, product candidates or potential product candidates,
and we cannot guarantee that these parties will fulfill their obligations to RXi under these arrangements in a timely fashion. RXi may not be able to readily terminate any such agreements with contract partners even if such contract partners do not
fulfill their obligations to RXi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If RXi fails to attract, hire and retain qualified personnel, it may not be able to design, develop,
market or sell its products or successfully manage its business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi&#146;s business prospects are dependent on its
management team. The loss of Dr.&nbsp;Anastasia Khvorova, RXi&#146;s Senior Vice President and Chief Scientific Officer, or Dr.&nbsp;Pamela Pavco, RXi&#146;s Senior Vice President of Pharmaceutical Development, or any of its other key employees, or
RXi&#146;s inability to identify, attract, retain and integrate additional qualified key personnel, could make it difficult for RXi to manage its business successfully and achieve its business objectives. RXi will need to recruit and hire a Chief
Executive Officer to replace Mark J. Ahn, Ph.D., who currently serves on a part-time basis as RXi&#146;s President. RXi also is seeking a new Chief Financial Officer, as well as other key employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competition for skilled research, product development, regulatory and technical personnel is intense, and RXi may not be able to recruit
and retain the personnel it needs. The loss of the services of any key research, product development, regulatory and technical personnel, or RXi&#146;s inability to hire new personnel with the requisite skills, could restrict RXi&#146;s ability to
develop its product candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may not be able to obtain sufficient financing and may not be able to develop its product
candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the proceeds to be received in the RXi financing, we believe that RXi will have sufficient working
capital to fund its currently planned expenditures through 2012. However, in the future RXi may need to incur debt or issue equity in order to fund its planned expenditures, as well as to make acquisitions and other investments. There is no
assurance that debt or equity financing will be available to RXi on acceptable terms or at all. If RXi cannot, or is limited in the ability to, incur debt, issue equity or enter in strategic collaborations, RXi may be unable to fund discovery and
development of its product candidates, address gaps in its product offerings or improve its technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that
RXi will need to raise substantial amounts of money to fund a variety of future activities integral to the development of its business, which may include, but are not limited to, the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to conduct research and development to successfully develop its RNAi technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to obtain regulatory approval for its products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to file and prosecute patent applications and to defend and assess patents to protect its technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to retain qualified employees, particularly in light of intense competition for qualified scientists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to manufacture products itself or through third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to market its products, either through building its own sales and distribution capabilities or relying on third parties; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to acquire new technologies, licenses or products. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We cannot assure that any needed financing will be available to RXi on acceptable terms or at all. If RXi cannot obtain additional financing in the future, its operations may be restricted, and it may
ultimately be unable to continue to develop and potentially commercialize its product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future financing may be obtained by
RXi through, and future development efforts may be paid for by, RXi&#146;s issuance of debt or equity, which may have an adverse effect on Galena and RXi&#146;s other stockholders or may otherwise adversely affect RXi&#146;s business.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If RXi raises funds through the issuance of debt or equity, any debt securities or preferred stock issued will have
rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the
holders of common stock. In addition, if RXi raises funds through the issuance of additional equity, whether through private placements or public offerings, such an issuance would dilute Galena&#146;s ownership in RXi. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms of debt securities may also impose restrictions on RXi&#146;s operations, which may include limiting its ability to incur
additional indebtedness, to pay dividends on or repurchase its capital stock, or to make certain acquisitions or investments. In addition, RXi may be subject to covenants requiring it to satisfy certain financial tests and ratios, and its ability to
satisfy such covenants may be affected by events outside of RXi&#146;s control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect that RXi will incur significant research and development expenses, which may make it
difficult for RXi to attain profitability, and may lead to uncertainty about RXi&#146;s ability to continue as a going concern. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Substantial funds were expended to develop RXi&#146;s RNAi technologies, and additional substantial funds will be required for further research and development, including preclinical testing and clinical
trials of any product candidates, and to manufacture and market any products that are approved for commercial sale. Because the successful development of its products is uncertain, we are unable to precisely estimate the actual funds RXi will
require to develop and potentially commercialize them. In addition, RXi may not be able to generate enough revenue, even if it is able to commercialize any of its product candidates, to become profitable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If RXi is unable to achieve or sustain profitability or to secure additional financing, it may not be able to meet its obligations as
they come due, raising substantial doubts as to its ability to continue as a going concern. Any such inability to continue as a going concern may result in RXi&#146;s common stock holders losing their entire investment. There is no guarantee that
RXi will become profitable or secure additional financing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_6"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as described in any free writing prospectus that we may authorize to be provided to you, we currently intend to use the net
proceeds from the sale of our common stock in this offering for working capital and other general corporate purposes, including the Phase&nbsp;3 PRESENT study and our other clinical trials of our lead product candidate, NeuVax. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result,
our management will have broad discretion to allocate the net proceeds from this offering. Pending application of the net proceeds as described above, we expect to invest the net proceeds in short-term, interest-bearing, investment-grade securities
pursuant to our investment policy. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_7"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net tangible deficit as of September&nbsp;30, 2011 was $9 million, or $0.21 per share of common stock. Net tangible deficit, or net
tangible book value, per share is calculated by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of common stock outstanding. After
giving effect to the sale of our common stock in the aggregate amount of $10&nbsp;million at an assumed offering price of $0.94 per share, the closing sale price of our common stock on The NASDAQ Capital Market on February&nbsp;16, 2012, and after
deducting estimated offering commissions and expenses payable by us, we would have had a net tangible book value as of September&nbsp;30, 2011 $0.5 million, or $0.01 per share of common stock. This represents an immediate increase in the net
tangible book value of $0.22 per share to our existing stockholders and an immediate dilution in net tangible book value of $0.93 per share to new investors. The following table illustrates this per share dilution: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible deficit per share as of September&nbsp;30, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase per share attributable to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">As adjusted net tangible book per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above assumes for illustrative purposes that an aggregate of approximately
10,638,298&nbsp;million shares of our common stock are sold at a price of $0.94 per share, the last reported sale price of our common stock on The NASDAQ Capital Market on February&nbsp;16, 2012, for aggregate gross proceeds of $10&nbsp;million. The
actual shares sold in this offering, if any, will be sold from time to time at various prices. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of common stock shown above to be outstanding after this offering is
based on 42,985,453 shares outstanding as of September&nbsp;30, 2011 and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,451,569 shares of our common stock subject to options outstanding as of September&nbsp;30, 2011 having a weighted-average exercise price of $3.29 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,261,285 shares of our common stock reserved for issuance in connection with future awards under our 2007 Stock Incentive Plan;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">231,176 shares of our common stock reserved for sale under our employee stock purchase plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,050,642 shares of our common stock subject to outstanding warrants as of September&nbsp;30, 2011 having a weighted-average exercise price of $1.05
per share. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent our outstanding options and warrants are exercised, you may experience further
dilution. The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options or outstanding warrants to purchase shares of our common stock. The exercise of outstanding options and
warrants having an exercise price less than the offering price of the shares in this offering will further increase dilution to investors in this offering. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_8"></A>PRICE RANGE OF OUR COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common
stock is listed on The NASDAQ Capital Market under the symbol &#147;GALE.&#148; The following table shows the high and low per share sale prices of our common stock for the periods indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2010</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter (through February 16, 2012)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;16, 2012, the closing sale price of our common stock on The NASDAQ Capital Market was
$0.94. On February&nbsp;16, 2012, there were 706 holders of record of our common stock. The number of holders of record does not include shares held in &#147;street name&#148; through brokers. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_9"></A>DIVIDEND POLICY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have never declared or paid dividends on our common stock. We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying any
cash dividends in the foreseeable future. Any future determination to pay dividends on our common stock is subject to the discretion of our board of directors and will depend upon various factors, including, without limitation, our results of
operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_11"></A>DESCRIPTION OF COMMON STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following summary of the terms of our common stock is subject to and qualified in its entirety by reference to our charter and
by-laws, copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information,&#148; below, for directions on obtaining these documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;16, 2012, we were authorized to issue 125,000,000 shares of common stock and had 47,524,094 shares of common stock
outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The holders of our common stock are entitled to one vote for each share on all matters voted on by stockholders, including elections of directors, and, except as otherwise required by law or provided in
any resolution adopted by our board with respect to any series of preferred stock, the holders of such shares possess all voting power. Our certificate of incorporation does not provide for cumulative voting in the election of directors. Subject to
any preferential rights of any outstanding series of our preferred stock created by our board from time to time, the holders of common stock are entitled to such dividends as may be declared from time to time by our board from funds available
therefore and upon liquidation are entitled to receive pro rata all assets available for distribution to such holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
common stock does not entitle the holders to any preemptive rights. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred
stock which we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The NASDAQ Capital Market </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;GALE.&#148; </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_10"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a Controlled Equity Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> sales agreement with Cantor Fitzgerald&nbsp;&amp; Co., or &#147;<B>Cantor</B>,&#148; under which we may issue and sell
our common stock having aggregate sales proceeds of up to $10&nbsp;million from time to time through Cantor acting as agent. The form of the sales agreement will be filed as an exhibit to a report filed under the Exchange Act and incorporated by
reference in this prospectus supplement. The sales, if any, of shares made under the sales agreement will be made on The NASDAQ Capital Market by means of ordinary brokers&#146; transactions at market prices, in block transactions or as otherwise
agreed by Cantor and us. We may instruct Cantor not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor may suspend the offering of common stock upon notice and subject to other
conditions. As an agent, Cantor will not engage in any transactions that stabilize the price of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay
Cantor commissions for its services in acting as agent in the sale of common stock. Cantor will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold. We have also agreed to reimburse Cantor for the
fees and disbursements of its counsel, payable upon execution of the sales agreement, in an amount not to exceed $50,000. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor under the
terms of the sales agreement, will be approximately $150,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement for sales of common stock will occur on the third business day following the date
on which any sales are made, or on some other date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow,
trust or similar arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cantor will use its commercially reasonable efforts, consistent with its sales and trading
practices, to solicit offers to purchase the common stock shares under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, Cantor may, and will with respect to
sales effected in an &#147;at the market offering,&#148; be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor may be deemed to be underwriting commissions or discounts. We have agreed to
provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to reimburse Cantor for certain other specified expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the sales agreement, we may also sell our common stock to Cantor, as principal for its own account, at a price
negotiated at the time of sale. If we sell shares to Cantor in this manner, we will enter into a separate agreement setting forth the terms of such transaction, and we will describe the agreement in a separate prospectus supplement or pricing
supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering pursuant to the sales agreement will terminate upon the earlier of (i)&nbsp;the sale of all common
shares subject to the agreement, or (ii)&nbsp;termination of the sales agreement as permitted therein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cantor and its
affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M,
Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Cantor, and Cantor may distribute this prospectus supplement and the
accompanying prospectus electronically. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;6, 2011, we entered into separate exchange agreements with several
institutional holders of outstanding warrants to purchase shares of our common stock. Under the exchange agreements, these institutional holders were granted the right to participate, pro-rata, in up to 30% of the total offering amount of any sales
by us of our equity securities. These participation rights expire on December&nbsp;6, 2012. As a result, unless the institutional investors waive their rights under the exchange agreements, we will be required to offer such institutional investors
the right to participate, pro rata, in up to 30% of any of the common stock sold in this offering prior to December&nbsp;6, 2012. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_12"></A>LEGAL MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">TroyGould PC, Los Angeles,
California, has rendered an opinion with respect to the validity of the shares of common stock offered by this prospectus supplement. Sanford J. Hillsberg, the Chairman of our board of directors, is an attorney with TroyGould PC. TroyGould PC owned
or was entitled to receive a total of 123,491 shares of our common stock as of February&nbsp;16, 2012. Cantor is being represented in connection with this offering by Reed Smith LLP, New York, New York. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_13"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The financial statements of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) as of December&nbsp;31, 2010 and 2009 and for the years then ended and for the cumulative period from
inception (January 1, 2003) through December&nbsp;31, 2010, incorporated in this prospectus supplement by reference to the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2010, have been so incorporated in
reliance on the report of BDO USA, an independent registered public accounting firm, upon the authority of said firm as experts in auditing and accounting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-36
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements of Apthera, Inc. as of December&nbsp;31, 2010 and 2009 and for the
years then ended and for the period from inception (July 20, 2005) to December&nbsp;31, 2010, incorporated in this prospectus supplement by reference to the Company&#146;s Current Report on Form&nbsp;8-K filed with the SEC on April&nbsp;14, 2011,
have been so incorporated in reliance on the report of Lohman Company PLLC, independent certified public accountants, upon the authority of said firm as experts in auditing and accounting. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. You may
also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C., 20549. You may also obtain copies of these documents at prescribed rates by writing to the SEC. Please
call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus
supplement and the accompany prospectus are only part of the registration statement, and therefore omit certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that are
excluded from this prospectus supplement and the accompanying prospectus, and you should refer to the applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may inspect a copy of
the registration statement, including the exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed by the SEC. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suptoc303715_15"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information we have filed with the SEC. The
information we incorporate by reference into this prospectus supplement is an important part of this prospectus. Any statement in a document we incorporate by reference into this prospectus supplement or the accompanying prospectus will be
considered to be modified or superseded to the extent a statement contained in this prospectus supplement or any other subsequently filed document that is incorporated by reference into this prospectus supplement modifies or supersedes that
statement. The modified or superseded statement will not be considered to be a part of this prospectus supplement or the accompanying prospectus, as applicable, except as modified or superseded. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We incorporate by reference into this prospectus supplement the information contained in the documents listed below, which is considered
to be a part of this prospectus supplement: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2010 filed with the SEC on April&nbsp;15, 2011, as amended by our Form 10-K/A filed
with the SEC on May&nbsp;2, 2011; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2011 filed with the SEC on May&nbsp;16, 2011; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2011 filed with the SEC on August&nbsp;15, 2011, as amended by our
Form&nbsp;10-Q/A filed with the SEC on October&nbsp;28, 2011; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-37
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2011 filed with the SEC on November&nbsp;14, 2011;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Current Reports on Form 8-K and amended Current Reports on Form 8-K/A filed with the SEC on March&nbsp;1, 2011, April&nbsp;5,
2011,&nbsp;April&nbsp;14, 2011,&nbsp;April&nbsp;15, 2011,&nbsp;April&nbsp;21, 2011,&nbsp;April&nbsp;26, 2011,&nbsp;May&nbsp;4, 2011,&nbsp;May&nbsp;17, 2011,&nbsp;June&nbsp;10, 2011, July&nbsp;14, 2011, July&nbsp;19, 2011, September&nbsp;21,
2011,&nbsp;September&nbsp;26, 2011,&nbsp;September&nbsp;27, 2011, September&nbsp;29, 2011, October&nbsp;21, 2011, October&nbsp;28, 2011, November&nbsp;18, 2011, December&nbsp;6, 2011 and January&nbsp;23, 2012, respectively (not including any
information furnished under Items 2.02 or 7.01 of Form 8-K, including the related exhibits, which information is not incorporated by reference herein); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Schedules 14A filed with the SEC on May&nbsp;20, 2011 and May&nbsp;31, 2011, respectively; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the description of our common stock and related rights contained in our registration statement on Form&nbsp;8-A (File No.&nbsp;001-33958), including
any amendment or report filed for the purpose of updating such description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also incorporate by
reference all documents filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination of this offering; provided, however, that we are not incorporating any
information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on Form 8-K we may subsequently file. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statements made in this prospectus supplement or the accompanying prospectus or in any document incorporated by reference in this
prospectus supplement or the accompanying prospectus as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is made to the copy of such contract or other
document filed as an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">310 N. State Street, Suite 208 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake Oswego, Oregon 97034 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attention: Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: (855)&nbsp;855-4523 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Copies of these filings are also available, without charge, through the &#147;Investor Relations&#148; section of our website
(www.galenabiopharma.com) as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our website is not a part of, nor incorporated by reference in, this prospectus supplement or the accompanying
prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-38
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PROSPECTUS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RXI PHARMACEUTICALS CORPORATION </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g77o20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$75,000,000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Common Stock </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred Stock </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt
Securities </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may offer to the public from time to time in one or more series or issuances: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">shares of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">shares of preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warrants to purchase shares of our common stock, preferred stock and/or debt securities; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">debt securities consisting of debentures, notes or other evidences of indebtedness. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific
terms of the securities offered in a supplement to this prospectus. Such a prospectus supplement may also add, update or change information contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless
accompanied by the applicable prospectus supplement. You should read both this prospectus and the applicable prospectus supplement together with additional information described under the heading &#147;Where You Can Find More Information&#148;
before you make your investment decision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will sell the securities directly to our stockholders or to purchasers or
through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of the securities, the applicable prospectus supplement will provide the names of the
agents or underwriters and any applicable fees, commissions or discounts. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General Information </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is traded on the Nasdaq Capital Market under the symbol &#147;RXII.&#148; On May&nbsp;19, 2010, the closing price of our
common stock was $4.17. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;22, 2010, the aggregate market value of our outstanding common stock held by
non-affiliates was approximately $84,447,354 based on 16,241,125 shares of outstanding common stock, of which approximately 10,412,744 shares are held by non-affiliates, and a per share price of $8.11 based on the closing sale price of our common
stock on March&nbsp;22, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investing in our securities involves risks. Please see &#147;Risk Factors&#148; on page 5
and other information included and incorporated by reference in this prospectus, and in any applicable prospectus supplement, for a discussion of the factors you should consider carefully before deciding to purchase our securities.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B> </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of this
prospectus is May&nbsp;28, 2010 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_1">About this Prospectus </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_2">The Company</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_3">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_4">Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_6">Plan of Distribution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_7">Description of Common Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_8">Description of Preferred Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_9">Description of Warrants</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_10">Description of Debt Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_11">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_12">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_13">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc303715_14">Incorporation of Certain Documents by Reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_1"></A><A NAME="suptoc303715_20"></A>ABOUT THIS PROSPECTUS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities described in this prospectus are part of a registration statement that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process. Under this shelf registration process, we may offer to sell any combination of the securities described in this prospectus in one or more offerings up to a
total dollar amount of $75,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities under this shelf registration, we will provide a prospectus supplement that will contain
specific information about the terms of such offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement, including all
documents incorporated herein by reference, together with additional information described under &#147;Where You Can Find More Information&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus and any
accompanying prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement. This prospectus and the accompanying prospectus
supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any accompanying prospectus supplement constitute an
offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus
and any accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document
incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless the context otherwise requires, &#147;RXi,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar names refer to RXi Pharmaceuticals Corporation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_2"></A><A NAME="suptoc303715_21"></A>THE COMPANY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Business </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were
incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April&nbsp;3, 2006, changed our name to RXi Pharmaceuticals Corporation on November&nbsp;28, 2006, and began operations in January 2007. We are a discovery-stage biopharmaceutical company
pursuing proprietary therapeutics based on RNA interference, or &#147;RNAi&#148;, a naturally occurring cellular mechanism that has the potential to effectively and selectively interfere with, or &#147;silence&#148;, expression of targeted
disease-associated genes. It is believed that this specific silencing can be used to potentially treat human diseases by &#147;turning off&#148; genes that lead to disease. While no therapeutic RNAi products have yet been approved, there has been
significant growth in the field of RNAi development and potential therapeutic applications in this field. This growth is driven by the potential ability to use RNAi to rapidly develop lead compounds that specifically and selectively inhibit a target
gene, many of which are undruggable by other modalities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By utilizing our expertise in RNAi and the comprehensive RNAi
therapeutic platform that we have established, we believe we will be able to discover and develop lead compounds and progress them into and through clinical development for potential commercialization more efficiently than traditional drug
development approaches. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our proprietary therapeutic platform is comprised of two main components: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novel RNAi Compounds,</B> referred to as rxRNA&#153; compounds, that are distinct from, and we believe convey significant advantages over classic
siRNA (conventionally-designed &#147;small interfering RNA&#148; compounds), and offer many of the properties that we believe are important to the clinical development of RNAi-based drugs. We have developed a number of unique forms of rxRNA
compounds, all of which have been shown to be highly potent both <I>in vitro </I>and <I>in vivo. </I>These RNAi compounds include rxRNAoriTM, rxRNAsoloTM and <I>sd-rxRNA</I>TM, or &#147;self delivering&#148; RNA. Based on our research we believe
that these different, novel siRNA configurations have various advantages for therapeutic use. These advantages include high potency, increased resistance to nucleases and off-target effects, and, in the case of the <I>sd-rxRNA</I> compounds, access
to cells and tissues with no additional formulation required. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Advanced Delivery Technologies,</B> may enable the delivery of our rxRNA compounds to treat a variety of acute and chronic diseases using both local
and systemic approaches, potentially providing a competitive advantage in the development of many RNAi therapeutic compounds. RXi&#146;s suite of delivery technologies is comprised of delivery vehicles, which can be combined with various rxRNA
compounds, as well as <I>sd-rxRNA</I> compounds, which are chemically modified and have the unique property of entering cells and tissues to effect silencing without the need for any additional delivery vehicle. This suite of delivery technologies
has broad applications for multiple therapeutic areas targeting both local and systemic applications. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I>Local Applications. </I>An area of application of the RXi therapeutic platform which uses rxRNA compounds to target genes expressed in
tissues that can be silenced by direct, local delivery. The numerous diseases common to tissues accessible by local delivery represent significant unmet medical needs and large market opportunities. Most of our initial targets are validated gene
targets relevant in important biological pathways and are implicated in multiple diseases enabling us to leverage these targets and associated compounds across a broad array of therapeutic areas. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I>Systemic Applications. </I>RXi has active internal efforts to advance the therapeutic platform to optimize robust systemic delivery to
various tissues and organs of the body. In some cases, such as in targeting a treatment to the liver, the optimal route of administration is by systemic delivery. Efforts to improve the systemic delivery of RNAi compounds are currently ongoing, and
these efforts are supported by internal activities targeting an undisclosed gene thought to be responsible for elevated cholesterol. We have also in-licensed intellectual property developed by Dr.&nbsp;Michael Czech (one of our scientific
co-founders and scientific advisory board members) on genes that appear to be important regulators of metabolism, and continue to develop and validate this approach with these other potential target genes. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use our RNAi therapeutic platform and our expertise in RNAi to identify lead
compounds against multiple target genes, and advance them towards pre-clinical and clinical development in therapeutic areas that address broad unmet medical needs, in both acute and chronic settings. There are many well-studied genes that have been
associated with numerous diseases but have been difficult to target with conventional medicinal chemistry or traditional modalities involving both large and small molecules. We believe RNAi technology may play an important role in targeting these
genes and potentially treating the related diseases and disorders. We plan on pursuing disease areas with the goal of creating multiple clinical development program opportunities, either through independent internal efforts at the company or in
conjunction with partners through various collaborations and partnerships with pharmaceutical or biotechnology companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
believe that we have created and established a strong intellectual property portfolio. We have secured exclusive and nonexclusive licenses from both academic institutions and commercial entities to certain issued and pending patents and patent
applications covering RNAi technologies in the following three categories: (i)&nbsp;therapeutic targets, (ii)&nbsp;chemistry and configurations of RNAi compounds and (iii)&nbsp;formulation and delivery of RNAi compounds within the body. We have also
filed patents based on our internal discoveries in the each of the areas mentioned above, which enables us to further strengthen our broad intellectual property portfolio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our founding scientists recognized that the key to therapeutic success with RNAi lies in delivering intact RNAi compounds to the target tissue and the interior of the target cells. To accomplish this, we
are developing a comprehensive platform that includes local, systemic and oral delivery approaches that give rise to target silencing after RNAi compound administration. We work with chemically synthesized RNAi compounds that we believe are
optimized for stability and efficacy. We endow these compounds with favorable delivery profiles and properties either by covalent chemical modification or combination with appropriate formulations to achieve optimal delivery to specific target
tissues. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Local Delivery </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The local delivery method may avoid some hurdles associated with systemic approaches such as rapid clearance from the bloodstream and inefficient extravasation (e.g. crossing the endothelial barrier from
the blood stream). The <I>sd-rxRNA</I> molecules have unique properties which improve tissue uptake in local delivery models. We have studied <I>sd-rxRNA</I> molecules in a rat model of dermal delivery. Direct application of <I>sd-rxRNA</I> with no
additional delivery vehicle to compromised skin (incision introduced) demonstrates that target gene silencing can be measured after topical delivery. We have also injected <I>sd-rxRNA</I> to the skin layers and observed efficient uptake and target
gene silencing. The dose levels required for these direct injection methods are small and suitable for clinical development suggesting that local delivery indications will be very accessible with the <I>sd-rxRNA</I> technology platform. Target
tissues that are potentially accessible for local delivery using rxRNA compounds include lung, eye, skin, CNS, mucosal tissues, sites of inflammation, and tumors (locally). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Systemic Delivery </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Systemic delivery occurs when a drug accesses the tissue
of interest through the circulatory system. In some cases, such as in targeting a treatment to the liver, the optimal route of delivery may be by a systemic route. We have a portfolio of systemic delivery solutions utilizing our RNAi therapeutic
platforms. One novel approach involves the use of sd-rxRNA compounds. The self-delivering technology introduces properties required for <I>in vivo</I> efficacy such as cell and tissue penetration and improved blood clearance and distribution
properties. Systemic delivery of these compounds to mice has resulted in gene specific inhibition at 50 mg/kg doses with no additional delivery vehicle required. In addition, we have developed novel nanotransporter formulations to aid in transport
of RNAi compounds to both liver and various other target tissues in the body. These nanotransporters are chemically synthesized molecules that form nanometer-sized particles when mixed with RNAi compounds and alter the clearance, distribution and
tissue penetration properties of the RNAi compounds. Delivery of RNAi compounds to the liver might be critical for the treatment of many diseases and using rxRNA in conjunction with such delivery vehicles has enabled us to demonstrate gene specific
inhibition at low doses (1 mg/kg) in a mouse model after intravenous, systemic delivery. Target tissues that are potentially accessible using rxRNA compounds by systemic delivery approach include liver, lung, adipocytes, cardiomyocytes, bone marrow,
sites of inflammation, tumors, vascular endothelium, and kidney. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oral Delivery </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Most RNAi therapeutic products being developed today require recurring intravenous injections or other forms of administration which are not patient friendly. To address the desire for RNAi therapeutics
with improved modes of administration, we are testing a novel formulation technology, Glucan Encapsulated RNAi Particles (GeRPs) that may allow our rxRNA compounds to be incorporated into orally administered pills. In research to date, the GeRP
delivery system appears to be 5 to 250 times more potent than previous methods used for systemic delivery of RNAi therapeutics by intravenous injection. The GeRP system is very flexible and can either be used to administer a single RNAi compound,
multiple RNAi compounds, or could potentially allow co-delivery of RNAi, DNA, protein and small molecule combinations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Therapeutic
Programs and Markets </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By utilizing our expertise in RNAi compound design and delivery, we intend to identify lead compounds
to both tractable and intractable targets implicated in diseases that address broad unmet medical needs in both acute and chronic settings. The broad applicability of our RNAi therapeutic platform has the potential to enable delivery to various
tissues in both a local setting as well as in a systemic setting. Target tissues that are potentially accessible using our rxRNA compounds in the context of a local delivery approach include lung, eye, skin, CNS, mucosal, sites of inflammation, and
tumors (locally). Similarly, target tissues that are potentially accessible using our rxRNA compounds in the context of a systemic delivery approach include liver, lung, adipocytes, cardiomyocytes, bone marrow, sites of inflammation, tumors,
vascular endothelium, and kidney. We will continue to focus our efforts selecting targets to prosecute internally, and as we identify relevant compounds, we intend to begin preclinical development in specific areas as appropriate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal executive offices are located at 60 Prescott Street, Worcester, MA 01605, and our phone number is (508)&nbsp;767-3861.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_3"></A><A NAME="suptoc303715_22"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our securities involves risk. You should consider the risks, uncertainties and assumptions discussed under the heading
&#147;Risk Factors&#148; in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2009 filed on March&nbsp;31, 2010 with the SEC, which is incorporated herein by reference, and may be amended, supplemented or superseded from
time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
affect our operations. If any of these risks were to occur, our business, financial condition, and results of operations could be severely harmed. This could cause the trading price of our common stock to decline, and you could lose all or part of
your investment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, any prospectus supplement applicable to each offering of our securities will contain a
discussion of the risks applicable to such an investment in us. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#147;Risk Factors&#148; in the applicable
prospectus supplement, together with all of the other information contained or incorporated by reference in such prospectus supplement or appearing or incorporated by reference in this prospectus. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_4"></A><A NAME="suptoc303715_23"></A>FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus, any prospectus supplement and the other documents we have filed with the SEC that are incorporated herein by reference
contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of
RXi to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of
financing needs, revenue, expenses, earnings or losses from operations, or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning product research, development and
commercialization plans and timelines; any statements regarding safety and efficacy of product candidates; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. In addition, forward-looking
statements may contain the words &#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will be,&#148; &#147;will continue,&#148; &#147;will
result,&#148; &#147;seek,&#148; &#147;could,&#148; &#147;may,&#148; &#147;might,&#148; or any variations of such words or other words with similar meanings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this prospectus, any supplements to this prospectus and the documents that we reference
in this prospectus with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we do not undertake any obligation to update or revise any forward-looking statements contained in
this prospectus and any supplements to this prospectus, whether as a result of new information, future events or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_5"></A><A NAME="suptoc303715_24"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities
covered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercial expenditures, acquisitions of new technologies or
businesses, and investments. Additional information on the use of net proceeds from the sale of securities covered by this prospectus may be set forth in any prospectus supplement relating to a specific offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_6"></A><A NAME="suptoc303715_25"></A>PLAN OF DISTRIBUTION
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may sell the securities in any of the ways described below or in any combination: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>to or through underwriters or dealers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>through one or more agents; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>directly to purchasers or to a single purchaser. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The distribution of the securities may be effected from time to time in one or more transactions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>at a fixed price, or prices, which may be changed from time to time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>at market prices prevailing at the time of sale; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>at prices related to such prevailing market prices; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>at negotiated prices. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities, including the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased by each of them;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>the public offering price of the securities and the proceeds to us and any discounts, commissions or concessions allowed or reallowed or paid to
dealers; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>any securities exchanges on which the securities may be listed. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. Under no
circumstances will any fees, discounts, commissions or concessions received by any FINRA member or independent broker-dealer exceed eight percent of the gross proceeds to us in any offering in the United States of the securities covered by the
prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only the agents or underwriters named in each prospectus supplement are agents or underwriters in connection with
the securities being offered thereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may authorize underwriters, dealers or other persons acting as our agents to solicit
offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in each applicable prospectus supplement. Each contract will be for an amount not less than,
and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions with whom the contracts, when authorized, may be made
include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will be
subject only to those conditions set forth in each applicable prospectus supplement, and each prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agents, underwriters and other third parties described above may be entitled to
indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933, or to contribution from us with respect to payments which the agents, underwriters or other third parties may be required to make in
respect thereof. Agents, underwriters and such other third parties may be customers of, engage in transactions with, or perform services for us in the ordinary course of business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One or more firms, referred to as &#147;remarketing firms,&#148; may also offer or sell the securities, if a prospectus supplement so
indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as our agents. These remarketing firms will offer or sell the securities in accordance with the terms of
the securities. Each prospectus supplement will identify and describe any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#146;s compensation. Remarketing firms may be deemed to be underwriters
in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933,
and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain
underwriters may use this prospectus and any accompanying prospectus supplement for offers and sales related to market-making transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will
be made at prices related to prevailing market prices at the time of sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities may be new issues of securities and
may have no established trading market. The securities may or may not be listed on a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time
without notice. We can make no assurance as to the liquidity of, or the existence of trading markets for, any of the securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain persons participating in an offering may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with rules and regulations under the
Securities Exchange Act of 1934. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a short covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters
may discontinue any of the activities at any time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_7"></A><A NAME="suptoc303715_26"></A>DESCRIPTION OF COMMON STOCK
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following summary of the terms of our common stock is subject to and qualified in its entirety by reference to our
charter and by-laws, copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information&#148; below for directions on obtaining these documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of May&nbsp;21, 2010, we are authorized to issue 50,000,000 shares of common stock. As of May&nbsp;21, 2010, we had 18,372,759 shares
of common stock outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The holders of our common stock are entitled to one vote for each share on all matters voted on by stockholders, including elections of directors, and, except as otherwise required by law or provided in
any resolution adopted by our board with respect to any series of preferred stock, the holders of such shares possess all voting power. Our certificate of incorporation does not provide for cumulative voting in the election of directors. Subject to
any preferential rights of any outstanding series of our preferred stock created by our board from time to time, the holders of common stock are entitled to such dividends as may be declared from time to time by our board from funds available
therefore and upon liquidation are entitled to receive pro rata all assets available for distribution to such holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
holders of our common stock, other than CytRx Corporation (&#147;CytRx&#148;), have no preemptive rights. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders
of shares of any series of preferred stock which we may designate and issue in the future. Under our agreement with CytRx, with some exceptions, CytRx has preemptive rights to acquire a portion of any new securities sold or issued by us so as to
maintain their percentage beneficial ownership of us at the time of such sale or issuance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holders of our common stock,
other than CytRx, have no redemption rights. Pursuant to a stock redemption agreement dated March&nbsp;22, 2010 between us and CytRx, we are required to use 25% of the proceeds from the exercise of certain warrants that we issued in a March 2010
registered direct offering to repurchase from CytRx a number of shares of common stock held by CytRx equal to 25% of shares issued upon the exercise of such warrants. We issued warrants to purchase an aggregate of 540,000 shares of our common stock
in the March 2010 registered direct offering. We estimate that we will be required to redeem 135,000 shares of common stock from CytRx for an aggregate price of $810,000 if all of the warrants issued in the March 2010 registered direct offering are
exercised. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nasdaq Capital Market </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed for quotation on the Nasdaq Capital Market under the symbol &#147;RXII.&#148; </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_8"></A><A NAME="suptoc303715_27"></A>DESCRIPTION OF PREFERRED STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are authorized to issue up to 5,000,000 shares of preferred stock, par value $0.0001 per share. Our board of directors, without
further action by the holders of our common stock, may issue shares of our preferred stock. Our board is vested with the authority to fix by resolution the designations, preferences and relative, participating, optional or other special rights, and
such qualifications, limitations or restrictions thereof, including, without limitation, redemption rights, dividend rights, liquidation preferences and conversion or exchange rights of any class or series of preferred stock, and to fix the number
of classes or series of preferred stock, the number of shares constituting any such class or series and the voting powers for each class or series. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The authority possessed by our board to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control of RXi through a merger, tender offer, proxy contest or
otherwise by making such attempts more difficult or more costly. Our board may issue preferred stock with voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of common stock. There are no
current agreements or understandings with respect to the issuance of preferred stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we offer a specific class or series of preferred stock under this prospectus, we will
describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title and stated value; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares offered, the liquidation preference per share and the purchase price; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the procedures for any auction and remarketing, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the provisions for a sinking fund, if any; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the provisions for redemption, if applicable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any listing of the preferred stock on any securities exchange or market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated) and
conversion period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated) and
exchange period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voting rights, if any, of the preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs
of the Company; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as
to dividend rights and rights upon liquidation, dissolution or winding up of the Company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preferred
stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and
Registrar </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable
prospectus supplement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_9"></A><A NAME="suptoc303715_28"></A>DESCRIPTION OF WARRANTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of May&nbsp;21, 2010, we had 2,100,642 warrants outstanding to purchase shares of our common stock. We may issue warrants to purchase
shares of our common stock, preferred stock and/or debt securities in one or more series together with other securities or separately, as described in each applicable prospectus supplement. Below is a description of certain general terms and
provisions of the warrants that we may offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the
warrants: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the specific designation and aggregate number of, and the price at which we will issue, the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the currency or currency units in which the offering price, if any, and the exercise price are payable; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation, amount and terms of the securities purchasable upon exercise of the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and a
description of that class or series of our preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon exercise, and a description of that
series of debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if the warrants may not be
continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms,
although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any applicable material U.S. federal income tax consequences; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other
agents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if applicable, the date from and after which the warrants and the common stock, preferred stock and/or debt securities will be separately transferable;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information with respect to book-entry procedures, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the anti-dilution provisions of the warrants, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any redemption or call provisions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the warrants are to be sold separately or with other securities as parts of units; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_10"></A><A NAME="suptoc303715_29"></A>DESCRIPTION OF DEBT SECURITIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be entered into between us and the trustee identified in the applicable
prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have previously
filed a copy of the form of indenture as an exhibit to a previous SEC filing. Please refer to &#147;Where You Can Find More Information&#148; below for directions on obtaining this document. The indenture will be subject to and governed by the terms
of the Trust Indenture Act of 1939. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may offer under this prospectus up to an aggregate principal amount of $75,000,000 in
debt securities, or if debt securities are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold for an initial public offering price of up to $75,000,000. Unless otherwise
specified in the applicable prospectus supplement, the debt securities will represent direct, unsecured obligations of RXi and will rank equally with all of our other unsecured indebtedness. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the
detailed provisions of the indenture. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will describe the particular terms of each series of debt securities
in a prospectus supplement relating to that series, which we will file with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prospectus supplement will set
forth, to the extent required, the following terms of the debt securities in respect of which the prospectus supplement is delivered: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title of the series; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the aggregate principal amount; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any limit on the aggregate principal amount; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date or dates on which principal is payable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date or dates from which interest, if any, will be payable and any regular record date for the interest payable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the place or places where principal and, if applicable, premium and interest, is payable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any integral multiple of that number;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities are to be issuable in the form of certificated securities (as described below) or global securities (as described below);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal amount of the
debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the currency of denomination; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest, will be made;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies or currency units
other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency or currencies or by
reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the provisions, if any, relating to any collateral provided for such debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any events of default, if not otherwise described below under &#147;Events of Default&#148;; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to other indebtedness of the Company.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue discount debt securities that provide for an amount less than the stated principal amount to
be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt securities or debt
securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do,
we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exchange and/or Conversion Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities which can be exchanged for or converted into shares of our common stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the prospectus
supplement relating to these debt securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer and Exchange </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities that will be represented by either: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;book-entry securities,&#148; which means that there will be one or more global securities registered in the name of a depositary or a nominee of
a depositary; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;certificated securities,&#148; which means that they will be represented by a certificate issued in definitive registered form.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will specify in the prospectus supplement applicable to a particular offering whether the debt
securities offered will be book-entry or certificated securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certificated Debt Securities </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you hold certificated debt securities, you may transfer or exchange such debt securities at the trustee&#146;s office or at the paying
agent&#146;s office or agency in accordance with the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or
other governmental charge payable in connection with such transfer or exchange. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may effect the transfer of certificated debt securities and of the right to receive the
principal of, premium, and/or interest, if any, on the certificated debt securities only by surrendering the certificate representing the certificated debt securities and having us or the trustee issue a new certificate to the new holder.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Global Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of the depositary for the global securities or the nominee of
the depositary, and the global securities will be delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued
in global form. None of RXi, the trustee, any payment agent or the security registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt
security or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>No Protection in the
Event of Change of Control </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indenture does not have any covenants or other provisions providing for a put or increased
interest or otherwise that would afford holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control of RXi, or a highly leveraged transaction. If we offer any covenants or provisions of
this type with respect to any debt securities covered by this prospectus, we will describe them in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Covenants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit of any covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of
indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidation, Merger and Sale of Assets </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have agreed in the indenture that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety to any person,
unless: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the person formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred,
sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District of Columbia or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and, if we are not the surviving
person, the surviving person has expressly assumed all of our obligations, including the payment of the principal of and, premium, if any, and interest on the debt securities and the performance of the other covenants under the indenture; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">immediately before and immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of time or
both, would become an event of default, has occurred and is continuing under the indenture. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Events of Default
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise specified in the applicable prospectus supplement, the following events will be events of default under
the indenture with respect to debt securities of any series: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we fail to pay any principal or premium, if any, when it becomes due; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we fail to pay any interest within 30 days after it becomes due; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we fail to observe or perform any other covenant in the debt securities or the indenture for 60 days after written notice specifying the failure from
the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of that series; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain events involving bankruptcy, insolvency or reorganization of RXi or any of our significant subsidiaries. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal of or
premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs,
and is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount,
plus the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based
on such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all lawful interest on overdue interest and overdue principal has been paid; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rescission would not conflict with any judgment or decree. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if the acceleration occurs at any time when we have outstanding indebtedness which is senior to the debt securities, the
payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment
under the terms prescribed in the instruments evidencing the senior indebtedness and the indenture. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an event of default
resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or
other act on the part of the trustee or the holders of the debt securities of that series. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holders of a majority in
principal amount of the outstanding debt securities of a series will have the right to waive any existing default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of
conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the indenture. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or for any
remedy under the indenture, unless: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holder gives to the trustee written notice of a continuing event of default; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written request and offer
reasonable indemnity to the trustee to institute a proceeding as trustee; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the trustee fails to institute a proceeding within 60 days after such request; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give the trustee a direction
inconsistent with such request during such 60-day period. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These limitations do not, however, apply to a
suit instituted for payment on debt securities of any series on or after the due dates expressed in the debt securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Modification and
Waiver </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we and the trustee may, without the consent of holders of the debt securities of one or more
series, amend the indenture or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to provide that the surviving entity following a change of control of RXi permitted under the indenture will assume all of our obligations under the
indenture and debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to provide for certificated debt securities in addition to uncertificated debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with any requirements of the SEC under the Trust Indenture Act of 1939; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights of any holder; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to appoint a successor trustee under the indenture with respect to one or more series. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding series
of debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each
holder affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt securities in order to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt security;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the rate of or change the time for payment of interest or reduce the amount of or postpone the date for payment of sinking fund or analogous
obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the principal of or change the stated maturity of the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make any debt security payable in money other than that stated in the debt security; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">change the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which no such redemption
may be made; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">waive a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">waive a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities; or
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">take any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by
following certain procedures described in the indenture. These procedures will allow us either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to defease and be discharged from any and all of our obligations with respect to any debt securities except for the following obligations (which
discharge is referred to as &#147;legal defeasance&#148;): </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to register the transfer or exchange of such debt securities; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to replace temporary or mutilated, destroyed, lost or stolen debt securities; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to compensate and indemnify the trustee; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as well as any additional
covenants which may be contained in the applicable supplemental indenture (which release is referred to as &#147;covenant defeasance&#148;). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to exercise either defeasance option, we must deposit with the trustee or other qualifying trustee, in trust for that purpose: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">money; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) which through the scheduled payment of
principal and interest in accordance with their terms will provide money; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion of a
nationally-recognized firm of independent accountants to provide money; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">which in each case specified above, provides a
sufficient amount to pay the principal of, premium, if any, and interest, if any, on the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, defeasance may be effected only if, among other things: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture, stating that as a
result of the defeasance neither the trust nor the trustee will be required to register as an investment company under the Investment Company Act of 1940; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there has been published by,
the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities will not recognize
income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and at the same times
as would have been the case if legal defeasance had not occurred; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding debt securities
will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case
if covenant defeasance had not occurred; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain other conditions described in the indenture are satisfied. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance
of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign
Government Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration. We will, however, remain liable in respect of these payments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;U.S. Government Obligations&#148; as used in the above discussion means securities which are direct obligations of or
non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;Foreign Government Obligations&#148; as used in the above discussion means, with respect to debt securities of any series
that are denominated in a currency other than U.S. dollars (1)&nbsp;direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged or
(2)&nbsp;obligations of a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which in
either case under clauses (1)&nbsp;or (2), are not callable or redeemable at the option of the issuer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Regarding the Trustee
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the
applicable debt securities. You should note that if the trustee becomes a creditor of RXi, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain
property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires
any &#147;conflicting interest&#148; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceeding for exercising any remedy available
to the trustee. If an event of default occurs and is continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or her own affairs. Subject to that provision,
the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee reasonable indemnity or security. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_11"></A><A NAME="suptoc303715_30"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the issuance of the securities offered hereby will be passed upon for us by Ropes&nbsp;&amp; Gray LLP, Boston,
Massachusetts. The validity of any securities will be passed upon for any underwriters or agents by counsel that we will name in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_12"></A><A NAME="suptoc303715_31"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
financial statements as of December&nbsp;31, 2009 and 2008 and for the years then ended and for the cumulative period from inception (January 1, 2003) through December&nbsp;31, 2009 incorporated by reference in this Prospectus have been so
incorporated in reliance on the report of BDO Seidman, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_13"></A><A NAME="suptoc303715_32"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed a registration statement on Form S-3 with the SEC for the securities we are offering by this prospectus. This prospectus
does not include all of the information contained in the registration statement. You should refer to the registration statement and its exhibits for additional information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are required to file annual and quarterly reports, special reports, proxy statements, and other information with the SEC. We make these documents publicly available, free of charge, on our website at
www.rxipharma.com as soon as reasonably practicable after filing such documents with the SEC. You can read our SEC filings, including the registration statement, on the SEC&#146;s website at http://www.sec.gov. You also may read and copy any
document we file with the SEC at its public reference facility at: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public Reference Room </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100 F Street N.E. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, DC 20549. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Please call the SEC at 1-800-732-0330 for further information on the operation of the public reference facilities. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc303715_14"></A><A NAME="suptoc303715_33"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we file with it, which means that we can disclose important information to you by referring you to those
documents. The information incorporated by reference is considered to be part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information in this prospectus. We incorporate by
reference into this prospectus the documents listed below and any future filings made by us with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act until we close this offering, including all filings made after the date of the
initial registration statement and prior to the effectiveness of the registration statement; provided, however, that we are not incorporating any information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on Form 8-K we may
subsequently file. We hereby incorporate by reference the following documents: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2009 filed with the SEC on March&nbsp;31, 2009, including any amendment filed for
the purpose of updating such Annual Report; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Report on Form 10-Q for the quarterly period ending March&nbsp;31, 2010 filed with the SEC on May&nbsp;17, 2010;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Current Report on Form 8-K filed with the SEC on March&nbsp;23, 2010; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;23, 2010; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the description of our common stock contained in our registration statement on Form 8-A filed February&nbsp;8, 2008, under the Securities Act,
including any amendment or report filed for the purpose of updating such description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may request a
copy of these filings, at no cost, by writing or telephoning us at the following address: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi Pharmaceuticals Corporation
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 Prescott Street </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Worcester, MA 01650 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Investor Relations </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: (508)&nbsp;767-3861 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Copies of these filings are also available, without charge, through the &#147;Investor Relations&#148; section of our website (www.rxipharma.com) as soon as reasonably practicable after they are filed
electronically with the SEC. The information contained on our website is not a part of this prospectus. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g37e58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$10,000,000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Common Stock </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prospectus Supplement </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g303715g68n37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">February 17, 2012 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g303715g29a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303715g29a33.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X005:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-SDY1D4T-C<U.3,T,3%%,4$Y-#DY,#8Y-#=&
M-34R14$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-SDY1D4T-C8U.3,T
M,3%%,4$Y-#DY,#8Y-#=&-34R14$B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IE-C<V,S-F,RUC9&5C+30W.3`M.3DS9BUE
M869D-V5D.#%F8S<B('-T4F5F.F1O8W5M96YT240](G5U:60Z.38R,&4T,C(M
M.#<X-2TT,V$R+6(S-3,M93$Q-V$Y-6%F-S@V(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG<V5K87(\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\
M+V1C.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!,041/0U-?,C(X
M-SDQ7S@N9&]C/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R
M9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A
M8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<
M`5H``QLE1QP"```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N
M``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!
M`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`__``!$(`&8`C@,!$0`"$0$#$0'_Q`#```$``@,``P$!
M````````````"0H&!P@!`@4#!`$!``(#``,!``````````````<(!`4&`0,)
M`A````8"`0,#`00#!A0'`````0(#!`4&!P@`$1()(1,4%3%!(A9182-QH207
M&0KPD;'!X?$R0K(S4W,TE"4U)H9'.7>W*!HJ.EH1``(!!`$#`@0"!P4&!P$`
M``$"`P`1!`42(3$&$P=!46$4<2*!D3)"4A4(H;$C,U-R@I(D)1;PT6)#8X-5
M%__:``P#`0`"$0,1`#\`O\<4IQ2G%*<4IQ2G%*<4KP(].>"0HN>U*CLS9Y&,
M88DS=`X=BJG8L@Q\/)`&Q.78J2@J]A_6&"6:*JLW61[]:'D;6Y"WNEQ2$*Q'
MN5IP&IC*^P)Q116[G3>W^UW.K;8JZ13R#_E8"K/D9;WL1%&@9Q&!T,S`1@].
M7>W+;KR[5:.2^:P7#B'*>=F5(8%_]<CD+R^4:\G(_=ZB\>^R?G?Q['+R%4U.
MK/\`&%(IF6:?QHW1J^BJ4BH'N)?*KE;[F<_80*;H9-5T+!$?00*J4?6P/M[_
M`$L9VS]/8^>Y!Q,0]1C0%6F/8VDD_,D73H0H=C\U-4B]YOZY=;XX)=3[7X0S
M]B+K]WDADQU/47CA'&66QL;N8E'0\6!KLKQO;!Y-RM`Q$3EJUN;=?+;C%78"
M>=.D6;0D1"7K)MKHN/X:+CV*#5I%1!8?'+QRDBF0`/\`([Q$PCUY&?OAXYX]
MH/)I\3Q?'3&TV%*F&H4EBTD<"33.[DEG?G,%))_=`L.U3U_3!Y%Y=Y3[88GD
M?G69)F>2;5ILQBP51'"\SPP1QHH54C"0EE51^\3U-2I<A*K&4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE!'IZCQ3M6/62UUJGQ9YFTSD9`1A546Q7DH[2:)+.W)
MP2:LFH*F`[Q^\6$"(H)`=9900*0IC"`<R\'`SMGD#%U\4DV003Q522`.['^%
M5'5F-@HZD@5K=KN-5I,,Y^WR(<;#!`YR,%!8]%5;F[.QZ*BW9CT4$FU1#;4>
M6;%];R5:]0]<,@8_7VM>5B194FVY);N5\!0.73'9F@L57FQQTM&K1UKGVQUD
M$5#&&.C904$)`Y!.H0DK>,>T6\S-0GF&[Q\@^,I(#)'#;[IL<7YSQH0P9%(O
M\&>/DR`@`F+]_P"\OBFN\B7PS%RHDW\\7Y))0?MTF:Q2&9K@H[=ODC$*]C<"
MBYL3GW:;(&5[!6MH[#:V]QH]JFHJ5QA*QS>H5O'MF3>J&FF,1CR%0CZW!N57
M)Q.=TDW,N\*8%3KK`<#C=?P?6>,:W7QS>-11?;RHI6927>1+#BS2.2QMV"W`
M4@@`=JIW[U#R?:Y#?SV:5@C,IB-E2)NMP$6RJ3?O:[+8DGO6<8TF'4HX81S,
M#K/'[AJR:)$$1.LZ>*D;M4B?I,HNH```?IY*F)F)%&992!&@))^``ZD_WU1C
MR;0239*X\2WE=PH%NY)M;]-7!?%E/MI+?KR&4:-6*M`:X8LTUUEA@3$#()JX
MNJ%W0M0I=`#M,XO3Z444Z!ZJ"/W\^='NP[Y?C>JW4P_YC:9VQS6_">6,Q_JB
M""OM5[3:V'0POXQC?Y&HUFNPA_M00MZA_3*SD_6K`'(*J8Z<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2J_'E$\PV5]/<UU_5?$>O4BIDB_LH%:EY<R8X9M\=6#\R
MNT(AN6A1C-^D6Q/8R<=$:.SR3V.19.0#W4CI&(<T^^U/M-HO,-?)Y'Y!G@:G
M'+>I!#?U0$'(^HQ!X@J"RA%8L.S`]*@+WD]T/*/#!%IO%->)-UEV6*>;_)#-
MT'%;CDP8B_-E4?$$5$1Y%LO^0K7]@G$VFHY^O&>YV&^1?-K%Z)9G&*,+,)IO
M[KW&FK"L1%#48J:!F[%";NB:+9PF83M8SL`#O%)I\/RO`?(1_+]$V!K_``]'
M`&&KHN3FLG:;8,S>J\1(O%BEF4BS37Z((.VOA?G7C47_`'AYI+F[KW(=3QR7
M1GQ-8K@DPZZ,#T4FL;2Y:HK*/R1$7+M7KI9C++]7"AU7*BIU'1G"AU'1UU5!
M.LHY,J85S+J*B)C&.(G$X]1'KZ\L9AH@XK%;A86MVL.P'TZ6L.EJJ%Y=+DF5
MY9N7J\B;GN3^/<F]2MR=4A?(10H*BW63C(#<^C0K2!P=F2:<(,&.?:]$-P1@
ML!YIF5Q32);FB10;5"TNC=Q3"2.?G,D9)4D<;GQ[*\$S)/)?'XVD\1D8R9F&
M@+-BLQN^7BH/_;_>R(!\+RQBX85)OMY[O8'G^&GMGY_.D7DX01Z[/D(`G/:/
M#RW-@'_=QLAC\1%(0"K5SMH#2Y%+=/%E#RC!RE8/B[(4A;\LURRL5X^1KD3@
MQA*Y%O,=8(]P4BS,S)C3UDURF```!$?4!`1SO,?(4B]O\[8ZN19/NL01X[H0
M0[9-H8RA'>YD!!IXOX#)E>[>LTNVA,8Q]@)9E86XIC$S2<A\`5C(/XVJ132[
MR*Q7C4RZC:LNU%[=KOO=97VQFUJ;==R-NPGCR^2LK/X!B(2-%4K9_<EH2TOK
M/.L'(`L:-E&#=,R:Y!ZPGY'[=Y'N1J6QM5*L.+I(EQ,+I^3)EC55R68]U3DB
MPQ,.G-'8W6K<R>YF+[;;.*7;1-+)MI6R,L@_G@B=B8.(^+<6,DBFQXLH%C5W
M'&>3*'F*BUG)F,K3#W2B7&+0F:W9H-T5U'2;!P`]#$'H55!P@H4R:R"I2+(+
M$,FH0IRF*%/]EK-CIL^75[6%X-A"Q5T86*D?WCX@CH001<$&K*:K:Z[=Z^+:
MZJ9)]?.@9'4W#`_W$=B#U!N"`16=\PJV-.*4XI3BE.*4XI3BE.*4XI3BE.*5
MP-Y%=!L;>0?7Z6Q1<%4Z[=X15:RX>R:W;]\OCJ^(M3I,I!-1/M<N8"3_``H2
MC,#`#AN(&+T621.3L_!/-MEX+O$VN&2^(WY)XKV66(GJ#>XY#NK?`_0D'EO,
M/%-;YAI9-3GJ.1'*-[=8Y`.C#X_0@=Q];&JS^S6<=W]?VF-;R\R9E;$6474$
MMB38"KQ-KEE*H&>,+MX^NR]FCXIZJZKTE7<NT!2#MD<N5O[+Q.25,`=Q5`"Z
MWMIJO;OS/39>FS-?@9N/BS>MBR-$OK?9Y19XT+C_`!`^/+ZL#@M=>"CXBOFO
M_4-G>Z?M;YSA>4>/;;9X$&UQPF1&DTOV_P!YBA896$98Q<9XQ!.HX=6D<CL:
MX2M'D\RI-'%/.6%=5=D6X=2K/,I8)K$9;EB_WQB7K&X4FR).!_RHJG-U_3SI
M)?:K2:YR_B^=MM2W<+CY3M$/_JG]5+?2U:;2^]GDGD,"8_G&!I]W%;JV3B1"
M7]$T`AD!^O*]?(I>W^DN2K"QJ[S2#/&/;A+."),D=4\MN,G_`"'2A@*3Z7BW
M)\!(3:_17H)46LMU#["B`^O/R<[W(\4B.1_.=;GZ]!U^_P`<06'UG@=5`^K1
M5OE]H_9WW.;C%J=QJ-FQZ-@9'W"<C\?0R$9@`>P64"K`N'\%Z]7JMW_:;+,E
M/P69<2:X9%JDN;9&LL<-WJQ8FFZP$9'K[.URJSV1)=:.K3=HI$!8@0;3#R!<
MN6Z[=;V45"US\Q\@WOK1:W18!QM!L=C$_'%<Y&+]TC\V.O=XX0"_^8T`+1+*
M%9&7D15J?:WQ;7:>9L;R'>8^Y\JT^#(J/,L<.<F&Z^FB[)$EF)]/_*CG;A*\
M9*R*Q16JM+D'Q_;JY?OMOS'7'^(-O9.\3\K;K%:=8<V8ZRNX>/)=P9T8R%&8
M3$;>XI@U0$J+1F,246K5)-("`!``)PT'GGAFEQ8M3EC*U,,2+&B9>/+"`%`'
M65@8R2;EF,EV8DU&7N1X#Y?Y).VRUWV^QF<LS?;31R&Y[6C#"2W2R@+VKN;Q
MX;D;.>,Z\!3\J8XR=&88LLHD:\XEOU8L-4=L':@@BM;*(%D8L48VQHD`!62*
M)6LDF0"+=#@FLGD><>W?B/O!JCDZ?+Q#Y#%'_@Y,3I(&`[1S<";QGYVYH?S+
M?JIA7P[W;\Z]@=Z<??X.:?$9Y!Z^--&Z,I[&2#U``L@'6W[,@_*UK*RW@,19
M=QYG/']<R;BZRL+73+.Q([C91BH`F34`I?DQLDU']O&2\<J(I.6JP%604*)3
M`'IUH!Y!X]N/%=Q-H=Y`^/L8#9E;L1\&5NSHPZJPN".H-?3;Q+R[QWSC0X_D
MOB^5'EZ?)6ZNA[$?M1NO=)$/1T8!E(((K9G-/724XI3BE.*4XI3BE.*4XI3B
ME.*4XI4='DVTX'<'6"X4FI-J]'Y3BI.!NE%G9C_9[49FO**LW32:E&K-X^+'
M.ZQ(O4.I4UC$,8@E*/0`Y*?M#Y]_V#YC#L<KU6U$L;Q3(G4E6%U*J2`660(W
M<7%^HO4*^_?MD/=+P&;38_I+N<>9,C'=^@5T/%PS`$A6B9P;`]>/0VJET\Q/
MHMBMTL7(60,A;975BJHDZJF+T7>%\*M7Z!Q(NRD\@VF/=9.M*""Y1(H$=$PX
M'Z#VKAZ"-ZT?W`\FM)C18^CU3CH\Y7*RRI[%84(@C)'8/+(1\5KYP/L?:[V]
M0P,<OR3?Q@@I"K8>"KCH5::53DR@?-(8@?@_6]?;)MW/5F(=U7!U7H&M-+>H
MBV=P>"Z\G59R6:CZ`2TY+>.97)]J5,4/VGRY<R2@^OME#H`;W5^WGC6+.FPW
M'J[;:KU]7-;U@#_\</3'B^G"*X^=ZCOROWK]SO(<5]3JYH])H&N/M]>AQPRG
MX2S7.3+TZ'U)B#UZ6Z#J?6JU&;8^H5"<G.O*[KW+:ND."+'54<S-1Q;J'DN+
M8*+*&.)G:3S*6441Z'[^YS'A]X<BGWGS!L=R#';[;1XN)+T%@LN1G0WO\!:#
M'^G1ZM'_`$;>,/HO%L[;9()S=_G2P`DW+0XN)*_<]2&GG`[GJGSJMYCPDJ$_
M"$KR<B%D6*T(P3@2O/KBKT>WL(Q+&!]1.Y$X="@D`GZAZ<E+'?']%VRBOVES
M<O;C;ZWZ6K6>>QY_WL:X`D^[XBP2_*]NEK=;]*M0Z.X)\S5TA(IG#R.4JKC%
MPD@?LV?D$I"E*1ZH%`!0HV5(^TSCYH9(?P@WC.PP?88/MY$?EWDW]/FL9I-K
M%BS[=?\`\]2L_(=O\;':-%/SY2?HKT^,^&?U7[QEAT$V5C:1R"?YFROC$7['
M'RDE9E(OT2$CZBK/6I&N5EP)`S:MT>8E=6ZU'9N9\V&\;'Q?6'+QJ0Y!>NX9
MG,J0DI*'`P%%ZE&1RQB`!3%$O0"U-]Q_-=?Y?F0KJ4V*:W&#"/[W)^ZE`-OR
MJ[)ZB(.O^&TLH!Z@BKM^SWMGMO;_``LB7?R:=]WEE3*==A'!A9EO^9XUD,,D
MG4#U4QX&(%F!%@.PN1M4T4XI3BE.*4XI3BE.*4XI3BE.*4XI7@?Z/[''UI5%
M'S&Z\QL)L;L5?<:1#."N>/'<-?,YXSB$/BI2.,LA"@:E;,46.`>]Y67TPHM`
MW9)$#!#V)J#PP%;/P%.]OLGYSDGQ[7Z?;R-)BS@Q8L[7($D5^>'*?W7"V?')
MZO$P07:.Q^?_`/4)[-8.3O,ORSQZ%5R%*R9D"CX/VRHP/W&:XF`_8D'+L]Q`
M^%[["F.*WX2E,8>AA]`*`C]H??T#EB!D$GH?E_;\ZJ4/%"SA>/<U8BT=UUN&
M:/(MHGC&-%W'4W1O5"H9ES1())$,DWN6>D+'D]W4ES'-V?5+4;),7'J!U!=-
ME'+B`=40Z5.]PO)\;&\2WVWEL^3N=H^/C@_Z>+PA#_[*>B[CX<F'SKZ)>U/B
M+ZS^0Z.!2F/K-<,B;IU]7++S%3]2)57YV7Z"K7>NNBNHFI[,K?`&`<=8]?=`
M]^S,H1*3NCXWXA.=_=)P9*T.A4,81$IG?8'7T*```!6#>>9>4^2G_KF=D9"?
MP,Y$8_"-;(/^&K$:WQO0:AN>MQ((9?X@@Y_\9NW]M=8"4!^T.O[O7G,V%;L@
M'H>U>WV>G/-*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*UW8,1XMM<U*V2S8[
MI4_8YRF/L<S%AEZQ#/YV1H$H9T>2I3J8<LU)%2K2!WJIEF/N?'5,H(F*(\S(
M-CL,6)(,:>:.&.82JJNP42*`!(`#;F+"S=^E8TN'B3LS3Q1NSQE&)4$LA[J2
M1U4_%>U4'/(1X?K+J[O)AS'-';2$CK)M+F:KUG%EG/[[C\DFL%E9_FC&%F=A
MWB#^JP:KAS'.5/\`3XI+NZBLW<=+M>#^[2>1>'9>=F.%\@UN([3)_J<5/"1!
M\F8`,/W'/R(JI_D_LYK]7Y/CIBQ$ZG-RD"'J0A+`LC'X6%RI_>7Z@U<1\=NM
MR.'ZEE[,T]$A'Y*VQRU/9?GTED2)O:_CM#_AO!6/S]O3VD:CBN-8&42`I03?
MO'(=.50\XWS;3*Q=7$W+!UN,L*V[-*?SY,G^_,6Z_%0M68\?U*:^.?*9;9>7
M,9&^8066)/\`<C51;YDU(MSB*Z&G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2L<L-1K-L)$$LT!#SY*_/1MI@BR\>V?_1K)#'4/%3T8+E-064M'F6/
M[2Z?:H0#F`!Z&$!]L,^1CESCR.G-"C<21R5NZM;N#TZ?05^'CCDMZB@\6!%Q
M>Q'8CZCX&LA*4"E`H```4.@``=```^P`#[@#GI'05^Z]N>:4XI3BE.*4XI3B
ME.*4XI5?;>+RY[68U\A,3XV-"=,:IM)G5C@9#8&^2&1\SQN)*]%5E[)F8-XJ
M",]9&2D'[-`[==PHL[2$WRR)I)'[%#@I6+$W1_G&B@"/\CKK23H/3HINW42B
M/H'J'[8?3UXI4GVAV3_(!E:HW>>WVUGQ+JW8F4^QC,?TC&V6@R^_FX9-B9Q,
M62Q33%((2*05>+IMV35)11P845CK`0HI=ZE=KVBS0%+K=@N-KEF4#5ZI!RUE
MLDY)+@VCH:`@F"\I,2S]P;\"#*.CVJBRIQ]"D((\4JLCXX/YQL;=G=2$U[R;
MK8YP!A+8MOEE[HCG":FI10NP!,46Y_!O8M\RE8R.CF,S)Q$6Z4*1FLL5&2;"
MR'N.JD8RE6BONZ_:/3^MQ2HD</>2.W9-\OFU/C1>8PKL54-><`43,L5E-K/R
M3BQV20MZ>/E%X20KZK(D8Q9M/SHH!%4USG-\<O4/Q#T4J6_BE:YS#DZN83Q+
ME#,MP^7^4L2X]N>2[.$>D1=^:O46NR-GF2,4%%$4UGIXZ+4!(ICE*900`1`/
M7BE5JL(^<_R@;4XSK^>M8/!;D3)V![XM-+8YO;K;7%5:<62(AIN0@5WJD/-5
MQD];'2DHQ9$_0ID152,"9SE`#"I71^*O)'YF+_DVB4:U^#&?Q16+1:X6$LF3
M+=N#C-[6:'`O7R*4S:Y=K`5:1EY!K"1HJ+@W:HJ+.3D*F3H8P""E6"5#"1-0
MX!U$A#&`!^P1*41`!_I<4JO!XG?YP9A7R%9"M&N^7JDVUJV68W"]1F-:O*2[
MIY1,\U:HV&3A5I#%EKEV47]3MT.,<<DG"F*9P4R9E6QEB%6(W4J;C9+*CW!>
MO&=\V1L0UL$CB'#N2\G,(%ZZ59,IIY0Z;,VAM$NWB":R[1M(+18(J*$(8Q"G
M$0`1#IQ2N>/&-M_/[\:(ZZ[>VBF1&/)[-U6F[#(TR!E'LU$02L3=;/5"-V4G
M(-VKUTFNC7RK"*B91*942^H``BI71NPV=L<:PX.RIL+EV;3KN-</4B>OEOE#
MB3W"14"Q5="S8I',0'4M*N03:,D`'O<.UTTB_B.'%*@E\.?GCG_(YFJXZ_;"
MZY!J?D^9Q57=A];(9Y/RDJGF_!$V[D6KBSQJDS&11E'\>BFV=)_%!5!XT.X5
M3Z%:J"*E6/NOW\4JJ!60_P#E_9$]/3^3,C.OI^E_4/MXI4TV]E7\I-J?8]:>
M.S)NI&*HABUFW&39?9&IWZZS,Y(KJLDZ_&U6,J;4(V+C&#9)PJZ775.NX663
M(0J94C"HI4<7A[WOW]SIO-Y'=+MYK=@F[3FE?\4\5%6/!M"EZ7!RTS<C6!W,
M/"J3DBXDGK#X+5J1,BR"!TU"G'U`P=%*Q7S]9VR1G.<UR\+&K4VLQSQY`I]`
M^<;'%&.JOB#4"O/5'61[--?&3549MK6UB7B78;H+N.C7K4`$[I$#*5$1Y/+@
M]R/J9A37G2SQ)>4?#F3?&W>ZU9=(MD4M<3QE<B$,6RC1O,SDJJC*&M/Y9R/$
M0X3;LRK(72\J@V<+I"/ND,I5L7Q6[]4[R4:18;VBK?PV%DGX<*SEZIM3B)Z-
MF2K)(,+]6E43E*L@T&2$'T?WAW*1;ULH/J?BE0]:H?\`VL/)E^K1C"?7]7\&
MP5]O%*M+\4KBKR2_]O#>W[__`$>;*?K_`.CEQXI5>OQ+X^\H%]\,OC53\?>P
M>LN`Z[%X]S$IDEQG/%ECR=8+5..\YWPL"C`IQYRQ4'!Q$>@J901`SEPX7]1*
MFF`&4J;/1[$_E3I%XM\OO[MCKIG"C+5E!A1J?@K"#K'+MI9UI%-9[/V2?ECB
M[7:,XQN*#=HW*)55'!E%#![1`,I4F*_^(6_S2G^`/%*I4^'SQJ8`\D_B'OU(
MRLE*T_)M!WSVNL>`MA:*L:*RU@:^M[16'\9:*1/MU6SPK,LJS05>QIE2MGH)
M`;JDX(BX24K=ZWD?V5P-AS;#Q0>71FQA-H9/4W8>+U2VZC4!98AWAJ[7%%O:
M0O;*"@A'0.9ED4R)N6:@-S/7@^RJD@].B#U2I.?YN5_V4=!?_#2X_P#G#D?^
MIQ2HZ/-UD*>\@NX^%O#EC=2X2>&,=UX-T?)2]QE&25AMB>',=)%LM'PE#Q40
M@H\DKKD!RFW.PCDC"LXE)2&5*7L25Z*5&%Y4=K<N79_I[NIJ5XDO(]J5G;QL
MR#%_7[UD77Y&N8A7U9KL4K^:\6WQS79>6>QU-BH=F9)#N0,W;1S^13.)06[R
MJ5;M+Y.-<3^-$_E"+/)&P2G@H,QJ)%7*,BG,"@2,#&1^B8]EQ'(BA:S[0E_W
MH8"?8(#Q2N4]Z?"JVVLV\@]Y\&;H[#:0;(-L3(85M-SPD6'?DN%%922TDQ:N
MD)%Q&O(QX4ZI4ES).3(N$6Z(&2`Z?>92M"_R(V^O_P"@?R(?ZA`C]O\`S7_:
MXI7:7C-\354\=MLV/R]-["Y=VKV'VIG:K*Y=S9F(L4UG95G2FD@UK\8UCHH5
MRD,4THL=RY7<.%5Q*D4/;(D!14K-M:/&;4,%;P[:^0*[92LN<,_;/!#UF$DK
M5`1<-'8,Q!`&3",Q/CM!F[?J?2!0CXY-R[4,FLZ^G)G,0#J+F44J3CBE13:.
M^+"GZ![/;@9JPCE^TML-[>VHN1IG5MU6X=&A8YR8=W\Q_;:+/-WH2+1)^+U\
MB=C\8B/QET$A,)62'12N1MH_!7><V;VY@WVP9Y(]D-.<E9GI=*H-GC,*UF`(
M!JS3("NPZ44K/KST>_?L)!Y66[TZ2B0`1<`Z"(%#BE8@/A&WU$!#_P!P1Y$`
MZ@(=?@0/WA^JV@/[_%*G$D,#,[?J\]UBRG<[-DEA9\$.<%Y$R%,*-VMROC:9
MH!Z':[G)JI%7:M[/94G"[Y8Q0.F1TL(@`@'%*KM8:\"7D:UDQU`8/UJ\[&;\
M6X-HRDNWQ[0$];J!+EK,1+3+^=79?4'EU,HX44DI)9902E32]U4PD3(`]H*5
MU'A'Q:>3ZE9<Q[;LS^=#8/,&+ZS9XV<N6+8S!6.:"XOT5&+?,_*R]O0FY]S"
M1<NX2(D]41:G7,T,H1(R2ABJD4J?Q0O>0Q/L[RB3K^CN`0Z_O\4J/;QG^/NM
M>-?7ZQX`JN2I_*D=8LTY,S.M9+'!1M>?M7^2WK!Z[@TV,4Z>-CM(PS``(L)P
M.KWB(E*``'%*V%O9H=KEY%-?[-KOLI34;'5IA-1[7+$R*@UNF.+8DB<D7=Z%
M/&167A+#%J&^X#-W:(F;N4UD%#IF4KVT#T_AM!].L)Z@U:[RV0X;"5=FJ]$W
M>P1+*'E9M.8MEAM@.7\3&N5V;<6J]A%`"IJCWD1`PCW"/12M*>/GQJ5/1:U;
M3Y;E\JV78387<#,#O*N7\UW:O0U>GG#--(Y*SCV#C8A=\E%4VIF=NC-6Y5S!
M_"`)T*FBB0BE222L5&SL7)0DRP:2L/,,'D7*QC]!)TPDHV0;J-'S!ZU6*=%R
MT>-5CIJIG`2G(80$!`>*5`CBGP$8CQIJ!M'H`\S_`)&N6G^QFP>-LY0.)I>M
MP;<^&XJDYSHN9[#BVJ6%)^LYDJG?F^/6$,Z46115:I^Z[2*+E943J5*]D'<S
M6K%M[F,97;)B$9?:_'PDI.UAA6+K99&'C[(@NY@7,G^5ZW,MV199NU4.@"AR
MF4*0P@'H/.GUOAGDVWUZ;3`Q>6!(S*KF2)`Q2W,+S=2>-Q<@6N0+USF=Y;X]
MK<U]=F9(7.C569`DCE0]^);@C`<K&US6WL7Y4Q[FFDPV1\66J,NE(L`ORQ-A
MB#+?$=+14B[AY1J9)TBW=M7L9*L%VSA!9--9%=(Q#E*8HAS3[35[#2Y[ZS:P
MO!G1VY(W<<E#*>EP05((()!!O6VUVRP=MB)GZZ59L.2_%E['B2K#K8@@@@@@
M&]?V-<BTE[D"9Q6TL<>XR%7JM!76;JB9E?JD=5++)3$/!3C@HI@B#*3DZ^]1
M3$#B;O;GZ@`=!'\R:[.BUR;9XF&NEE:)9.G$R(%9U'6]U5U)Z?$5^USL1\U]
M<LBG-2-79/B$8D*WX$J1^BOEY6R_C7!]3-><K6V.IE6"5B(%.3D2.UQ>3D^]
M3CH2%C6$<V>R<I+2KY4J:#9LBJLJ;^Y*/0>>W4Z?9[S,&!J87GRRC-Q6W14'
M)F8D@*J@7))`%>G9[77Z;%.;LY5AQ>2KR-^K,0JJ``268FP`!)K4=)W5UCR)
M<Z]CVJ91:N;G;57[>KP4M6;K5G%@=QD<YEW[&'<6JMPK)_(-HMFLX%NFJ984
M4CG`HE*80V^?X5Y/K,&399F*1A0A2[*\<G`,0JEA&[$`L0+D6N0">M:S#\N\
M=S\N/!Q<E6RY;\%*NA;B+D`NJ@FP)M>]=%6.QP=1KD];K+)-X:MUB%E+'8)=
MX)BM(J$A6*\E*R3HQ"G.5LQ8-E%3B`"/:4>@#SG,?'GR\B/$Q5+Y,KJB*.[,
MQ"JH^I)`K>Y$\.+`^3DL$@C0LS'LJJ+L3^`!-<MU???4BXR],A(',4>L]R)+
M0T#1U)&KWJ!B[1,V),5*_&Q$[/U>,A'3R=('\#(#CJY$0!/N$0`>KR_`/+\*
M&>?(PF"8R,TMGB=D5/VV94=F`7]XVZ?&N<QO-/&,QX8X,I2<AE6,E)%5V;]D
M*S(%);X"_7X5U-8K##5*`G+38Y!")KU:AY.P3TJZ$P-HR%AF2TC*2+D2%.<&
M[)BW.H?M`1[2CT`1YR>/!-E9$>+C*7R)75$4=V9C90/Q)`KI)YXL:%\B=@L$
M:EF)[!5%R3^`ZUALWF/&-;Q>AFF<N41&XL<P=?LJ%V<&7"&4@;6:-)79,IR(
M&<?&ECS#4$OV?7]L7J`>O3.@TVTRMJ='CP.^V$CH8A;ES3ES7O:Z\6OU^%8L
MNTU\&O&VFE1=<45Q(?V>+VXG\&Y"WXULKKZ=1`0_5]_I^YS67K/_`!K5CS-^
M)H_+<1@9[?:ZVS'/U1[>(;':KT"V.1JD>Y4:NYANU[?;%%-5!40()P643154
M(0R:2AB[1-+MY-,_D*8\ITL<PB::WY!(1?B3^D=>P)4$W90=:^XU:;--*\\8
MVLD7J+%?\Y0=V`_0>G?H3V!K:G-4:V5<:SOD$T_K;FU-IG,K!J2CS-BK]OD4
MZE?WL%7I>HOW$9:&DI8F%3=0+;\O/V:J3Q07/M-S)&[S`!1$.U@]O/,<A86A
MPF/W"HT8]2(,ZR`-&0AD#?G!!7IUN+5RDWG'BT!E$N6H$#LDAX2%49&*N"X0
MK=6!#=>ENM=>1LDPF(YA+Q3MO(1<HR:R,:_:*D7:OF#U`CEF\:K)B9-9NZ;J
ME.0P#T,4P"'..DCDA=HI5*RH2"#T((Z$$?,'H:ZB.1)8Q+&0T;`$$=00>H(^
MA'45A%%RWC7)K^^15`ND#:Y7%US?X\R)&1#TB\A3KK&-VSI[79YF;L<,7Z;9
MXFH7N+V*D-W$,8`$0S<_4[35Q8\VQ@DABRH1+"6%A)&Q(#H>Q!(MT^/>L3#V
M>OV#S1X4R228\ICE"GJD@%RK#N#_`.!7C&67,:9G@Y.S8JND#?*]#6FQTF1F
MZX\!_&(6FHR*D39(8KPA01<.(F12,DH9,3IB8/PF,'KSSM-1L]+D+B;:"3'R
M7B20(XLW"0<D8CN.0-[&Q^8KQK]IK]K$T^ME2:%)&C+(;@.ALRW^8_5\J_/+
M68L8X(HTKDK+]TA*!1815@A)V2?7.BQ;N)1XC'Q[<"HIKN7#AV[<%(1-),YQ
M]1Z=I3"'G4:?:;_8)J]-!)D;"2_%$%R>(+,?@``!<DD#X=Z\;3:Z[2X;;#:S
M)!A):[L;`7-@/F2?D+UF?Y@@_H/YI^K1WY;^D_7_`*]\QO\`2?H?P_J'U?ZA
M[GQ?IOP/VWO=WM^U^+KT]>8/HS^O]MP?[GGPX6/+E>W'CWO?I:U[]+7K+]>'
MT/N>2_;\>7*XMQM?E?M:W6_RJ`C-LI:(?R&[<*5JI[GW(KRA:MB_2U#M#^NM
MX<S>IW@K<N0TS0J[1X_?D4.:-%)<XE1(L!P((AUL)HXL6;VWTXRIM+"5GS[?
MS!%<M>2*_H_F!`'3G<"Y*VOUJ#MPV1%Y_M6QDV\I./A7&"Q4+9);>K=""2/V
M+,;`->W2N^/%64X:58\,KT!96[YU751=N'KNT,UU\X9#5<,,B/)"/BG;S)[%
M8YDK&L9ND"DP1<Q0[1`1COW7(/G638=H,4=+",VQ8ARA"EE$)[Q`$VC*CO7=
M>VXMXG#<@L9\DGOS!.1+<2D@$S`])387?D>U?7IJ)0\FV?%_E-C'/IQKJD+0
M`=?*2*3+&>#?(4[FA67L*B?M+VKG4[BCW$*':)O7G,?_`.8:];=/YSE]?R]_
M0Q?KR^7<6^M9.*!_W[F&_7^5X_3\W^M/]./ZB3\Q7RO),XD&&.==9B%C@GYZ
M#W<U7F("I)ODXN1NLPRR&D9G4X65>HFA(N9F!,)4%Y-=E')B4?><)!T$?=[:
M+')L]C#.WIX\FCSU>2W(1*83>1U!Y,J_$(&?^%2>E8WN`637X$L:\YDW&&RI
M>QD82BR*W[*LWP+D)_$PK3^9,A96R!LWX_&62<`67`T9$[%7*5BYFWW[&US0
MM$L77W+35*L13'%]@N+UG*JM7*KDJ\@5DP*BW4+[_NF33/MM-KM5KO%_(7U>
MQCV#OKHE98XIHRB_>8YYL9TC!4$`$)R>[#\M@Q&!M,W99N_TJY^%)A(N:Y!>
M2)PY^WF'$"%W(-KM=@J]"";V%=W;9E*?5+9@ACH)%-K[F8IE''O?&3`V.K(`
MJ+_'27<>R0!ZF["'/TZ]I1'H'.$\/-O*]4>I_P"HXWX_YR?,C^TCZUV'DPOX
MYL!<"^%/U-[#_";Y7/3Z7J-C'>'*+&87T:L6PFV>R5CJ+6P:I2./*!+TN!:8
M^DLQ'B8$V)8!S*U'!$5:B5]&R*)%14?23=L;VT_F+AU$1DO9[K8R[C>XWC>H
MU<668\Y9I4D8RC&NWKN%DRVCY%+\@B%N_!:C[7ZG$BU6GGWFTV,F.&PS'$T:
MB(SV7T5)CQE;CRZ#FX%K<C4G&T)>_6C8@G>BGW8+RX7W'/N`W3`U`GP[U_92
M65]DG7J;M(<W3["B/IR,/%S;RC6GO_S^/\O]5/G8?K-JD3R$`Z'.!-A]G-\^
M@]-KGH"?U`GY5`MD_'E+:^.>J23;.N]$E*)XBUW<%KUZB]B$\#KN1D<:F48/
MG4MA9E6@I9!$2M3*.R-A3!+HITZ#R?\`5;'-?W(EBDP-"L'WF6.<387W0'&;
MJ`N26]3^+\A-[]*A'8Z_"7P2-USMXT@Q<8\9%S/MCUBN#RQPOI_P_F`M;K5E
M9RHHBU<+(MU':J2*RB35$Z*:KE4A#&(W34<*(MR*+&`"@*ARD`1ZF$`ZCRL2
M@&RL0%/Q^`'SZ7[?0?HJPKDA20"2!V^?TZV_\OT56^N%+SU+6:WVJ2SA@NI[
ME2NU6/\`(]8Q$^Q-DZ<R75\K-\>R<QAO76.RG%6<M=D<32&"V,G#RUC:PKBJ
MIIOIIPX=`HFNH2RF'F^/100XL.#GR^&)J)H7R!D0+`\)F1<C,:!DYK.N44D2
M'U!.2L"A+%08'R\3=R3RY,N9A1>4MLHI4A,,K2I,(BT&*)58!H3`&1Y0AB`:
M4EKAB+%=9?S$I7H*3L$&M5YR1B(Q],UI=^QE5J]+.F2*\C"*2D6JO&R1HMX<
MZ`KMSF16[.\@B40Y7#)2*+)DBA?U<=9"%>Q4.H)"MQ;\R\A8\6ZB]C4YP-+)
M`DDRF.9E!9;@\6(%UN"0;=1<$@U71L&,,V.M3]J+Y0MC\J,,=16R&[LAF7!$
M+6H)O4[AA-+,.36^4Z[1LBN\,6.U4^\N(+Y;I-V=639"]*J@`))G!=&R6/M=
M*GENHP,[68K;%M;K%QLIGD,B9/V\)QWDA&2B21<^*E0(SQLUR1Q,!#6;=O&M
MEFX6QRA@+LM@9\8(HC>#[B;UDCE..SQOQY'E=UY`@6!Y"P1B-:ON<3XS<51F
M^CZJMCVFJUEC**)K23.O*5R--"MI!9)5PDJ]0C12*J8IS`8X"/4>5YW"Y(VN
M4N6RG,&1('('0OS/(@&W3E<CM4Z:LP'68YQ@1C&"/@#W"\1Q![];6O\`6H,:
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M8"ZG-_E9C.O.VRO2X7XA.8X@7`_=MV_7>]8?N7$93M.R&!BR%TQ)B7$%-=RY
ML;N<STJ>R;2\Q9\M%*N8/T)N+K5JJL72T<8XQBI,T4M8'S9.4DI58&J2JS9(
M>9/ALVHQ/&]@5@S,S;SJOK#&E2"3'Q(Y8_V6>.1I#/,T?,1*QC2,<RH=J]?E
M46RR=]A%YL7&U,1;T_71I4GR71_V@K((Q%$'X%V'-G/$$J*T;4:GE)[XNLKX
MSN&68:&Q%#1]==XGV:9T3(3Z$N6H,A9:O<)^.E,.H.#YB@XR!QM]8J(E<&(9
MQ`@VD$G1D!47+T&9F:E/=7$VF'AN^W=G&1A&:$-'L0CQHPR"/MV9I_3R/RWM
M+RC*AK+6EQ<;9/[>9.!E9*+K$"F'*$<I5\$NCL&A_P`]0L/.'K:Z<7#<;M7_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g303715g37e58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303715g37e58.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X005:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-#4P.3A!.#<U.3,T,3%%,4(V-$8X1C9%-38R
M.#@T,38B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-#4P.3A!.#8U.3,T
M,3%%,4(V-$8X1C9%-38R.#@T,38B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IE-C<V,S-F,RUC9&5C+30W.3`M.3DS9BUE
M869D-V5D.#%F8S<B('-T4F5F.F1O8W5M96YT240](G5U:60Z.38R,&4T,C(M
M.#<X-2TT,V$R+6(S-3,M93$Q-V$Y-6%F-S@V(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG<V5K87(\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\
M+V1C.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!,041/0U-?,C(X
M-SDQ7S@N9&]C/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R
M9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A
M8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<
M`5H``QLE1QP"```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N
M``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!
M`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`__``!$(`&8`C@,!$0`"$0$#$0'_Q`"X``$``P`#``,!
M````````````"`D*!08'`0($`P$!``(#``,!``````````````<(!`4&`0,)
M`A````<``0,$`0$%`@83`````0(#!`4&!P@`$0DA$A,4%3%!82(C%AD*\%&A
M,[<8<8'!,K)#4W,TE&5VUA<X>#D:6A$``@$$`0,"!`('!08'`````0(#`!$$
M!08A,1(3!T%1(A1A(W&!,D(S%0B1H5)3%K'!8G*")-'ADJ)#8Q?_V@`,`P$`
M`A$#$0`_`-_'2E.E*=*4Z4ITI3I2G2E?`CVZ\$@"YI5>6W^13+L@VJ!QR-JE
MET-&+DDQY!ZE"OX&!R/C#7G#911K):CH-I?Q=94M+M44Q2K+)RM.G:F%4&XF
M%%)?N-+P#:[K6-L5=(97%L:$JSSY;]K0Q(&?P`Z&8@1@]/+O;E]SRS5Z-[YK
M!<2(7GF9E2''7YR2.0OE\HP2Y'[O47KZY)>=[-(I22JG%&M'TB73.JT+IUP;
M/(BAMU`^1,7<!`"=G8K)[3=C)G<?CT#>@A\I1]9_]OOZ6=EM3'L.>9'V>&>O
MV\)5YSV-GD^J.(6Z&P=CV^DU2;WE_KCU'&EFU7MCA?S#:"Z_=9`9,93U'DD0
M\99B#8_68E'?ZATJ67C:Y%ZGK<;%0^N6ES;+M<,RD>0,RY<MV;)*&@K;J-@S
MO/H6(CF*#9K%0X1N<R+E-),@`<7'O,)C=QZCOWSXSQSCW(IL3B^.F-I\*2/#
M4*2Q>58%GF=W8EGD\IE4DGIX@6%3A_2YR;F'+?;'&Y+SO,DS.1;62?+)8*JQ
MP&9H((XT0*J1VA+JH'7S)))ZU;#U!M61ITI3I2G2E.E*=*4Z4ITI3I2G2E.E
M*=*4$>WJ/2E[=377[':JW3XM2:M,Y&0$4DHD@+Z5=HLT%'+@X)-F;<5C%,Z>
MNUA`B*"8'564$"D*8P@'67@X&;L\@8FOBDFR2"?%5)(`[L>G10.K,;!1U)`K
M6[3<:O28;;#;Y$.-A*0/.1@H\CT"BY^IF/15%V8]%!/2JC>4?EJR*HZ?9.).
M`WVA.^4C^LRC"G6G1T7IL"K&O*"U_IK+]&L<9)1[N+L=@*=5`I^XLHN1%!&0
M.D)SD)*O&?:'D&?J%Y=M\>?_`$VD@,D<-CE/CB_J3Q(00R+:X[-(GDT=Q8F,
M-_[S\2U?(DX?!E1+O)XOHDE!&/',UC'%.W1D=^WR1B%>QN!A9Y(;]RLOVLV.
MJ\IYZULKA1K9,QLOE<E'(4VM9[9RO%#S#2)SV&18UR)<KKG%0SPB*KA\0Q5C
M.%P."@W6X-J^+:W7QS\9BB./+&I6<$N\B6Z%I&NUAV"W`4@BP[53WWK_`-4;
M6=OY[-*PC9E,1^E(FN;V1?I!8'OW9;7)%J[=F\XN^.T9M0.LZ=*(-FZ9!$3J
MN'"A44$R!^TQUE```_?U*V'E+&I>0@(HN3\@.I/_`)U17E.B>2<0HMW9PH`'
M>_2WZZV$>+>:0><_.>6?QZI583C3A_#/C/'?&(&2)(9[5KB[N8D[``%.O?IF
M4,H`?JIW[^O7SJ]VI6S>.:[=RC\_:['8YA'_``RRH(OTVB5!7VG]HM5%Q[$'
M%H/X6HU6NP_^N*%S*?URNY/XUH"Z@BIFITI3I2G2E.E*=*4Z4ITI3I2G2E.E
M*=*5G_\`*7YA=2X8;%7.,>4\>I%UH6@1L*ZINNZ2X:M\VG?S[E"+31HT:Q?H
MGL<E$S+HC5Z,B\C4F2XE%1-1$Y#FGOVH]IM)S/!DY!OM@%U>.S>I!#?U@$'D
M?48@^`902H56+`="#TJ!/>3W0Y-PI(M3Q;7B7<9=EBGF/Y(9N@LH(\F!(OY,
MJCN?(54;Y%-D\AV`M$6]NI6[7GD#.P9G%TY0&H-B=8QA4=/-`.ZSSB\E"1(T
MYA;T&3L49BZ@DBLU.8S:+[&*H\/-/#LG@&_0ZK0-@8'#D<#[19$&7G,AZ2Y[
MNWK-`Q%X\7R*L/JFZ600=MN%\[X\!S7F\F;NO<AE)CG9&?!U:N#^5KXE'H+D
M6-I,L(&3]B(W)D;.]35%'+DYW2JKAXJLHJ\.Z546>*.EU!.X5=G6,9PHY56,
M)CF.(G,<1$1[]QZL=AQHJHL5A&`/&W8`6L%^0%N@'2U5"Y?+DM))+/Y>L6))
M/<M?J;]R;]_C5K;ZL0OD&H4#GU]E8RO\QJ+`,:Y@>U3CQ".C=MK\,C\<)@6X
M3"XD2_J)%,/K5&UNC"HBH)(Y\<R!TU$XYW7'<K@V7)R;CL;R<4=C)FX<8+/C
MLW5\O$0?N6^K(@'<7DC'D"*DGV[]WL#GF*GME[@3I%R+P$6NV$ALLI'1,/+<
MV%ST7'R&/0D12&Q#5''@9G\J;FKE&7ZI`RM4<9]IRLYK-;LK%>.DJU$8VA(7
MV^L)YBN4BK3Z,34W!5N_\/L]0$2B`CG\MY''#P#.VVKD649&%X8[H;AWR+11
ME3\;F12*<>]OILOW9UFAVT+1>CL%>96%K)`WJR>7R'A&PJQCAYY'8_QP;(:_
M:S2G=UNG/BW2G)#D\@W=N/ZMQK)KW,3,SQ_BH&*%8C1U='D/8WMHEV3H"J*1
M$C'MTS)+`(A"'(/;F?W&U!P=7,L.+HX5Q,.X^C(GC51DLQ[J@95AC8=/45V-
MQ5O)?<W%]N-G%D;6)I9-M,V1E$'ZX878_;^(^+^),CJ;?2RJ+'K6W#+]0H6S
M4*KZ?F-IB;G0[G%-YJMV2%<`NQD6+D/0>Q@*LV=-U`,DN@J4B[=8ADU"%.4Q
M0J#L]7L=+L)=5MHG@V$+E71A8J1_M![@CH18BX(-63U.VUV\U\6UU4R3Z^=`
MR.IN"#_L([$'J#<$`BN_=8-;&G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4J!GD/X#
MY?Y!\!E\EO/QP5PB!<V#(=+;-@4FLVO16WQ-95J<@D6<PLG\9&\HS]P$=-1]
M/:LFBHGV7!N:[/@N[7:X)+8S66:*]EECOU4]Q<=U:UU/X7!Y?EW%-9S#32:G
M8J+D$QO:YC>W1U_WCXC\>M9H>2VX\ZN/43F5QE-1U7)]-3B'.*[U78BV2J]4
M<[CB36-A7=TC8I^H[@7U>V#.'<%:&#@C<$G8/7`]O>14`NI[::CVWYGJLS49
M6OP,V''E]?%=XE];[/*+.D9<?F>>/,)H74M=?%/@17S:_J'V/NQ[7<SP.3<?
MV^RP,79XXBR(TGE,'WF(%BD<1%C%XSQ>A,/HL6:0_`U`*T>3#3IE?OM^(\4N
M1Q"B8%WVH8/58JWN`$.QSC>LU"CV8KDW_*G54-W'OZ]=3-[6:77,3QC.VVI^
M2X^4[1#Y?E3^LEOPL*T&E]Z^1<@A2'G&!I]VGQ;)Q(UEZ_*:`0R`_CY$UQ52
MYC\(-#GV-;E>$6WYS:Y=P1!D3BQL#C1OLNCC[4RQ>7:G`R,NY$5>WM1:RW<`
M]`'OZ]?C[OW*XK&9TW.NS\!!<C/QQ!8?C/CNH`_%HS70#VF]G/<TE4U&WT^R
M9NC8&1]POD?B(,E'8#Y!916A'%,(X^7V!O')_87-H@=ARKCAI-<D5N2=69XM
MI%DQZ?J1H5%QR0@:O/Z#,NXNK,6YXE&R_7:S*\&[<-U45P11.2N/,^1;MI8M
M?Q_!^VT6PV43%<5SDXGW:/ZA^P=XX0&?^(\`+1+(%967R(-JO:WB6!I,DX?)
M=W#N.4:G!D]-IT2#8)A,OI*NQ1)9BPC_`(44[>$K1L5<-X*:S5:+X^N;VU7R
MW[;6'.0\OGMXG9"U3MIXM[/GVIBJO(*`JBV945E+1=ZB(N,8D3;,F/XHHM&:
M":12`!.P3;Q_GO"M'BQ:C+^ZU,42!%3,@EA%@`+F5@8R6-V9B_5B:C7W(X!S
M+DT[;/6C'V4KDEOMIHY"+]@(P0X`L`H"]K?"IG^//F9R;\:%]"FZ=0=)C<?G
MI5/^O<>O]<GZLY9NE3E1<VJCDL;)DG%6A!(@"H0G9M)$(!%NQ@363S^;^W7$
MO=_4_<ZC)Q3OXH_R<F)UD!`[)+X$WC/S(\D/5;]5,'</]W.=^P6_^WWF'F-Q
M.:7_`+C%F1T*GXR0>8'A*!UM^S(!XMV5EW%Y#K^>;IG]<TW+;*PM=,LS(KJ-
ME&*@"9-0H`#J-DFINR\9+QRPBDY:K`55%0H@8/T$?G[R#CVXXIN)M#O('Q]C
M`;,K=B/W65NS*PZJP)!'4&OIQQ+E_'><:#'Y+Q?*CR]/DK=74]F'[4;KW21#
MT=&`92+$5Z;UIZZ6G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4JO'R6\.R\P.,-WHE
M4:5]CJ;)[!7"ASLM[8]O^?K2JS<6<S*MF;MZ2->5V2?-A$$U13^4!`H]@#J4
M/:/GIX#S*#:91E;4R(\4R+U)1Q<%5)`++($;N+V(N+U#/OO[9K[I<`GT<'I+
MN(94GQG?H%D0V:[6)"O$SJ;`];&QL*Q9OLCX,92\<)Z1H>A\K;O'KJH/:?E3
M=UC.-,Y)L<R;IA+:-;(]WI5G;MW)!34"-AXGW]A]JX>@]7MCE]P>3A9<2+&T
MFJ<='G*Y645/4,L,9$$9([!Y9&'Q4U\W7S_:[V\4X\K9?(^017!CA5L/"20=
M"KS2J<B4`_&.&($=G%[URY>7$Q68IQ6,,J&=\::>Z3%!Q$8=7$ZW8Y1#MV`+
M+J,BYE]1LJQR!_,%Q+_$H/\`Q10[`&^U?MYQO%R%V&Y,VWVB]?4S6]90;_\`
MQP"V/'\QXQ7'S)ZU'?*_>SW,W^*^JU,L6CT+7'H:]#!Y+T'YD]SDRFPL?.8@
M]>ENE2HXQ6I5&J9E5'SA=Q*\T]5Y%YJY*Y566=3E1S?B1I\>51PLHH91ZBYT
M[6&'<#B?W.6)?VAU%?O3F#/V7IPA?M]'A8TP```23(S81V'06AQV^71C5G_Z
M-.,RZ709^[S/)LW?9[XP9C=FBQ<661NIZD-/.@-R>J?.LWF>!+H6"$)7?R:5
ME6(U29EKXO4YQ5W_```5-E^,]LD=P8Y>Q03[G$0].I0QVQVA=LKP^TN;^=O"
MWXWZ6K!YXF>N9&N`)/N_`6"7\KVZ6MUOT_NK4SP?PCS+7>'B&T*]U.L9JNBV
M4(/)Y^B_I)XY4"@46])U=A:9I\U,D;^$&T9[1+^A@_7J)>6\G_I]U;,^UCQ9
MMLM^FO4K/Y#_`.[&:-%/_-)^JL7C7#/ZKM\RQ:";*QM*Y!OLV5\8K?XX^4DK
M,I'P2$BU:@.(_'"T8+"SCB[/LC=6ZTBS6G38UFA\NK3ETU(8OW'T.SF5(.6E
M#`;V_=3BX]8R8>TP"7L`5-]Q^;:_EV5`FI38IK<8,$^]R?NI0#^ZKLGJ(@_R
MS+*H/46-7;]G?;+;^W^)D3\@DT[[K+\3*=;A'!A9A?ZGC63T9).P]5<>!K=#
M<6`F+U&E353I2G2E.E*=*4Z4ITI3I2G2E.E*=*5\"`?K_A_M=/QI6%KS'<>(
MV)Y'\B;WF\(UKU\H"L7I&UYI$IF20L637U5,*IR=H3#_`#CJ$_.G6@;TV1`W
MXF=;$D!`&S\12O7[)\YR1Q[7ZC;2-)A37AQ9V_=EB'U84Q[!O'Q?&8_MQMX?
MM1V-`?ZA/9K!R]UE\LX_"J92VDS(%^*N>F7&/\+-<3#LL@\NSDBA8+T!2F.*
MW\)2B(]C>@``"/ZA^X/3JQ0R"3T/R[_C\ZJ1_I0E@OCWK0UP=XZW':_()X_,
MNB%G$55N$7%^J\AMHD4TB&*VMV]/9S3QJJGO-[!EK2VNL)'J=^RR;)DN(!W1
M#M5'W#Y/C8O%N0;>6SS[C9/B8X/^7BA8?+_E4QR./AY,/F:^AWM-Q%]:G'])
MC@I!K<`94_S]7+9IO$_]+HOZ%^0%:P>.W!+B'Q0;`E@6`9UG\B)A4<6=K")2
MMU>JG$QE%'EUG32=H7^0YQ$2"[^,/T*4```"KV\YERGDO3=YV1/'_@+D1C]$
M:V3_`-M6,UW&]#J&]378D$4O^((//_UF[?WU+(2@/ZAW_P!D1ZYBPK=GKWK[
M?IZ=>:4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5Y[/9-F%IG7UHLN>TN>L
MTG3I#/']CEZQ#2$\[H4N9R>6I:TPZ9JR!JO)G>*BX8_)]=85!$Q1[]9<&PS\
M:%<?'GF2!)A*%5V"B10`KV!MYBPLW<6[UCR8F+,S/-%&[-&4)*@DH>ZDD=5/
MQ7L:P.^1KP\V?B[S5R*B9PSD)+C/RHV&L5++;"/V'`Y^_LUE9HV',+,\$3G!
M>M0Z[AY&.E![OHI(>XF6;N.KM\#]W(^1<1RLO8.!R#6XKO,O^:$0^,B#_C(`
M8?NL?D153^5>S>OUG)<=<*(G4YN4BJ>I],E@61B>HL+E3^\H^8-;"?';QK;9
M!7=GVR;B?Q^B\K-6E-+D45T2IO:[E4"D%.P.A&]H%!)*MY?%,W"J8%*!'T@X
M#MZ!U5'G'('VF1B:J-O+"UV,(P1V>9_KR9/^J8L/T*M66X]J(]>N1E%;965-
MYGYA%`2)/T+&HZ?,FK&^N'KHJ=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=
M*4Z4ITI77I^JURTDBT[)!Q$\2#G8RSPI9:/;/PB+'#*G6B9R.^RFI].5CE3F
M%%=/VJ$]P@`]A$!]D,\^.6,#LGFA1O$D>2MT*M;N#\J_#QQR6]0`^)!%Q>Q'
M8C\1\#7/E*!"@4```*````'8``/0```]```Z]0_&OW7VZ\TITI3I2G2E.E*=
M*4Z4ITI6?SG7Y<>4N5>02K^-G@;PVJO*7?5L&'D'=7>B[+'9)7(FJ+2KJ-;Q
M<(J]8G1D)%LDW(X<'6=I=P=)D22.(',52NH)\T?[QHH`C_8Z\:B=A`.RG-JH
ME$?0/4/YP]PZ4JSC@;J/D&U>LWN<Y[\8\CXLS3";CHS/*;F^N%U^2L$65F=Q
M-6.PR[!,(2(:?:61;LFR:BCDYDESJ@F3XO>I4XK#8(2IP$W:;+*,X.N5J'D[
M!/S4BN5M'1$)#,EY&5E'[DX@FW91[!LHJJ<WH0A!']G2E9B_';_>.!YI<WH'
MCSH7&UUAF!<C5=C2X*;],3$J)-^7R"S.XM]'/V,I&L(QA)RT/'N3E3:+K_!)
MI%9#[U%4S"I6HO\`9^_M^W_=Z4JI',?)';K_`.8?D;XR'685V-I^'\;J9ND;
MJK>P22UDGY&T#0`6@'U>49$C&;%L%T/[%DUS*#]<O</XA[*5;?TI70=6T:OX
M[EVDZY;1=%JF64&X:/9Q8HE</@KU'KTC9IH6:!U$B+._QL6K\9!,4#'[`(A^
MO2E9G\.\ZWDXY89K"[UQ8\&.B:E@EW>3H9W?7?+/*JNYL<9!3;^ONW:L+-5U
MF[:J(2D8N@I[041%5(X)J*%#W"I4C<Q\DWF<O>D4>DV;P66#+JY9[7"0=@TB
MV\P\R=5BC0C^010E[7,MX&K24L^8P<>91P*#5%19P)`3('N,'2E:#E#"1,YP
M]1(0Q@#U`!$I1'L/[AZ4K.MXG/[PEC7D(TNT<<MCIK?C5R0:W*^1665Z0EG;
MZ@;U6*=./XETXS.UR[&+^[=X7Z)PDH0P&6]I!5;'6*"R;=2KT-_TEWC6#[9L
M$?%MIQ_E.1Z1I+*%>.56;28=T6G3-G;1;IV@FJLU;R"T6")U"%,8A3B(`(AV
MZ4J+WBXYDV#R!\#./7,&TTF'SF?VJ"M,O(TN`E7LW$0:E>T&VTM))E*2+9H]
M=$=(5HC@WR)E$AU1*'<"@(J5)[D!N&>\:<2U3D!K$TE7\XQZC6+0+A**'3*=
M.'KD:N_6:LR*G3*YE))1(K9F@`@9PZ632+W,<`Z4JACP\>>BR^13=+-QYY%<
M;/\`5-T:TY'!\BN,,<\GI:52W+#I-_)LWE@CE)J+BOE?LVR"#Q#Z@*HO6A7:
MI/:5J<14K2-TI63UL`__`'!)#T]/[,8@CZ?]IL@[CTI5V'.RL^4&TJY\Q\=N
MD\2\K9,R3#O3)SDC5K[=)28<*"U2@(BJ0]3:?CHZ/:I%76=N5UC+JJ'2(0I"
MD.912JT_$-SQ\@>U\_O(KP>YT6[!KO,<,8C)TXRR8709BEPDM-W@7\A(NBJS
MLBXDWC$D89LF0BR"!B*E./J`ATI7#^?[?]+UYQQX\,W%686:\BO(?8D8_5YV
M,,HHMD7$>$=JKZ=;YPS9-4[!E9VD8Z;_`,0E^U&1\B@7NHLD`J54%Y-K&YT+
MAYD'%;A;XD_*/EVD^.6]5F?X0<F&O'-6+KL:ZRZ::(3UM?+)R8VP:]J$5%J3
M;HZC+[3B6(U=+I>XIR"I6K/Q/^0"J>2K@_D')F&^E'721C34_:J>V$2*T;9Z
MFFBPO4`LU.4B[5F[>>R2C@.`&/&/FYA_B$0!2JB>.0=_[V)Y`!_8'CWR+O\`
MN[CA?;O_`(NE*U+=*5$'R$?^@?G!_P"T'DK_`*&+ITI6<+Q`9_Y.K]X6_'$E
MX^N0/&C`X6+K.\*:<[W3+;%ITY:99UO%X)6V]=2CCDBX.&B62#DRYC`9RY77
M+ZE(EV.I5W_"')?*S2;]:ICGWRTXY;=0%*N5C2Z;A6'.LZ?H6I>1;JKSUCL,
MN<72K!A%MSHH-&Y1!91R)U#`"10.I5FZ_P#F%O\`FE/^`/2E8F_#5XV\#\DW
MB-UZ@:PG*5#1J/Y".4UEP7D%1E?Q>M8)?VSZ@OXRUT2P(*MGB3<LDT14>QPK
M$;/BI@(BFN1%PBI4D(OR,<F...9\GO%1Y>21\;R*EN+N_0W$?F0Q1.PR;FY6
MD<NML?#-G<LJBA&U[:3(_"FY:KB@H]=F^)9--X=$T@I5B']VQ_\`A(X'?]RM
M+_T[:ETI4`O-YJ$]S]Y>8KX9LI4MTKEE0B2<Q/)5(YO&R-@LS+#,T22MM3Q:
M)C8=,7DC=-"601.RC4S?,XE9&$$I1)\O92JR?*ARRU>]CP^YD<4?$;Y'^)^\
M>-68C9JH7S1>/B%>R/\`U7J]%*IW/*KVXK\O+/XVEL8-G[$.Z!T&C!W()F]H
M.!4*I6M(GE)XV*^,5;RF)S7R86WP\-:<,2.$SS"%C'XH0,I6$I1(E<QTI<E8
M!,P`7\D<H?[P0-TI4:>>'A99\M>6U6YQXES+Y!\(^2D-DX8I/WK$BP[[^K*"
MA)NY5FR<MY)>.>1CQ-5Z9)91!R*3A%-(#)>Y,#BI4?\`^Q&YZ_\`Z!_(A_U"
M!_\`%?2E3+\9_B4JWCRO/(_;;#R)V#E?R-Y3R-27UC;-C"+:3DC%T9H]:UZ*
M:QT49P4#E^^<SERX<.%5@31(7XR)]C*5W[CIXSJ?BO._E;Y#;OJ5EVW>N23*
M&IE8<6B`B8>*P7'X)1(S/+<\29NGZRD>X3CHXKIXH9)9R+$#"0#KN!44JS?I
M2JJN%/BRIG`[E;S#WS$=;M#+).8EC;:!9.+SBN1"5!H6FD<F>/[G29UN]+(,
M_P`FO(R)5&0MBI?`[22]PD:-_:I42>5_@QN^\<[]0Y]8AY'.1G#C3]6S^EYK
M86&*UF``35:G0T#&%C%;`XGH]^]8R;RN-GBB2B0`1<@=A$"ATI721\(W/;L/
M;^\$>1`/00_Z!`_M#]UM`>E*O%)A*$[Q?'C-JEXM.IM9S"5,-T71YY1!I=-$
M;RU!/0[;<YA5`%VS:SVI%PX>KF(!R$=+B(=P#I2LZ^,>`WR)\7<[A</XP^=3
M<,HPJEN9H,_SXG'#/YH*U&S<T^GW;0TB[N8'<K+R<DLNH8A$DA55.)$TP-[0
M4J3^,^+'RAT[5\_M6Q>=;D)K.8URT14Y<\RBL(SBB.[Y#1C@'BE6/;TIJ?<0
M4?,JHD0=K(M5%_J'4*D9-0Q%2*5H"4+[R&)^GO*)._\`B]P"'?\`R]*57;XR
M/'E6?&A@=PP6J:98-6CK?N>E;@O8[)`QE=?,I#2#0HNX!%C%.WK=5G&?A2B1
M8QP.H*ANY2@`!TI7J/.7@GQP\A^!V7CQR8I#:U5&9(H\@9ML"32XY[:TVZJ,
M7=J%/_$HY@K)%&5$2F*!T'*0F0<IK(**)&4K\7CWX:P7C\X<XMP^JEXF-'@\
M6B;+$Q=VL44QA9>;2LEVL]U%5]%Q:Z[)N+)>RF;E`B@^]-$#"(&$0!2O&_']
MXT*;P:N_*W:)34+)OW(CF+KSS4==V>YU^'KLP:-(*QZSG-?BHEP^1B*;4U'S
MHS9$JYO<"Q""`)H($(I5DTK%QLY%R,+,,6DI$2[!Y%RL8_03=,9&-D&ZC1\P
M>MEBG1<-'C54R:B9@$IR&$!#L/2E4'Y+X`L<R_BERKX'.=[T:X<-^2W(7,MU
MA\7EZ_"(!CL?1-RHNR3^8U.S)/UGDC4[^QSN.@GBBR*2[=`AW:7=THJ8ZE6K
MZ3S7XRY)?93+[YI0QE_@XN$FYFL1E,T"UOXF*LA'BD`\DCU"J3S5DG+DCUQ0
M!10IC@D;L'H/75:OA/)]SKDVNOQ?+7R.RJ[2PQAF2WF%]21"?&XN0+=1UKF]
MAR_CNKSFUN;D>.<B*S((Y7*J]_$MX(P'E8VN?A7L64ZYG&XT:(TK*+7'W2D3
MJLFWC)^,([106=0LF\A9ADNUD&S.08OXJ7CUVSANNBDLBLD8AR@(=NM+M=5L
M='GOK-M$T&<@4E6MV90RD$$@AE((()!!K:ZW9X&WPUS];*LV&][,+]2K%6%B
M`00P(((!Z5^YOI-'=:+*Y*WL;%;1H2H0U^E:F4''Y)E3[#+R\!#3ZHF1!J+)
M_,0+Q`GM4%3WH&[E`.PC^'UV='KDV[1-_+9)FB63I8R(JLR][W"NI[=C7L7.
MQ'SFUJN#G)$)"G6X1B5#?*Q*D=_A7&:UL6:8537&@:Q;&%-J+>2B(895\@_>
M&<3-@D$(J#AX^.BFDA*RDK+2+DB+=LV0565.;L4H^O7MU&GV>]S5UVHA:?,9
M6;Q%A944LS$L0JJJ@DDD`"O5L]KK]-B'.V<JPXH95\C<_4Q"JH`!)+$@``$D
MUXQ1.<G%O2+M7,YJ6GBXNEP7?M*M"35)T2H'L#V,BW<T^CXE[;ZE!1KV10B6
M"[GZY%A6,BB<Q2B!1[;K8<'Y3J\&799N+;"A"F1EDAD\`S!066.1V`+$"]K`
MD7/6M3A<QXYL,N/`Q,D'+EOX*4D3R(!)`+HHO8$VO?I4F+#88:J5Z<M=C?HQ
M->K4-)V&=E'7O^O&0T,R7D920<?$513X&3%L=0_M*8?:4>P#US./CS960F+C
MJ7R)'"*H[LS'Q4"_Q)(%=#//%C0/DSL%AC0LQ/8*HNQ/Z`#42:KY"^'MSEJ5
M#0&Q(*NM&F(.`HSF3I&DUZ%L\S9P+_3<=%V.PTZ*KZSB?$Y09`+H`<F,4$Q,
M)@`>OR_;OF6##/-D81"8R,\H66%V14_;+(DC.`O[WT]/C7,XW..+9DD,<&4"
M<AE6,F.55=G_`&0KL@4EOAUZ_"I<V">B*M!35FL#Y*,@:[$R,[-R2X'%".B(
MAFM(23]<$RG4%%FR;G4-[2F-[2CV`1].N/@@FR9TQ<=2^1(ZHJCN68V4#])(
M%=---'CPOD3$+#&I9B>P51<G]0ZUT.=VW*JSDJ.[3UUBHW(W%<KUN1O2Y7@Q
M!ZW:PC1KTN!4VIWOUI4)AK\?\KW_`,XON`/7ML,?1[;*W'\@QX'?<"5X_2%O
M+S3R\U[VNOB;]?A6'-MM;!K!N)IE76&-7$AOX^+V\6[7L?(6Z?&O4N_IW["'
M[OV_Y.M2"#6QKR:0W7(HO8('`9"^0+39;/4W]XK^>K+JEGI2K1BZ[=Y+-B_"
M+3V$.T7,5(RI5U4FZRA"&314,7;1Z/<2Z63D4>/*=+%,(GFM]*R$`^)^/Q%S
M:P)4$W90=9)NM5%M$TDD\8VTD1D6*_UE!>Y`_4>G?H>G0UZSWZU5;.H3S_D6
MX:UAY;F<ULJ;<*%.6.MW*1;T/3Y*!KDU3WSB-M+*4LD92GE>0_IY\T53=J?:
M%)`4S>\P``CUV\'MQS3*2!X,(G[E$:,>K`&=90&C(1I0_P!8(\>ES<`=:Y&;
MG?$X&E$N6`('9)"(Y2J,C%7!<1E;JP(;KTMUZ5,F)EHV>BHV<AGK>2B)F/9R
ML5(LU2+M)"-D&Z;MB^:+$$2+-G;58BB9@'L8A@'KBYHI,>1H9U*S(Q5E/<$&
MQ!'S!%C7512QSQ+-$0T3*"I'8@BX(_`CJ*Z51=;S;3)&_0]"N,+:)?++F\SS
M18N,<_)(4ZZ,&3*1<P$XS5*DNT=@QD$52&]HI*IG[IF,`#VS<[4[/5Q8\^Q@
MDABRX1+"6'22,D@.I[$7!'S![BL7#V>!L'FBPI4DDQY3'(`>J.!<JP[@V/Z#
M\*^N8Z[FFSPLO8\LN4+>8""MMGHDI,0"YG<<VMM-DU(>SPI70ID2<KQ$FD9%
M0Z0G1,8!]AS!Z]>=IJ-GI9TQ=M`^/DO"DH5Q9O3D'DC$=QY`WL;'Y@5XU^SP
M-K&\VNE2:%)&C9E-P'0V9;_,'Y=#\":_GKFQ9E@U#F=/U^XQ-#H5?,Q)+V29
M,X^FU5DWS>-8(@BS0=/7*[IZZ(0I$DE#^HF$/:4PAYT^GV>_V":K30OD;"2_
MBBVN?$%CU)```%[D@?#O7YVFVUVEPGV.UF2#"2WD['H+FP'2Y))[``UW+^HH
M+^G_`.J_R\=_3/X?^H?S_P!QO^(_`_2_)?F?R'R?5_&?C_Y_S>[X_B_B[]O7
MK"]"?U_M?!_NO/P\+'R\KV\?'OY7Z6[WZ6O69Z\/H?<^:_;^'EY7^GQM?ROV
MM;K?M:J#=ZE+9"^1#E.K5:CS(NOW<KXL_DF_$6V2-9)"BVBM0!I_YBD-`.F+
MYS)$54&*%)P8R:23D#E+[@'JP7'XL2?VWU(RIM-!XY>?XG81J_E<P7$/U@CQ
ML/4N+$E+7L:@_=MD1>X&S;%3;3%L3"\A@N4\;">QE^@@E@?R[,;`->UQ4\?%
M64Y>&U1,L8WV%]-Y`N7"$@XD'EO8.G.YZ"NZC-+?2<9#NW^IQKA0R-C7,V2*
MK+)K&*`E$!&/?=<@\WFL+6Q<0=+"-K8L0#0!2RB!AUA`8VC*@];UW'ML+<5C
MN06.5E$WOY@G(E)$Q(!,P/24V%WO;I7.5E$@>3W8'`.VHJ&X2X<B+$`=_<3*
M3:MJ/]I03,RL/KJB?VE]JYE?<4?<0I?:8WJRV/\`^78:^)M_/,GK]-K_`&V-
MT[^7R^%NW7O67CJ/]?Y+7Z_RF#I]7^?-U[>/]AO\Q:N+\E:K]GDF(2T.R),S
MT'S+XHS5?JI7HQC^ZS<?K,,JPJ$+++-5XB)FIU3^4W<R2C2.2/ZKN$2_Q=>W
MVS$;[C.BF)3'DTN>KR6\A&IQWO(Z@AF1>[*EW/[JD]*Q?<$LNKPY(QY3)ML)
MD2Y!D83K9%:Q"LQZ`O9!^\P'6O(M?T37=!Y'<!6&F\>['@<3%<D;++QD[;-$
MS>[-[-,)\?=C:H56,CLOG+<^9RSALZ5<E</P9L")-E"BO\IDDS[;3ZW4Z[C?
M()-5L8]A(^M165(9HBB_>8Q\R9TC!4$*"$+/]0^FP)&#L\[9YN]TR;#"DPHU
MSF(9Y(I`[?;S`(!"SD&UR"P"]"";VJ>_)\I3\8^1!!.BD0^%:X457'S?73*:
M@6$!47^NFNX^$@#W/["'/V[^THCV#K@N*$CD^L/4G[_'_3_&3M<C]5R/QKLN
M0B^@SA<"^'-U-[#\MOE<]/PO^%5>YICE$CN/O!JQ<A>6G)*?H[62XBR=&H,A
M2X-KG<CK1F%5/D5=6EJI@T;;R5A.VJ-B(*O9%N@8$T_N.`[B891VFZV,N_WN
M-QO3ZN/-*YZRRK(QE&/>3[APKY;1^?IW\@B$]_!:CC7:G$BTNGGWFTV,F*#A
M&.-HU$1F^CT5NF,K^/G8`NX%K>9JU3D:4#\>]W(*B*0'QG4"BJX^3X$P-2)P
M!46^%-9;XB?J;V$.;M^@"/IU%/&[CDFO(Z_]]!\O\U?G8?VD"I*WH!TF8&-@
M<2;KUZ?EMUZ7/]@)^59]M5SNE-_&=7)%ON_.1_)DPSC^X+`W>*Y$IX"JY%3.
M#*,';F3Q5I7`HY#")6ACNB-A1!+L?V]AZL1J=EFO[G21/K]"L'W^6/.)L+[N
MWYW4`9);U;?M?3>]^E05L=?A+[?HXSMVTHP\<^,BYGVQ_A7!OCA?3^76UK=:
MTT+'.DW6421.X4324.FW2,D11<Y""8J*9UCI(%.J8`*`G,4@"/J(!Z]5=4`@
M!B`I^/R'ZK]OPJQ!)"W`)-NW^[K;^^LY-[I.^3ECNUFFMSPRC\N9SE1FF@4W
M*I#)--LFD4K5&U'?RF%8%$Z?!V<E>E\RDL8C92,F[`SA7582)(SZSAS[DG!T
M[(8&=QZ""#&@P,^?B$>HFADG&1`D,L)E5<K+:!D\UF7),;QPF19SX8ZA;%08
M*S</=RSS9$V9@P\F?8PR1PF&5Y8YA&3CXPE5@&B:$,KR!#$`TQ+=&(T-5.0G
M9:L5Z5LU?4J=BDH6*?3U65D6$P>N33ID@M*08R\6HM&R@13TYT`<(',BL!/>
M0>PAU7;+CABRI(L>3U<59"$DL5\U!(5O%OJ7R%CXGJ+V-3?CO-)CI).GIY#*
MI9+@^+$"ZW%P;&XN"0:SGR>7;(]XI\O;S1.2.HQ>>Q7)KF]([#AT#6H5&H7#
M%T=2T)'4ZW3]"=XK9;93KV[@3.G";WY)-C]TBB!2II*?.C9*+:Z>/EFFP<W6
M8K[!M7K%QLEG<R)D^A$<=Y(1DHDD0>P*@1MXD-<D>)@*+5[9N-[3-PMEDK@K
ML]@T^.J*(W@]>7UD24X[2(_C<^0+KY`@6!\AH"Q)Q776+Y*YJ#&0BZBOF5$5
MJL=+K).95C6U*M%F@FDDX05627?H18I%5.4Y@,<!'JO6\7*7<YB9C*V:,J4.
MRCZ2_FWD0#;H6N0#\*G34&!M3C-BAABG'C\`>X3P'B">HO:US\ZI&J]`AK;K
M',H^5;T_R756.\;^;E$C1*+>[I+S_%.1E(D1;":MUQPE!;Q".&<B%&<I"ZF`
M;NI'Z;9XD'=&<,S8R8FHTJ[;7KEZMM=B?8&66*-4SU!ZD,X\\5[H<E39/)8O
M-T/[42P84&3L-J==FMC9XS<G[STXY'9L0L+CZ5/CD+9A`PN_BS^*L.TX?%VC
MG:.,;&&1.Z\[RI3EAOBN<&JH.P@D:2I.QPUENQ^XT9J>U&(!(#=@4#W]^YS'
M]W7$>ZC;)MWA'<+*NV&HQ?6]2WD9?$^9-B>[7M^'86M74>VRZ]=1F?RHQG7'
M:Y7I>%_$)YCQ`N!\+?\`C>]=9YGQ&JVGD)@:;NZY3DN.TZ4DEZ&]V*ES^F4S
M8-]L]*NR/X^?B*Q9ZO'TV/S3-8R66CG%@?M6\G*R8D;)JK-T1'W<,FT^)Q[8
MGT,S,W$R#U1C2I!)CXB2Q$E6>.0R-/,T881(S)'']1"L:_/*X=GD[O"\IL7&
MU,3'T_7C:5)\ETDL&"L@C$40<H78!W:R@E14>*?4=!=^+C6\SN6O0<3A40PK
M,KD7)IC0=(>P%MXC2-KK5PL=;F,;2<CLT+`U^AI2]0]ZZA2N:RJUD$G9D`57
M+TN;F:Y/=;#VF%A2/O79UR,(S0AH]B(WC1UR2/MF9YO3R+"]I@\;*&LM:'%Q
F<YO;O)P,O*1=.O@8,H1RE7PC(CNC0?QU"Q><-ST,95PWB"U?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g303715g68n37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303715g68n37.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X005:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-3$R03DW.#<U.3,T,3%%,4$W,$)%138Y.3$T
M1$,U,CDB('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-3$R03DW.#8U.3,T
M,3%%,4$W,$)%138Y.3$T1$,U,CDB('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IE-C<V,S-F,RUC9&5C+30W.3`M.3DS9BUE
M869D-V5D.#%F8S<B('-T4F5F.F1O8W5M96YT240](G5U:60Z.38R,&4T,C(M
M.#<X-2TT,V$R+6(S-3,M93$Q-V$Y-6%F-S@V(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG<V5K87(\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\
M+V1C.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!,041/0U-?,C(X
M-SDQ7S@N9&]C/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R
M9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A
M8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<
M`5H``QLE1QP"```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N
M``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!
M`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`__``!$(`#``J@,!$0`"$0$#$0'_Q`"F```!!`(#`0$`
M```````````(``<)"@0&`0(+!0,!``$$`P$````````````````!`@4&`P0'
M"!````8!`P($`@@%`P4``````0(#!`4&!P`1"!()(3$3%%%206'1(C)"%0IQ
M@9&2(Z&Q%L$S)1<8$0`!`P(%`@4!!P('`0`````!`!$"`P0A,1(%!D%187&!
M(A,4D:&Q,D(C!U(D\,'1X?%B,Q7_V@`,`P$``A$#$0`_`+97<L[BU%[>N'S7
M.80:6/(=E,O'XYH9E_26F7Y"@"KYT)#`HE%L.OJ5.`AOML&K#Q?C5?D=[\8E
M*G:Q/[DF./8`]UI7UY&TI^P&=?-NP\?)5HYCN[=[M;#C[E"UQ[6(3CVI('*W
MNI\70JD&S0.X])$A7#M3]1<M$U#@G[@2"4Q@_%KJE'B'!_KAM33GN,8.8_++
M%NN>8_I4&;[<-&LU`('KI#>A93:<).[]`9PX$Y!Y09B6@*Y<\+MI>+N[%@=-
M",FIUNT%2!6CFP*"*7Z^J<H`B7\(@;;PU1=_X;4LN14MJV_5*A7(()?VA\1]
MBE;6_!LY3KM\L,'[GI@H6^+7?ZYJ9.Y<XMI.09:@IX=R#DYI6U8=G2(]E)-H
M&<DA:1::4V4/<&<-TCE`ZFX[CYZO&[\$V&UV>M7M*50WM*D^K42\AG@_=1MM
M?W-2N":H-(SR;[D4_=[[R'+/B1RV7PQQZGJ,SJE?JL2_G&\]4H^P/5)AXJJ9
M9$SUUNJ@7VQ0$"AMY[ZB>&<+V?<]G%]N<:DZ\IEFD8X=/3[ELWU[=T[DTJ)&
MD#)@4]G*;O(9)@>VA@WE1@B7J<?EO(%C3J5J:RT,SFF<=,Q#0X6(J<0L8R*`
M*.@*H0/RD/X:T-GX7:GE-QM.XPG.RI1>)$B'!R+AG[>:*^XUA94JE(Q^<X2<
M9>BC/>=XSO.N<8PN6*[264GCO]"4EIW(+3"3%U4VQ4E!!5564Z/0;HH%_'\!
MU<8<*X0+CZ2;"Y)80^:6M^S.HRGN6XS>1E+1'!](8_<FWH/?&[Q&5D+$ZQC&
MUF^MZG&FE[.XK.&8N4;UV+*`F&3EU$B@1DR*`"(G..VP:R5>#<-MY"G5@8U)
MX1$JTHN?!SFLAO[V,215,I#M`$>N"D#XI=W3N)<\++1L%<?JQCNOVRO5\LMG
M+-]JK:;N*CB%64,[<Q];0$8]JF0A!2;I`43JJ`(ZKNZ</XMQ^E4W&^-2I3D0
M*=+41CD?<[D>I62G?[G=Q$+<B,^I8%O1E*EBONI\5:W:5L#9=Y=5^X9N:RKF
M"?.W-`>4>,;3C<AR+,`;E:(I)I)+IB/4<H;@'@.J==\5W*O2&Y[?;:=N+^W6
M9R;/LZD[?<:$/V;F4I5Q@9:1&(48F=.9/>R0RQ(,>)KS$W*#$EAE90:3;L/T
M>LV:/C6S(XBI7[2[<+HGB9ED0HE'W`E%4Q1$N^K18;9P:-D*F\4JU"[$`91G
M4G$R)_I#X^@R6D;G<3,QA,2@9%C$`EO%@FKX@][/N`M^9U)XN<NZ/5E7EHNC
M.AV&`2J36J6VGRCT!%-V8(Q04')$_`=C=13$'<!UO;QPGC];8SNFT"4(_'K$
MC,R!;IB2BWO[WYQ&H=0)8A@&_P"5<*07/Z8"8"B(B(CL&P;[_#XAKBT';%6)
M?MZX_*']=/0EZQOE#_7ZOMT)'&75<BL8/RAX?7\="5=!6,(AL`>7T[]/\Q^C
M3988]4H5?/O$]XB8X0N8W#.!`K\UG>902E)A_-LBR<31H4_09N=W'',4CI_(
ME,()E-N!0\1UT;A7#*6^1-_N3BU`:,06U^N?WJ&W*_JTOV;9A5&9S^U0$1'[
MB_N0L)1B]E)W%4U&MW"2SN)-CN+9@^:@<#*-_=MNA=$RI"B`'*("7??70S_'
M/&)@QA1JQEW^21;T=F"C8[A?`/.K##/VC_160>W!WM,*<VGK#&U[28X=SHL0
MI&56D'A!@KBJ0A`.>K23A0!.Z4.([-CCUB'EOKF'*.`W^QQ^ILC]19DN>DH#
MQBV7<NI6QW,5A\5<"%;I_P!AW\%.`FJ=380#80$`,`AT[[^>Y=PV,`AJB"6+
M$N?\8J5_!9NGH5%K]RU,3[OF?BJ$FC/24]ACQ@M%@<%!9E4=/V_ZNNV#\!EB
MI[]8!X[:[S_&8I4]DG.F1\LIG5X-^4GL%6MV/]RWZC%@IH[QW'>W;QAX(X4K
MUI4KF=:M*T2KP(8>I:4'.2#U5%BW6DU9B&D7"+%DFWD.HRGKF*;KW$`'5#GQ
MKE%]OMS<T(RIU_DE(3)T>V1RC(Y^BWA>6,+2%"HTNX[>?95X>YOW#>/V?,/4
M'#/$?"BW'6BS4N:ZY)@S0</7'DX\(0[2%%^WKZJS9TW20`52`8QC>/D&^NA\
M2X[N>WUIW>]RE5O3A`Z];#[3FHFZN[>Y)IVP$8PQ]1D@FR_DOCVRRKQ'GN-\
MB_/'8QI^+&>0)%_7GM>44R'$339W9)!,CM)%1ZDH83?YR[E,`>`ZLEI1W`V5
M[3W&F14J5:A@!BT2&&7?-EA_9U1-*7L&DGOJ=RGQY+,9+GKW'\B.*RPLTW"V
M:0B(YLYJ\<M-R)B,ZVT]J+)HW`3+%<NC#N!0$0+N.M*QG#CG&8UZ[Q$(^[!^
MI`_%)=3G6NC&VD-<Y=\PAFM--LD)77G&FTYQKE:)4;S)OPH-IK]VAB1-L4*#
M)9NZDWD82&:.54T@`PBIL)O'4K1G3K&.YTH1-,TW,@7)B,1AF[K1G(4IF)'[
MHPTOU[JQ5*\JL)/^U<TX!8DO::')A:@MHV7IMI82=&9'C$2F>V::3GYYNQAW
M<`9`@'2<$5$K@!#IWUQG;]PM[OGGUTA(T1/#VEWR!;/-62K3J4MGT@@52'0'
M<(JS=,0]H_N(YAKB@MY>U6BOXK1EX1X<3C7F9S(V15L]:B`G9"*I0*<!Z#$$
M?H'5WWZ5M<\QVZUG[H0!F01^IPV:P6TI"RK5H#\V`\B,2C/_`&TMPQ'1ZGR9
ME+=;*S7;2BXKSM96=D6L<Z&KL6KQ9TY1.Z4(*K=)?Q-TB/C]>HG^4+.^NZEG
M1MZ<I4GD"PR.83]GK4;:4S6D,(8`^`4)7,>ZM.1?<`SYDS$"17E?2LD]/-9=
MBETMABH)$S=>;,HD4"D06.7[IQVZM]=`X[2GMVS6]&\:-0``Q)QR41?U!4C,
MTOUR=$1V?UN?X9!R3=^'BZTU1:HA^J9PI3NYQE9CYB*DO<@9]$-Y==-LM9VJ
M8'5;*)%$P'*&_GJ#YB>.RMJ=#>O97G(BE,0,I..F`P&.>2VK.-W3#VAPB'EB
MV"-CM@T2CV+NW2%GRI_RG,\Y:HNQY#Q-D2P2"3Y>%G8XZA)5O;4R`8CB:@!*
MHT*8H@4BA"B`;&#41RRI<4^%_P!B!0C`1$XC^DX!O/,IVV2^2^:H?=(O_NKK
MA0Z0Z?H`?#P\]_'?X_3KA,1$!HY*W29UVW`/$?(/J$?]O'3D@\$UF2<W8FQ$
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M0I$;QZ;L=R$5.;H`PAN.F;_RVAQ^ZA;7-*I*A(_^C$1'@_5,M+6K=PUPTZQD
M#GX(J.9G:`E>$V`\#9GQ%,Y@N/(Z=N$(D\A8>,]16H3R2)'73!IPIW#DXMGZ
M>Q%1$`.3S\!U$;'S.CONX7%G>&G#;!$B+D#4/$G)9+JSKVM*%4R)J$Y`.0>W
MDK9';6RSR(RUQFHLEREQS/8WS%#M$X:<;6$B;5]:V3)))-C;2,@/[EL+\FP+
M%4*`^KXZX]R:PL;'=JD-NF*EJ9.&Q`?H.C!3]A<_46P)_,"V.!4B.H-;BCTY
MX=N/`/<`JT9!9;92438JT*YJI>JZH5O8(05^GU$>I3=-ZR5$H;I*`(?`0U/;
M#R:^X]7/TIB:-7\\9.7\NWV+5N[&E=1U$Z:W2791.XB_;+\8J9;6\_DG+-YR
M;"L'8.VE6*P;5YDY`A^M-&2=(.72RZ/5MU`0$P-X[ZNE[_*-]7H?%94!"KUE
M*6H#R`$?Q47#9#(_W$Q*'@&)\R^*(C'O8$XC4W/!,WSDW:;XB@_</6F.+*WC
MUJ6BF<H)LV!FA2>JJSCT@Z4RF'R#<=1EU_(F]7-A]'`1A5TM\@)!]`%DALE"
M%75(DTG?3ECYK9.7?8QX=\F)RO6UNB]P<2I0CMDXCL6Q<;%1LHD4ZCP\A((G
M(8JCQ`I1`#!^4-M:VS<\WG::1I5)2KN7>4G(]3BLM?::56>JBU,Y81&/X?:F
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MEY%<;-NE3<HTQ.O,'`Y8EW6U<V,;BWC1?3$>&?WHB\X5S`_;*XD5/@'B6!1Y
M'7_E'=W%2J^.+5,1[)Y*-;'Z#:P6F=>-0,6,C:^SV524-TF,<`Z=)N'(K_<-
MZAO)'QW$)`Q'8A.HVD*5L:!]P(013G[8Z[J32;ZB<F(RJUV89ME)>%=PLNXD
M8D72:2CR%0>L'B*4NR9K"<B:BGI@<I0$0\==%I?RK:&B!>6DY7(S.L,3W`TX
M.HJ6QW)<4YP,3W&(_P!5*!@[L4<=L0<<<D87:VZP25VRY%M(JZY?]DU).HL6
MRGJJQM<9+&42BHYP?\1>L3'#S$=5>]Y]N%[N5*\$!"SH$Z*;XE^LC^KP<+9&
MS4XT--26JO\`U,B,X*=K7%/`V@9;H=!O%ILXY<0]I+3L\W8I24:V!DX:)I,O
M;E`A@3!P)PZMPZ@U'[_R^[W^YHUZL8Q%"6J,<^WAX+/;6/TT)Q)<R#.W^2UC
MA?VD\5<,,G+Y1K&2KE=YKU["HQ0LZ#'T8Q&SJ`M*HMCM]CD256*4W\0UDWSF
MEYO-G]'.F(0(`.(+MZ+%:;4+6O\`,9.P/1LU+/N`_2/EN'F(>/CXF'Z/AJEQ
MDP8YJ6+DXIG<^9SQUQSQ1=LP92FVM?IM*A74G)/7*Q4Q76214.VC6A-Q47>O
MUB@FF0H"(B.L@<YLR=$=>BK4<987+?=<SL/('*3M**Q%#VUC9F-?=(%<,*?C
M2M/?U2J59B^'=JVM-I?H(NY!5/[Y&I/3,(;[:"!$.R(#$R.16]Y`D'?=[[D%
M9P[47CU_P3X23+6>R+)1KE9&%R+EB(,F:)@043%,LBS9.D_3,'WR]"8C^;38
M@B+=2D&)5G5JU;,T$&[5%)!HV22;MFJ1`*FW0;D*DDBDGL`@1-(@%`/#8`\M
M(``3$Y$(=U24_<C\6)&E9YJ/)^&9+*5C*4>E7+$Z22V186.$13*Q!P</P"^1
M$>D=O$2[:[I_&.\4[G;ZFV2/[U$NY/Z2<%6MTMC"N*A_\Y8GS[*`SCMG3*_'
M7*]5R+AZX2E/M3*:B4558]90&DJS5>MB+1TNPZO0D&:Q3B!B'*(!OX:Z+N5A
M:;E9FUNH"=(@@.Q9QF/%1\SI/S4W%3OV]%Z3]GS!7V^"<:FON1XO%5XS338J
M.J=^?LFOMXB]35?2=$=LOU$@L$%TEE!4(10Y`$`V`=>8*.WUO_JUJ=G3-2E2
MJ2D8Q)),8R9L`<QX,K37JTS;0^60C4E$,>Q;-53.(^>\Z<>^\O7\=9-Y3K<E
MXBXSCZA3%OB[2XEZJ\:31S@Q(6*25-&1DDP<=(&22(`$-Y#MKL.[[99;APWZ
MJRLXVOM<`Q:88.7+!W[JOVM>=.\]T]478ESCZ%U>+UP=AXJU+"4_[AA^O_;R
MTAB27'1"Z:<A+2N4+5[9::C58I1[<['7ZQ#NC%CC2%EF&$''JKOMVZ;$KV27
M;-3.G?7T)I@(G.([``Z9(2(]OV)T0^)4%_,G$&;<:TEM@#"W).0KM*S18YYS
M3,=P$`U8SL77I8RTM;#O\D%4$8&CQB*ZCE18"`82F$H&\=].&09/Q<L0RK4X
M$X;6GECRKL3#`,ZTEN-G$B/D&4WF'(4FHRQBVN9$W*5AML<V4!1G(`VD#JK%
M#Q67!,ISF\0T99+&X&62/W!.>N/;&BV"@9+K,;D[@5PAL,K;5<]S3V4B+'EK
MD<18T@I#T"$9NV[64B3/R[)D,!P22`#&^&D8._5(F;CLN1)O_<?='RCA^JW3
M*=N>-9_CYB;(-BDHVI87Q+$O46L%:Y?H6,N6X71P1-O&,$>@[H>HVW2&DCB2
M4YL'4Q;CO)9XB:+ABD2/'JL/>8_(^%A)[%F"*S,/GS>F4IZW`RN0,N/EA$U<
MBQ0`7*3<>DQ6Y-S#XAIW5!PP0RT#OM9SJ^1,NN^0;C#QL(X&>O*=+V.BLG)I
MK,.55_\`''4O'*3AZ=)5%B\,";ESL*9"!UF\](0#FFI[,;][/+(5G.EYR_CV
MDQ3*!KD9:,8Q$`[>+QD(V7346?-;M9C&]JY/'M!3$QD1`IUS^D41'R33%*Z^
M+@C]PY#RV.LOYDY%XVBZ%CR@56OA4!KDA[RPY(R//N7WI5&!C5W*BQBGCVY%
MCGV'VY#;G'?8-!@)!BZ`4Q-G[S/<FD<FXHI%:Q1ABD3?(MDA<Z3CFS%?.;)B
M'#P.`6)D3*LBHZ1;1B4E"@+DJ:@)])-AV^\`:(Q$<DA[H;.=_.FD=Q7(*5&R
M)D-:J<%.(Y&TWGV]0*JT<EGW*L<`)%I=!8D5Z9)&0D0,DU(/6()?Y!\-*P=^
MJ5RS+%O'<,YI1^&<:83XSX-QOQVQERH8O,;\>,8-8]P?+B-".B+%[F"QR22J
M*L>C^G"8PJJDV$.HP#L`:5("0K,?:NXQXHXM<3*-2L82Z-L<S!74]?KZ")RK
MW*[.5E/UU^9RLF1PY;H/0.DF<=P$A0VUAE\@DX_+DL@'M4D0;B`&WV$H!M\?
M'Z_,=98N1C^98T(7.'B53>:''FZX2MQ03/-M?>UN7Z2>O`V1B(+QLBB8Q3&(
M0%R`53;81(.I?8=YJ[!N,+^GB`6D.\>H/?P6"ZMS=T/APUNX/<]%YNW(?C?E
MSAWFA_CG+]4D8.8K4\DYB7CANH2)M,:P>D69R4,_,F"+MN]12`3=(B*8CXZ]
M-;7NEGO5I&ZM)B5O,,_6)[2'^:JLX5*6JE+VUO%$+S$[FO(GF-6J=CRV/6%1
MQ70&,,UK5)KQ#HE*]A6)&"$P]D3',[7>J)%_$!@`/(-:&S<9VS9JU6YMHGZN
MO(ZB2X8E\.Q*6H:MQ&$+D@Z,F6N]L&$E[+W`.+T=$MU7\@.4(:06'_(JI[9F
MN1R[<+'^\?9-(HF$QA_B.L_(ZT*&QW,ZA:/Q2`]00EH1!KB$1E->GGKRNK>L
M)3\9OXZ4$C)"Z:1"Y#RW^L/^NA"!'N!<)H;G3B.!QQ+65W6'5.O<!DBNJE]P
MI"R<]6U@<,HJSM&ZJ2CN$<J$`%`*.X?1IKRA+5%.!P0@9NX%<QN5,C!0^1\W
MT#!M$B*:ICR74PO'2SZW6&HK@W2>LHV1F3IA732#5#T%3)#U>F80#PTY(ZV5
M'M@N:M@Z?XN8DGJ]B3C^PK4NWKT#6&[DUOR-<I*.43+/Y8LB@IN'S,9!7U3M
MR"8IA\]-E)BP1BH]2]@O(A.(4+A@<EU5QD-G?F,ZZ9&*_3QT6!"0%Y,&]D0W
MK.9Z7$0]=8P"(D#TP'ITY(MFY#=EKE)D*J8[J..\R8=C(&@W.HW-W"V:F+/V
MEZE8%J#9`;.0#E27@*H4.F*C=A1*(B8WWA'1@$H.#=%&)S>B\B\?N7#[#O$G
M(%?Y&\V.46-X+$=VML6R77LN*U4`4;VK]`5:BK#52-<QRQ4"))*%%DS1V'81
MVT)P88_J1LQ'[=6TQF#..D0YNU)MV5:/=#W;)C"WM'0TZ27D$DE'+,I&:PGD
MWC)YN9193<7(EV$0#0FDDYHJ.0'9>R#F",Q;AJ,R9`0N#Y6>;6+DM)1T>6&L
M]T;1BB:L31J>Q:"5O"U)B)!V3ZOOCL8WCH0&?');_P`M^RKBZ]QW&'_YGH.*
MZ0XP'>F$_-0UM8N7$'>XEA&>TCR6$C<1_4G+-ZF5P8#E'U>GH'P'0E.EW"9"
MJ=C'*\KR"Y"YFS=R';7DN4:VM&5X\;'.(Z4+O%BWC:H^,"P$BZ%#N^DI&3;I
M*9%,H"&P:5TA+ETTCO\`;TW-WQQIF/E[O0%[M3,H,;PC74F+UI19QHC)"\D%
M["Y1,#R2E7J(%3`3@)4DPZ2^>D2(D:WV?,^ARJ=9KNV<*I-5V7QW$T1NJWA%
M4IK&-<;`FE+4S%4?U>Q@XU^Q2]M[L.E8$C&'S-H0I^*;48&BUF$J=:CTHR$K
MT>VBHQFB4`(DU;(E(41$``#*G'<3F\S&'38N1[NZ5RMGTYTB7^NWE_+Q_P!]
M"$&G,?@O@/F[05:1F2IMWSE!)8U>ML>1-I::L\4+T`ZC),H`L!-Q`12$W08`
MVU,;'R#<^/W'U%A/3&8:4#C$@=6R6O=V="^`-;"J,B,U5_RG^V$S4QLS@</9
MXJ$[4%7(BQ+<8]>.F6+4YA$".C-U#(NCH$V#</$PZZG9_P`J;>:0^KMJ@K#\
MQU`B7EV4-5VNZ$F@1.'V'_A2K]M/LM-N"5KB\MS]MK^2\ON2J,7\DXBA1B:G
M#K='N$ZJ0YCJ?J2H%$#+FV'8=M5/E'.#OU*5E;PE3M07!?&0[%;5KMM2WJ?+
M.0EX?[JP)J@*76(<IA.80*80W^`Z$+IT'^4W]H_9H0ET'^4W]H_9H0ETG#\I
MO[1^S0W1#.N/3-OOT&W_`(#H0N>@_P`AOH_*/V:$)=)_E-\?PC]FA""'N$QG
M*:<XUV.M\1&IE,J664B()X\;O8N-F(NER+D$+4\K[R:<-(]O-?IASD15,<#(
MB;K*`F`-(0^:5T*_;>[8<=Q5DYG-V4$HF?SU:V"<7&F0ZWZ6-ZD8!6/!)3+D
M5%Y^V2;M0ZTK+&-U.5#=)1Z"AH.H1]@Q3@6B_5U,,!#A^4=]MA^Z/V:(OI#_
M`)DQ+H-MMT&V$=]MAVW^.E0ETG'S*8?Y#H0ET'^4W]H_#;X?#0A+H-Y])OZ#
MH0D)#CON4WCY_='[-"$N@_RF_H.A"70?Y3?VC]FA"70?Y3?T'0A+H/\`*;^@
DZ'9"YZ3_`"F_H/T?RT(2`I^H!$IO/Y1_G]&FRZ>:%FZ<A?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g303715g77o20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303715g77o20.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.R:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN
M<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D1O
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M+3`W,V,M-&$P.2UB9F%D+65A.6$P,#5C-CEC8B(O/B`\9&,Z=&ET;&4^(#QR
M9&8Z06QT/B`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G5N=&ET;&5D
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP"
M```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N``Y!9&]B90!D
MP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`$(`0@,!$0`"$0$#$0'_Q`"?```"`@$%```````````````)
M"@<(!@`!`@0%`0$`````````````````````$```!0(#`P4%"A07`0`````!
M`@,$!08'`!$((3$)05$2,A-A%!4V.7&1(C,6%S>W.`KPH6,T)355E78G5V>7
MUQA8F!E)><'A0E)B<B-3@[/3)&3$U$569D=W2(@IJ1$!````````````````
M`````/_:``P#`0`"$0,1`#\`'IJ`U./=._W/E#4C96Q53H3FC_2Y<VHJFN+3
MU;576%15K<NU$+5-734Q-#<!B#A5_,O%#E*5(A2%'(`RP$`?C$ZX^]YTI_8[
MK3[9>`U^,3KC[WK2G]CNM/MEX#TX;7U<B>?DC8S3II3<.SHN%^@-O:R(0J+5
M(ZZRJBAKE@4A")D':(@&>`/OP&)G3'Q$ZRO?:?4MI@M`K7-$4U#5[1LI0WK@
MT>Q<4RK)IP<RP?,&]>.4W+U&0?-U$U.D`]GT]F6`'KQ`;Y'TK:R+^V"I'3GI
MN"DK=ULXCZ6+,TC7,C*EIU\U;2L(1^^/<<IWCDL<]3`RH@`G':(!G@*=?=ZU
M)][II;YO$2M]_-[)'+@.TQUX5"N^8-U=.>ESLW#]DW5`M"UN!NS7=(I'#/UR
M/0B)#CD.`.MZQ5DOJ9Q/E"?6T\8J]]B_ZFGC7XG_`!'T[XK@%Q]?@AZN--?<
MT`Z'\^8/I#4WOY,!6\MA+Z'AB5&2R]UCT\HQ"33G26_JDT.I&F3[8L@21"+%
MH9D9+T0*@?H"7;GE@(G,4Q1$IBF*8HB4Q3`)3%,`Y"4Q1`!*8!W@.T,!:W3]
M083%I-6MRE4^FC;>TT1%)&$NQ.0N-4?@9HL53>FLCX+,)0WFZ0[<`4GWM16\
MK2_%*M_3S)84XVX=MKI4_.I@(_SAM%4A)U+'$R`0#(DM%HF'//8&`A3C,U.T
MJ[B;:M95D(=@A7S2!$2F*8HN*9IV'@'7HBB8,^^8XV>>T.7FP`UHF(EIV1;1
M$'%R$S+/E.P91D4R7D)!XL;JHMF;5-5==0<MA2%$<!Z:T#-TU5#*%J2&E:?F
M64Q%$>1,VP=1<DU$[MJHF5RR>I(.43&(8H@!BAF`@.`;_P`O-\IUGNY>??U<
M`KAQ`?'33?\`F_M$/M"4YNV[,`]=1^I2Z%JY[@R6*I5S!EMIJ$M$$1<^$D*=
MAI!>7;P]OX=>+,UDW;-5_&"U<+F.8$#D!;/(X&#9@$H^,Q;VDK6<3S5]1=#P
MS*GZ997%CY=E$1R!&S%FYJJD*<JJ6!JW3`$T$E9:97.!2@!0Z6P`#`2GP^K8
MN;IZ!^+=$T^P5E:NI^T]BJW91S5(R[Q>*I6OIQZ^!JD`]<$U%#&$-H$(.>S`
M2+[W58%0XE-)W%>9%IBTMH;SUU5#T3"5)C&$M_-QS5RJ<!`"IFD'B11SV#G@
M!RZB;BFNY?\`O9=,QSJEN-=:OJS3,ITNEV%15-)2:!`*(CT")I.2@4H;"@`!
MR8#/M%M<W;MMJAL]7-B*&;W*NY3U5MG]#T.Z0,Z;U%,$(8$F"C=-RS,J!RB.
MSM"^;@,\UY7(OO=K657]>ZEK;-K1WGG*AI0U86_9ME6B$"LV91#9BF1%9X_4
M`7+%--41,J<1$V>`9%V\WY3OFY.?=\/`*X\0#QTTW?F_M$/M"4Y@'/GT;)/K
M[\`)=E'OGB#&V,FY?+M6BZ[=DW);F",=9VNFF9)LF`!O.8H#R8!3;CBS$;.<
M5K62_B7B#]F6O:>CA<-E"JI`]A[>TA$R3?ID$0[1I(LE4CAO*<@@.T,!;;WM
MS>BFJ*UPU+8NMQ2/1VJNUD[:Z09N%03;R<DR;OW\=$G`<ND:20=N$RY"`@.[
M;@+057I/#@_NN+-4D5/L9*G:KM=2NGC3R[.<`D"I:@IH\ZYC1%-10Z<]05(P
M[L#%$<SI)$5$0Z6`6>VCO$1'E$1$<^4<^7:.`);P>ARXE6DH2B(?3-CN7(=J
M:O-W!P$O\<D<^*[J`S'/*I+>!MS'9ZFZ<``YLL`9C+]MY3OF#S\`KAQ`/'33
M=^;^T0^T+3F`?-HO4S,6YC>$SIH"E8:7I+5+8LU+5/47;OXVL:82C;>1)T'-
M+3<>NBXCCK"N(*B02J9``E,40SP")G%0L93>FWB#ZI+,T@_FY.FZ4N$5Y$O:
MDEG<[/*(59`P]8F3E)I^8[Z5=-UIXR8KK&.LKT.D<QC"(B%,+>5K55MZ\HVO
MJ'>/&-8T=4\)45-.(\ZI'@3,7((.6*"(HB54PO%B`B8@#F<J@EY<`^\AI62X
MA=/57ISU)SU.!?V7T]HZHZZ1AI'P6ZI+4'>1&'C[8/F]/IG!V6"H2AH<[1RW
M,F9)-1^8NP3@.`2"NM;.J[,W,KRT]<,31U6V[JJ;I"H&ABF(`2$&_78+JH]H
M4ACM7`H]HD?+(R9@,&P0P%Z^#WMXE6DO?MN9'Y\V8IJ<^`E_CDY?C7;_`.7^
M)+>Y\H9^IRG=^_9@#-9]W\IUE^JW_!R;L`K?Q`,_5IIOWA_Y_:(=N6?^@E-\
MG+@',YCV>_>_'^V\AR?6Z@>7?@%5..WY676/]&%%^U90V`QS@TZ5&>KKB!62
MH2HF!GU`4=*J73N$`J=@B%/4,!9=%!5R("FAWU+)(`'2V&`I@R'`6AN!Q);B
MVXXP%Q]9=+S3I".BKUOZ1F89BI\C:CM)2L@%&OZ87;@J9%>/?1,8HJD8=J:A
MP5*('#/`2K[X6MO2K;5Y;_4K;\B*E#ZN[%V\N['.6J9$6RT@$26$54!-,.R[
MY>Q$:S=K"7KJN#&-F81$0IWP>LOQE.DO+ZIT=M_@U.?<.`E_CD^5=U`?1);W
ME_RY3@_##`&:V_\`TZZ6[D\[K?#P"N&OX.E6VFTH;!'A_P"B$N?,(V%IL/.V
MX`VTWQHM+2US>%764?"7)<1VC.F#P%W$EJ>(@X5.YIB-@55Z7*+D0ERHK,C*
M`'H,RB`=W`!7XG>HZW&KG7-?G4=:<)].A;HR]-2L.WJ:."*F6PQ=%4Y3KQ%T
MR`Z@)AW[$*&(/2',A@P!^_>TEM(RE["\0[5>^Z)9&G*%<VV@UU$2"+$L;14O
M6+UTT5,`'(JZ<2*"2F0Y=$@8!65=^YEU7$J_/VKZ56<23]0<P[5W(JG=NS[]
MQUUC#OSV\N`*_K$NB>Z/#LX:"TV[6?5;0\;?*WKQPL?IB-/TW7;DE,MRB<3*
M=FQA%T$"!U0!/(,!5[0'?>C=,NL"Q=]KA(2R]&6WK%K/SR,$T[]E5&:*9B&*
MR:](O;+"([L\!(?$BU*V_P!7NNFY>H*UJ$XWH>O)^C5(9*HV(1LP4D9'0T6N
M+MF!U`0Z3AH82ATA]"._`,.]'S/*<=+<'G=;=@%?=>[)\M6VFI1%B^73'0%H
M@`JJ#)TLF(A8:FP,`*)I'((@._(=F`HSX-D_F7*?.U[_`"&`UX.D_F7*?.U]
M_9\`\]P7*%4CN`_J7EXQFX0GJX6U`N7A.]5&[M56";.H1J(@*1%U1[P8@`".
M>S8&S`)7-HV2[V;Y1DGZ0ENC7@;R%V#^X9X"7JSKV?JJVUH+<>"9=&,M=&U4
MDF0T>\%-Q*5154K.NWR>2(B419NFZ(AEO1P$3^#9,=\9)[=@_(YYG_$;0V8#
MOQ<;)^%8GY&2?RUC=\<]$?C]OD(CV&S++`.$]`_[VIY3WH]4W7_6]7K=S?@(
M.L)[G339[MGW/MI_E7XI^*K/V/OK>?,?^A]'`2AS>[BW!UO,'?W/TL!Q_#DP
M%M+8>Q6_\KQ_?GL>>QQUEOCW^M]W/`5K#JE]WWU0ZN[X/T,!OR?\_-X>;RX#
D;\/S`<T_3$_=_>F$ZG7ZX=3]GS=W`5N_#V\HM\'_`&6P'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g303715g82s35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303715g82s35.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!'P&M`P$1``(1`0,1`?_$`.8``0`"`@(#`0$`````
M```````&"`4'!`D"`PH!"P$!``(#`0$!``````````````$(`P0%!@('$```
M!`0"`P4-#PL0"`0$!P`!!`4&``(#!Q$((1(4,1,5&`E!42(DE!96EA=7EU@9
M87$RTB-3TS0E5=6VUC@:@:'1X414U)4V=YCPD;'!0F)RDC.DM#4F=C<*4H)S
M='6U)[=%*'@Y\8/TUZ+B0V2%9H<1`0```@8%"0<#`P4!`0`````!!)%4!086
M%Q%A`@,5\#%!4:%2$Q0T(7&!X1)D-<$R!['1<F)3)$0V(E7_V@`,`P$``A$#
M$0`_`/OX@$`@$`@$`@$`@$`@$`@$`@$!J&^:RIMZR]V'"A'*R>L(UNG<I)"@
M7E`3!13(MU0.$C<F/[JG6EE'G@(0&J&OEXI*C<;JH9O9F.VA114E0-?]85@1
MVHV2(&YON(,<)@\S]N`D'%J)=^G,?X85SV.`<6HEWZ<Q_AA7/8X!Q:B7?IS'
M^&%<]C@'%J)=^G,?X85SV.`X)O+:1I%#50;YYCBN]%S.!BM>)7"4MC+.(F@$
M20X"&&/G0'#;^7$J91$@U5OQF%5JE5/*5:JE0O"L"651$M(`'!P)Z0G";$,,
M,.;SH#-<6HEWZ<Q_AA7/8X!Q:B7?IS'^&%<]C@'%J)=^G,?X85SV.`<6HEWZ
M<Q_AA7/8X#U<6<CW[LR'AB5_P.`P#7R[%#Z`F&:M_LPR[5K%O558O=E7V8Z`
M&1F$9>D<=.YN!N0$DXM1+OTYC_#"N>QP#BU$N_3F/\,*Y['`.+42[].8_P`,
M*Y['`.+42[].8_PPKGL<`XM1+OTYC_#"N>QP$<;.74J93ZM6I?[,,L>Z2M0V
MRA=A6T;,LGY=C'I''!/#I?S@'S("1\6HEWZ<Q_AA7/8X!Q:B7?IS'^&%<]C@
M'%J)=^G,?X85SV.`<6HEWZ<Q_AA7/8X!Q:B7?IS'^&%<]C@(T@9=B9BHN;Y?
M[,(L`4<ATO2"A=E7Q2Y0`B/`]?I$`$2,P!YF`P$EXM1+OTYC_#"N>QP#BU$N
M_3F/\,*Y['`.+42[].8_PPKGL<`XM1+OTYC_``PKGL<`XM1+OTYC_#"N>QP$
M93,NQ2JK.*G4O]F%.4BBF3H42%"["MOZ5BC)YH"9GI(1$9QZ9#3S0\Z`DW%J
M)=^G,?X85SV.`<6HEWZ<Q_AA7/8X!Q:B7?IS'^&%<]C@'%J)=^G,?X85SV.`
M<6HEWZ<Q_AA7/8X"OB+;Y;KYAKDV=KW^O769Z6T;)/A,(]?YWKH35)>*9@49
M<(=<>P[=P<MT&XGF]FQPQ3\=R`[&(!`(!`(!`(!`(!`(!`(!`(!`:/S*5=ZR
M]WPK>M6FN%\6%']H(#HX:G+Q)=-N(99/R:W=5BJ<F%4^BHIUP;;"6,BFDY"D
MPA-MPB'H?-#&/U?<_P`-WGVN>,I#W1?F._\`Y4NQ"/LA.4)#Y><OXDUY?"%;
M3\.B<EKT=Z3I8<V[K=V:H/+SE_$FO+X0K:?AT,EKT=Z3I,V[K=V:H/+SE_$F
MO+X0K:?AT,EKT=Z3I,V[K=V:H/+SE_$FO+X0K:?AT,EKT=Z3I,V[K=V:H<8Q
MR\96K1JTPR27BJC4HC2WNM<*VVS3:V@0FZ='$!QT\V)R5O1HT?\`#T(S9NQI
MYIS1[GH3N7>+DB!,KQ'[LT`*%Z%"<N1N';D2A?>91EU2H!-+C++JZ`T1&2EZ
M/LS-F[&GFFZ&0\O.7\2:\OA"MI^'0R6O1WI.E.;=UN[-4'EYR_B37E\(5M/P
MZ&2UZ.])TF;=UN[-4'EYR_B37E\(5M/PZ&2UZ.])TF;=UN[-4'EYR_B37E\(
M5M/PZ&2UZ.])TF;=UN[-4'EYR_B37E\(5M/PZ&2UZ.])TF;=UN[-4,4D\NV6
M34XF2XCMUB8TI-[$HD7`MT*:5#6$<"DP32@,F([F&[$Y*7H^S1'^6KLQCIT3
ME#*^7G+^)->7PA6T_#HC):]'>DZ4YMW6[LU0>7G+^)->7PA6T_#H9+7H[TG2
M9MW6[LU0>7G+^)->7PA6T_#H9+7H[TG29MW6[LU0>7G+^)->7PA6T_#H9+7H
M[TG29MW6[LU0>7G+^)->7PA6T_#H9+7H[TG29MW6[LU0Q*5R[=`F5JTPR-78
M)],FC&\I]P;=`7$#1FH:'$0&7$]A/B9##1-I\Z<E+T?9HC_+5V8]$Y0RWEYR
M_B37E\(5M/PZ(R6O1WI.E.;=UN[-4'EYR_B37E\(5M/PZ&2UZ.])TF;=UN[-
M4'EYR_B37E\(5M/PZ&2UZ.])TF;=UN[-4'EYR_B37E\(5M/PZ&2UZ.])TF;=
MUN[-4/"IR]A*E)-5K9*KQTZ-/^5J=T&VHA+YW3P0R4O1]F9M76[DW0[`LB&>
MMK9R+/JEWD&UJTP"AFXSK;X(0JS<<ILW1238D>N4V>13XDM51-%I@'3B&C=T
MQX*U;N3MCSOD=KG>XD;<DIV2XA#]JZO7]0['')_(ZWM0CN_Z/]9;GFQH<-F]
M3?\`/RO7'M?O7Z5"<`X!<FC?PQV,B`=`./OCHQPB>&3FH\_*]<>U^=?A?WB<
MGW)CTH0^ZIL!^[ON4/11/#)S4>?E>N/:_.Z`6['W#U$1^$8<+G=1Y[=]4>7P
M>77\4WS5X!<F&'\KLA'#_F$.%SFI'GI7GTQHB@UF[L-"[1NY:@S:!<2C5?D[
M*53U`GLI@XO(Z.FF58#M0<!-SD:A\"X#I]#]6->8W'D_9T-G=;WZV^HPLI`(
M!`("FB%2K<=NZ57@XKO7<FL+T[B&T^V\R`8\[#'1SX"Y<`@$`@$`@$`@$`@$
M`@$`@$`@-'YE/F\WQ_-/<'XLJ41N>?XD7P+L-P+B,VZ-)+6%(G2K5S?J!<W_
M`/O!W(O=(>CBI7:'K8<NA,.OAY=DBAU6,=31!C\8Z^'EV2*'58PT0/&.OAY=
MDBAU6,-$#QCKX>79(H=5C#1`\8Z^'EV2*'58PT0/&.OAY=DBAU6,-$#QCKX>
M79(H=5C#1`\8Z^'EV2*'58PT0/&.OAY=DBAU6,-$#QCKX>79(H=5C#1`\8Z^
M'EV2*'58PT0/&.OAY=DBAU6,-$#QCKX>79(H=5C#1`\8Z^'EV2*'58PT0/&.
MOAY=DBAU6,-$#QCKX>79(H=5C#1`\8Z^'EV2*'58PT0/&.OAY=DBAU6,-$#Q
MCKX>79(H=5C#1`\8Z^'EV2*'58PT0/&.OAY=DBAU6,-$#QCKX>79(H=5C#1`
M\9%7P\'.::BZ5,KRE6*UDLV7KT=KPP'1S,?,C3W_`**+YW/KHN][D%S!@KDP
M0316MO-6B]GQN?WR4>;]6*K7D_+SON6;NY^$DO<[RNO-:]>+?7CA>#!UO%B_
M>O);WS^6+[GWIYF/[,/"/%B=>2UI]5+[OZN=^K[ZAX,#Q8G7DM:/52^[^KG_
M`*OO6'@P/%BBCX>"S5:ZS2WX:._%MGZ7U=JAY?93[5?.2PWCK0S*A2HFM\XR
M+LWZM7]KFAZWV[JB4YFJ`;OGQYRT/6._)^DV?B[5XTVR0"`0"`I*@RE./#=4
M=F/[=W);``)C[BUM3,K*`?PM[Q#SX#JCSL<H)G"RV9KKR(:$<353+<<?&3NP
M#(K$+>E5-=M/>2\:TSW(:67(;G(3`X&A=AJFUQ""<SCP*M[*(:!@-G6RY8EQ
M.A-4G]<*QJ+:RU5&_P!;"U)QW."X21M#)17VY;H-M8J7*1BFV+C4<32/,$I[
M;+$R)SAJ7##"`UQ;OE(\QESKHV8MUOR8SJF;]$LEF@M`%!I`O%;?9:V>D.TY
MFR;AU9%.Q7U!//,`H!,R9+`=`'P4##0&`86ORZ;AEM\LO4C91K/8JFWW:-JB
MAQJN1RE"AQGW&M=+<!(O#L!MO&UI/8-IQE#K\$P`3$"8ZTHA,.S0&TN4;SCY
M@[./Z^=&U=R"[*3[9V"R8+"$%'K-%#.*>8W-JHVW?CZX9?:<<:A`$!CMO9"I
ME3Z2(@>VH8#./N[^:%1O#EQ;%B\VFW\+Y8+EYA;X)SG2+!NBTJ$S&<S5MM,]
MS*UU&:T2A(#SYO>KE`$TFF01@(H"KHP`!$-<V*SRWO4T++&I.2Z9I^.%.S$9
M@;`WL670KVK"SEPS;5RLN"\)1W,6X]GV\1:BA:QBNAM%0%=V;;2<HFP-P&T^
M4`SL9H["K^52Y-F96V[+429?+VYA\SK$:"4#]-.RW#31+6I\SGM4[Y")4X=[
MFLUR9W(7E`)`6R!$0&7#=#4N07-9RA.9_,:VS0+DCBR^MMN9?U*[YQ79]MVR
MRP;5T\F;2NK.>:1DAL5U9KH*-Y'.7$2NS<"$T4>>,!J"KRJF:*V&9S.,F+QM
M,NPQ;6&<V!=BVM"5F%9DM3LVY+6D[=$5HXT4T7O;5O*2$[C`"J.;;N&S@=*;
M@8!;1Q<JM=1@7FO;:VY=CV:VR5@&`K*-Q'V#W5JZ2FN@K:AM7%(N5#:_!@7"
M=]HEL^X.`P.)Z5/,!TF)G'5'5@-.J?+)WK<5I$U:9UH;<MQ[O"W6;&DS5%7<
M2R[TI5O+E^-/\&ZCE6>V1-NDDSG@B-$50LIFND!'I;:<=,!OV\^<FZU2TO)S
MK*O?NVV7!J9ID126+X9HVBD-QY,1HK:59Z9\MIG,U;N0G'6.@]TATC,6`RN%
ML0V,2I7IJ:`UC<GEA7,P+P/6R+$9+*OO5:J,W$EM/LNK.)FE%1]F+D9?[;G)
M'W*#>.2)Z>OR7M%:+&TPJ),9".!434!GJ7*[7%(T3U%S6<MREN&WUL,QKY?3
M4[H+CE7[K.>PEU;H6B-,3*R4--`!?RF>4K;<)FIC.&Q$#TH"`B&(AL?+=RC5
M^;^O'+4RREC[;H%"\Z[>U1<3O"Y=-?0BEL;.HUKE@'&SRK1D<LT[B<%:Y.P<
M&*IHE,2J$A$1PT0'9CF4^;S?'\T]P?BRI1&YY_B1?S_VE^3Y+_;F_P"EQ>Z0
M]'%2NT/6PY="0QU&H0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0$7=_Y,*__#3/
M[,:>_P#119=SZZ+Z`>0C^9.D?WMN'\<#\56O'^9G/@LW8GX63Y=#NA_;^K^K
M]7M2.4[#V0"`\M'Z_P#K<S]?]7W'&!\(H]-#;4N;B6_8_;UOU&H#4G)9S_V-
MS'T]K$P-#,@[.DM&)3%O-[HL-/MW=^I'F[0]8]#)^DV?B[58TVR0"`0"`I8@
MU1X[UU*7#>M_TEL"'!'0^I#M694=ZW<.F/;O/]3Y\!;RJEIQD:H&4XE6"M6+
M5JLU<J7GV@P5'$K--B,PS3D\,)1'$0TX<W$,;UIMD!4PZW&_[MF`.K&*41Q5
MS5(``#2KTIT_4`0#HI\1T^;`9.DEI=*<I5I)Y"C4)EQ+DZM(J6DV8M6'26*S
M2@&]R3:NX'0CSM(P&.+M1LEJ56D3;:*4I5MJWRF72B1;':A':APE*RX[7^ZY
MX0$94+26Y5'V-RSS213;VJ,B:W-5=-E`,5#3&F6J;D!N&BL\PDSB<"X7`R$D
MTF(3>9`3$NA(A6CLQ9'3BI:4@*2-(NGEB]#@P`'I+4EE"78<!]`'0P$&/6<M
MD><;!=!EEMWA>UQ=TT&#7HE`*%VJ#Z)`DNX$E+*#2(4@7D^4*%0!E'H1$`TP
M$_!-3@ITJ0IQ?>Z9<2=$-F+8%BU8)99BH`(CT&@,0`!`?-TP`HGIY#6`D3+D
M]]V<*NSEZ!<)MXEV<L$TLH!CJ@`A+NB',@.)(VV_1KJ9JFAHTII8#W6K`E%`
M,*FJ'W=,$@"=_P!?$(#P,MIN'S]55.(2.;4JZ=,CUE$PFE*YHPE&1&:9-VL:
M>^S$AF'3((C*,!ZRS4;)8P3-%6ZBE#2>6,$29@LEDR]<F4,#+M),I@3DP)3Z
M-`="/.W8#W5VTW#*1303*$CUD2D$N]HU9+)U$N79\=4`(32"4`)=.`880#K7
M;H'3!_@-&VXYL^V'!2RFUFME'$OM!D*>M/O8AHQ@/.JWT.H8)G*J0D53*<)J
MLGUA3RPURE=0`0.SE9IL=[F.Z=;`0&8=T1@/!+;;?1J=*FD(",D4J(F!HTDU
M,)I\I<34V)L9)2@2RRB;'2.J`8\W&`UCF4^;S?'\T]P?BRI1&YY_B1?S^FN8
M+TF^2"K6+4>F3?F"&)R;SMR+W2'HXJ5VAZV'+H9W:"_KY3JO[<=5C-H+^OE.
MJ_MP#:"_KY3JO[<`V@OZ^4ZK^W`-H+^OE.J_MP#:"_KY3JO[<`V@OZ^4ZK^W
M`-H+^OE.J_MP#:"_KY3JO[<`V@OZ^4ZK^W`-H+^OE.J_MP#:"_KY3JO[<`V@
MOZ^4ZK^W`-H+^OE.J_MP#:"_KY3JO[<`V@OZ^4ZK^W`-H+^OE.J_MP#:"_KY
M3JO[<`V@OZ^4ZK^W`-H+^OE.J_MP#:"_KY3JO[<`V@OZ^4ZK^W`1MV&"]5N+
M&]UB_P#59O#]?]F-+?\`HHOG<^NB[_>0FJ4RN2=-JU:^\TNN^X?JV/\`_<E#
M#'S=$57O'^9G?@LW=S\))>YW.<*$/OXK^KZD<)U7GPHGX^VRVYY^[YGU/_JH
M!PHGX^VRVYYVYYGU?_I8#PX4(??Q7]7U(".NQ0)FF^J#2.%ZU42QS$-S]G<@
M-:\EEM/6;F-&K3*2TN,@[=YWG09'^S;2QVH?]+&/.6EZSX?H]#)>DV??%VGQ
MI-D@$`@$!3-"V_CMW2]02]D[DMA0"K_XEJ;7F0QT[NKKX?4@+F0"`0"`0"`0
M"`0"`0"`0"`0"`T?F4#?<O=[Z/KEIKA?K`VE$`_9@/E:)_Y;2[+C)DUT<XZE
M1I+Q8HLT2?<]1PV0%(F!P2F(K^Y*,P>='O\`,>V];P^`;&ZG.^C-W<\<Q0\'
MJ1\H8C,:VM;-@>QSZ,W=SQS%#P>I'RAAF-;6LP/8Y]&;NYXYBAX/4CY0PS&M
MK68'L<^C-W<\<Q0\'J1\H89C6UK,#V.XQC_+27;*T*U6EG(4:M6B7KUMYHV[
M1PVN8OAJ2Z7!B$T^(0S&MK68(L9Q$O\`RU=WCZ6FGZN<!:3:ILL5,5DTS;M(
MVLKM'HR9O^T&G4W!AF-;6LP18S*?1F[N>.8H>#U(^4,,QK:UF!['/HS=W/',
M4/!ZD?*&&8UM:S`]CGT9N[GCF*'@]2/E##,:VM9@>QSZ,W=SQS%#P>I'RAAF
M-;6LP/8Y]&;NYXYBAX/4CY0PS&MK68'L=AT/_+6WC64PFIF\X"VCUC>&_)BA
M;LGM9/S1_M#C#,:VM9@BQF8^C-W<\<Q0\'J1\H89C6UK,#V.?1F[N>.8H>#U
M(^4,,QK:UF!['/HS=W/',4/!ZD?*&&8UM:S`]CGT9N[GCF*'@]2/E##,:VM9
M@>QSZ,W=SQS%#P>I'RAAF-;6LP/8["(W^6QO"JDJANKF\64V>DH*Q*4JH6\)
M;1-*7-"5E/2S=<02B"A+)CB',AF-;6LP18S-_1F[N>.8H>#U(^4,,QK:UF![
M'/HS=W/',4/!ZD?*&&8UM:S`]CGT9N[GCF*'@]2/E##,:VM9@>QSZ,W=SQS%
M#P>I'RAAF-;6LP/8Y]&;NYXYBAX/4CY0PS&MK68'L=V7Y0.3*NSERLI0LR1N
MV9KEFNXW:,BP82":8#C-*:OPR35]C)RX"GZIL2V&[@`\X8\W:%NSDY:'G^EW
M)&Q).3D?(0YEG>)A=O<[J\N]^A]J?<^[AN[N$?'%?<S^0W9Q,;OX8]U>3?,-
M;'90PVCT6MCCAJPXK[CR&[.)C=[OLRAZ+1L@8]#CLO-_<\WG0XK[CR&[?G$P
MNYWV)>8'M3_2QVK^-S(<5]QY#=OSB8W@PQ[JY3?<-;VF/MG'T6[Z'"'%?<>0
MW;=^4/+_`#Y>TV[#?-5C)XTZ[DB]JZE6TDS9E3;2"4GE2];'"F1$AJCH'2.$
M<_?[_P`XVMQN?H7.C`RD`@$`@*6(-.GQW;J5.#3(5>Y+8$.&,)=E'1F5#?-W
M#&4.@\\8"Z<`@$`@$`@$`@$`@$`@$`@$`@-+9C_F_P!ZOS7/CXN*$!.V-^13
M/_NF@_\`)R$!+H!`(!`8I5"3@Q2US`E*>P&L3=+#?RTHEIP$U*.[KTPTAYT!
MCFM/3J-U#J45"NKTJR,FC24SN`FU/6*A,)LV(2`.O5QUA\T1TC`2:`0"`0"`
MAS)JT#+51ZQ56-+U&H7QI+"A@)LX&T3Z3(!@.MCH\Z`F,`@$`@$!#6;7+54>
MI4*JAE9I`M+X;8>$-H`QPR>"<EB(!_5X]+AH#'5@)E`(!`(!`0]L5:%2JY-Y
M6#*QO3K4Z%83(#[E&92J>,R,4W.D2$LVCS1&`F$`@$`@$!#44P7J+[NHTE<R
MHU:2HE[^GUL-G1Q%((B!4H(@&&^>V9N;C-]6`F4`@$`@$!2I!J4.._=2CPF:
M&MW);`CP1B&R2AAF5]3PU<,9Y>C\^6`NK`(!`(!`(!`(!`(!`(!`(!`(#2V8
M_P";_>K\USX^+BA`3]C?D6SO[JH'_*24!*H!`(!`<`\%0"9H:0EZ=79S&]U#
M&.S2C-+NF-`=#CN^9C`<)!VH4-)VZL0KFQ32H&JR=_5A@QLD@3S$\<<20CB,
MOF0&<@$`@$`@(TU=MX!3.$*Z8;/;QZO61P]RYAVB?$2FG#4"7#ZH0$E@$`@$
M`@(PV1.B2K">KIQJMPHJZM9)UMDF+"KJ&S8Z<-N"3#:<-&M`2>`0"`0"`C"$
M)W?5W;#";7EZX#@DQ3_1%BF!+4**6G5X2`?1>8(0$G@$`@$`@(PD"<!5<@&:
MR;5+\)E0)T26.UER_!!$,%36'T4PAC+YF',@)/`(!`(!`4T0A.\=JZ7JR?LG
M<EL(`4=.UZFV9D=8?X^'F0%RX!`(!`(!`(!`(!`(!`(!`(!`:/S*_-XOC^:>
MX/Q:4H#XIV-FGS0++;)FCV=?,0VZE'W/I)O=!<ADL)4KTF3V/8P_^,6VD?XY
MN7Y+3Y-5[?W^OIYW3YQ,.,GF1\?;,?X0W)Z6-S+.Y528,P+Z5SE2<9/,CX^V
M8_PAN3TL,L[E5(S`OI7.5)QD\R/C[9C_``AN3TL,L[E5(S`OI7.5)QD\R/C[
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MF`!2*%WPY-F*<X-:&6=RJDC']\].GS?MY:W,XR>9'Q]LQ_A#<GI899W*J2<P
M+Z5SE2<9/,CX^V8_PAN3TL,L[E5(S`OI7.5)QD\R/C[9C_"&Y/2PRSN54C,"
M^E<Y4G&3S(^/MF/\(;D]+#+.Y52,P+Z5SE2A[\S=YF&:TUEQ%<\F9!=,IQ7?
MR::7N"Y2NUF</OS=C%O_`..[ER?_`$V7<7^OG-_MG(:'9!R2;A>&8O*^WWE>
MG,+F0K.U26W8L'%Y/OQ=0L5-[4\%#I+@='<),B`15"U9;R=M3D5EK)F/.24G
M!VE=QIE>,KF8\/5[/EA&BW3N-,KQE<S'AZO9\L(!W&F5XRN9CP]7L^6$`[C3
M*\97,QX>KV?+"`P+LMNRVPVUY>#,)FB4JJ.FFU"BF%[\7@*[7LH>T_RP@/1R
M-]QG?<NR-_EQWN1RN0P3S97.3D>N[G8L/)52T"5HV].DD45ERGSBS,13Q/#J
MA,(:1'#FP'<'`(!`(!`1-&I;VMNFH"'P:-90)"*COX3`X`X'(X'-7=#8INE@
M\Z`ED`@$`@$!2M"I?^=ZZ57@09?^E-A?=?H?5?5,R'JW.Z7]I?\`S>?`74@$
M!TU<J"],YK#N7E>>N4TZ_E(A;!K9C[O78M,V4K:D"_#98K=M_++:Q7."2G`@
M\E1%6U0TU<,!%9)@&$!3:Q6?OE&32$FM:I9GA%0;>3$I=%'H77:K\)W8NP\3
MF7HY<9(<A20DFRIZDX>ZG1!"4T.8"4P`(@`@9'"`Y=S,]6<QSI9G,/:5D7;4
MV0:?#BRA-%A(%J;E(7"SIO?EZM8[[0Y@U5G.9`%;E3+;YC#2DAG%R4`($T41
M$0QF$1"</3/5G.LS="[5@V2R'+>`K8W+POT&X[7S9Y^\/7"OQ;@I9$JV487$
MC*)V5VI^8=0>*F6+*G2.Q^VAQV0U`;M<68F^=T+(\FJ]GX17+1NF]>:,HGWJ
M:J06<+--M9RH+-O<LMNRJJ"M,*@?E"Y#13$LUK8$EN8@/W(:`1"A%G%S-/>C
MD][,D.[MF\(YS+H7CM[;`VOM>X-ZTPU;)>>,I$T_'?=U&?5L&X40$!A,9'4U
M/@LJ!Y$$Z)4`-#M<!-KJW<O[;FKRC"!4NG>NXM%AHQ6Z]M+V==%U$-F6V>"#
MF!:2/;?+<#0=S0;33D?Z[-ATVVU(\16R(88:0&`[7;=W3SEN=[9PT.[-F4>W
M-N60BE*E@G>V72+@7G$8-6O358X),I,WB.W32+QPP.MB(E#8;+T6`"`=/S*S
M;<JE::WC,N!<9B&7H:JY%\HB@7HEBEQW.62E]^7I%N74N_=]'6&>VYN[`TF,
M&UJB44P'1SL8"QQK/!RB4C)N"_%1B6Q04)A,'*;24E)O6JNQ<5+!5S`.42=Q
M[UI`$5)&6W>S;,-5*X3-H":F;8.VAB:T!`:]NORGN=FW)G-`M4&';@+?6+M@
M+A9[B>%O[JM=2N&5F)6Q!N7?2&U-K'CS>=9UXJ8&4$#('B`$`E#IG0(:NNYG
M)Y2)VMB@Z&XNFD9FJ%I<[J0U*+7RSWB0.,>NV;=]OS=JW@VP!P$[BV777XQC
MJGP4!HS@`D30]-#A`7)*75SVYA[C7!L`M44ZUEMKC&,SC&MX]D"W]P$)XL;N
M`N:T`MQ:>+Z.*)U//#>A#=ZH5`2Q4CJRDA,E-J`1@.UC+A;AY6BLPQ;=W`?*
MC<EVM1&ID%=XJ,QPT:5JDND)A-'91.&QE``Z(>BYG,"`]^93YO-\?S3W!^+*
ME$;GG^)%_/\`VE^3Y+_;F_Z7%[I#T<5*[0];#ET)#'4:A`(!`(!`(!`(!`(!
M`(!`(!`:YNO_`(?N;_<_VI8Y<_Z.#;L_UL>70[O.1(^9BT/]Y<'QP/Q2:W/S
M,[RZ%O[!_#R;N)CENJ0"`0$(N3^03K_X(K?T*`AO(5_-WS!_^K.X7Q$MA`=W
M,`@$`@$!#$"<G,O/.6@:4ZYFFJ)@':)W$216L*.2WL$O6#T$]+#6_?8<R`F<
M`@$`@$!2E`F)<=^[(;6?VWN1Y>L:&G8];?<SN`X8>BU,1W-V`NM`81<62#=1
M%A=5*V\)R$G'590K<XHFE9CIJ?G8ZE,?/W(#J(MORN]KU%LF5J]%LKI6^!&R
MYV/S..!R(#,77VQ0;&8JXR^Q+5,]#.HI'AE<=ZA,0*2S2@4"43<TX?<XXAO%
M[\J)E7M>X'2TKDJ3^93M:330GJ?;+EMZKIJV;1UURM!GTQ)E)]28#I%SOI-*
MFI#(%`DGJ:,0#&`R#,Y1NRSHNC<*UZJU[L,8ZR;R,:R".O.ICG"C;>[\?EHY
MKQ)!-MJ!,3HX2-0L8&OM`2C+-)NX#H#S2>4KRVN*4_50:5UE<H4L6R\R%$Z6
MMDXY4Q8M._E3@9LK20JFI"A*I4/'0'$N8GICAC`:I=_*K9#URG;>F?Z_KG4W
M50M/<!ATV_8I_/PL3<K\G>!VT!0=D;9T$.X2^ML-4+)97`#H'B6`8;L!E[G<
MJYER:3`+NAG'5IU+COR\/?,!9@DK-];;R%<Q.9MN%2Y,[>)JYTE.<)+LR$D&
M-_D$KT&&Z.C`..QL^=H\R;TR_P!NPM[74$"[;D=#6>R!<]HJS9==M[U6^MLS
M\PK#3SS-=R9()Y.7VO-.II:D&@-D+"&`B(`&IB?+/6D2+[9BK5728JBQ6=8$
MS=F@=?J0OGGJJ*P6F>+"8QL#;%)M(@H`H.Q1?I44LLEFEL0`!`SJB("`6:)<
MIME44K@.6U=-P/*C<MH--5="\Q3#'6BCI(&4%M-YVNAB&DDT,LY&X;407BG&
M%)-,#(,@3#NX!`0XYRL^52JQ59YLJH_;CG$VPMS<Q$K4:S*/BO3,NTYMVH[H
M*&0.S%B=%=!SLQ1*!(`X:TN.YI$,G>/-TGO"WN5EI,G+B<O,\L[B.9<C)LU=
M]42;8I*2UV@T"-TW$JW3.+B`Z>#^`B0EMF*2IAP3AP0`-R`SKOY2O+C;!P/Q
MCW3-NIE7"MFW&JX7@TJ#46G*;-BYWDT+=2DF*=12&N_`(OEY)Z8$Y0MB9F$!
MEE$,<`('*>Y4')1K'R*X_*9!`8+XN/<M2/6T>!<K9%KL)9>+;<4UZS,R:$MM
M5$7/;5:3"Q4WI-G2,P2CS8#E6DY2_*S?-V6Y8EL5M[.EW706WLBI:&G6]<AD
MTW!MS*W33N//LR6(3I;20D\J\$P0,F3`@.W!S=T+-YE/F\WQ_-/<'XLJ41N>
M?XD7\_\`:7Y/DO\`;F_Z7%[I#T<5*[0];#ET)#'4:A`(!`(!`(!`(!`(!`(!
M`(!`:YNO_A^YO]S_`&I8Y<_Z.#;L_P!;'ET.[SD2/F8M#_>7!\<#\4FMS\S.
M\NA;^P?P\F[B8Y;JD`@$!"+D_D$Z_P#@BM_0H"&\A7\W?,'_`.K.X7Q$MA`=
MW,`@$`@$!%DFN;J*SGI5E8@>I45,J!4D7$-J2=9((")0Y*.`"-0>F`TX]'`2
MF`0"`0"`IHA5:W';NE2X1*[UW)K"])8!M/MO,@.'.PQT\^`N7`8A43"2REJ2
M0J4939!6(&R"B4$`$#)0V5F)FRP;FB>280\\8#KR8')EY?FVS6.V7E6==P59
MEVNM[9:JX9W`XVK0=5O;-W3GNI9\DY6^VU0HAGU"W2[J;&9U,0P''=``#*N;
MDQLI3F?-U[DG6H]2KSO2FO5%?BRD7-?B7M27<0XW%9^$DLE27@3TTJ[3C2*B
M:EEEU1P'#`!#`/<L\F9E'4B"FBTV<[D),4E.SBP7+-:ZMR&W(@+UDF=W.&&Y
M6W*BN,E,@N"FQ/<0X8+"`GB&@QK#I@(LG\E#DR1T1S-9):=Q$YN.EMV::!]"
M+7DNR*262LOPI_<?X)*FW6<D3SC%E2)-DF`1#$9M'JXXAL)D<G1E*MU1:M-H
M6X4$V1H*5G55!&J]7D<V15L2<?YJVIT=L79YC4R!5N4MB(#*(&@/#CCAC`:Z
MH<D?D4*J),]2M4M`!)@F[<%$SNAOK@PLWU.W+@M4='91<.J"@>8CC-)PF?1:
MHZ,!@)5;GD[+,6AN3:!^6],N1.(6L7[E/FNBN5P.%^*[VN"_6$W;5I+D<K[>
M:HMN:IUC6\1A3$PL$P!+).`[H#B'$7N2_P`G;K=S\>KH8+B7%NX#E=3S4RBM
M<M^&D%NN5]J[3<#]5V.W9W`*,Q3CO4F:G3*$Z7)3UQIX8X#I"3/CDZ\K5P%^
M]KD7F>XY*V8@M,-VTI%?#M0T-PKH2MPN+NE24A3IR$7<$K130`Y0U=!*7''=
M$,`G<F'D_32C.2*;%<:@A,1$NNA-MMK-P7DI(A.6]O786NFK"0.KE0)UYWDW
MBHRSF@U9@EGQ`0$`&`V&\<C5@WY;6RUKUTE<`"N724G1LX]D>ZMP4"Z[)`HW
M!:,PIUT4=P$GK-,HM6<4TX-<U,)PF.$V.B`UD2Y+?)J5>+I?@L!P&W([U4DL
MK!M0N8_%$9E%/?["ND!DMMKAJZDQY\6X2U(SI#7GD$-`#@`9^?DVLIG#CD6I
M&"M497ZAW.;-R$(M<%_%&Q<Q`NTYGF\7(BW(;)5P@CN\BGN:XZX:2MI`>!IC
MH@5U=$!L:SV32QEC%IGN-D)KCK.)A-)TL=KKKG>KD="F4;+S.-(XM)$\ZLHU
MI3-'69J:%`9L1DU1YH@,!L3,I\WF^/YI[@_%E2B-SS_$B_G`D\RELT$OP/56
M"U:J3,FR]:L7-D]EQVSF_P`&+F;B]5BR<E\%49B[<[.3NER.-5:WWQ_GQ+V.
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M05B8<$ENO`_I.>Z,5(MS\S.\NA:&R_PLG\?T=AWE4<LWOZ5_&Z1^'QRV\>51
MRS>_I7\;I'X?`/*HY9O?TK^-TC\/@'E4<LWOZ5_&Z1^'P&!='*<9:UU`6$:D
MY"U&JI)IM/HUN%D;[J__`)"`NMR#JFG+.6R_JHEG"JF0-YM+AC1.D30&2QH.
ML*UX:P#S!TP'>-`(!`(!`11(H5Z2TZ9YT<JG4JR@2&BHE]7:%_!((!MAP<-8
M)B0]+!S.AT0$K@$`@$`@*:H5.IQV[I5.!RLM/N2V%#A?[IJS;7F0YN.X7_D?
M_FP%RH!`(!`(!`(!`(!`(!`(!`(!`:5S(?-^O7^:U\_%Q0@-$M#(OE$/-)K'
M#>7NUE4P:;B"9,5A9+<#:*]=((ZTX^Y^D=$!(^(9DY\72TW:2V_@^`<0S)SX
MNEINTEM_!\`XAF3GQ=+3=I+;^#X!Q#,G/BZ6F[26W\'P&/4\AN3FFFJ0SY=+
M6#3$@;"J)=CMW:0E`OA-LGN>`A/J`.',Q@,:V,AN36HVT*H5R[6UV;@-,"AP
MBQV]PF);8PWL3F"?[?U9NB'F#`2+B&9.?%TM-VDMOX/@'$,R<^+I:;M);?P?
M`.(9DY\72TW:2V_@^`<0S)SXNEINTEM_!\!X\0S)YXNEK.TEN?!\!%F1D1R:
M5&NCU2.7:WP%=X'>>&60W.%,-IFF':_<_3-K!^M`2OB&9.?%TM-VDMOX/@'$
M,R<^+I:;M);?P?`.(9DY\72TW:2V_@^`<0S)SXNEINTEM_!\`XAF3GQ=+3=I
M+;^#X"/,#))E&3T.L50K#M`FG<..'U)1:20!K:>%CX',,2(AL&O[6_>^;`3W
MB897.\E;[M51OP"`<3#*YWDK?=JJ-^`0#B897.\E;[M51OP"`<3#*YWDK?=J
MJ-^`0#B897.\E;[M51OP"`G%F[>6\MHCNEN6U:@-!$!Z*IHXF%R95.*3*Q@J
MG"=,D@)X`)$<`U!W<<=$!NF`0"`0"`AB!L/#SRWCA':^%4SA#;,=BW_@8CO?
M!>/_`.GO>&M^^W("9P"`0"`0%*D#8^._=G^L-N[D>7K'[RUM]S.8?5WO'ZOF
M0%U8!`(!`(!`(!`(!`(!`(!`(!`:6S'_`#?[U?FN?'Q<4("=L;\BF?\`W30?
M^3D("70"`0"`QJA/O9`[4&ML@`7,CMNCI7I:;`W_`*@ACSX#@MR>I4;Z'5JJ
M,JQ4J)I*:JK4<`D5!`I+B=#<T&L-;ZL!((!`(!`("*-&O4,MM*JU5@'#4JEQ
MF%9HR[P!T`,"&L``("&KN#N8@'FP$K@$`@$`@(FUC$YI,JU)UJ5=F!97J`GJ
M,DI<)0+K1Z4"6$H_^'X;-NX=#YT!+(!`(!`(")MNM4JSN$9U>59WER*I>F-(
M-*7+JDAX''$?1$1FT^?`2R`0"`0"`BJ-6GJ+CJDF6`49*2B3"FGX2AP``)">
M.QS#AB.WS3"9#G:T!*H!`(!`("F"%5J\=RZ4G#&M3[E%A?<;1ZET[F0]1YW3
M'MWG^I<^`N?`(!`(!`(!`(!`(!`(!`(!`(#2>8ZKO67V]M7UNUC_`/BVI0'7
MHV>62Y/Q,;;>3#5W'%MB>B)*>;I]R:Z0B!DH3(E3("'6EI&2>;&/48#O?&.F
M,E-Z?<\U&]UV8_\`=E*6?\L_R>G?><7@FNG\D8C`=[ZE-T(Q;=BNRE/R/+/\
MGIWWG%X)KI_)&&`[WU*;H,6W8KLI3\CRS_)Z=]YQ>":Z?R1A@.]]2FZ#%MV*
M[*4_(\L_R>G?><7@FNG\D88#O?4IN@Q;=BNRE/R<,WRSG)\U2ING2NLX:T^S
M&1I4J]I+J`7,ZN("&/6B.(3#YFY"%Q+WZ=,)*<A'W&,+MUV5I<)#Y9OD_:*(
ME4S=SUI.-4B!.B93B-IKJ"6)F1*RS"2*X-$,=4=$H<[FQ,;B7OTZ8R4Y&/N3
MB^[5>E*69\L_R>G?><7@FNG\D8C`=[ZE-T(Q;=BNRE/R/+/\GIWWG%X)KI_)
M&&`[WU*;H,6W8KLI3\CRS_)Z=]YQ>":Z?R1A@.]]2FZ#%MV*[*4_(\L_R>G?
M><7@FNG\D88#O?4IN@Q;=BNRE/R/+/\`)Z=]YQ>":Z?R1A@.]]2FZ#%MV*[*
M4_)@6SRR^0`N@IU,_<M31S5$OC62T^TUTA*%NF)I-4J`-#'4Q''#GQ.!;WQ]
ML9*<C'W)C>Z[,>>=E*6>\L_R>G?><7@FNG\D8C`=[ZE-T(Q;=BNRE/R/+/\`
M)Z=]YQ>":Z?R1A@.]]2FZ#%MV*[*4_(\L_R>G?><7@FNG\D88#O?4IN@Q;=B
MNRE/R/+/\GIWWG%X)KI_)&&`[WU*;H,6W8KLI3\CRS_)Z=]YQ>":Z?R1A@.]
M]2FZ#%MV*[*4_)'&WRS&0$HG5J1^Y2HDU045:OLI&TUT=G$L95CP%#HX,^4`
M%0PQ\\8^HW%OAM;7_P!24Y&/N3B^[5>E*4C\L_R>G?><7@FNG\D8^<!WOJ4W
M0C%MV*[*4_(\L_R>G?><7@FNG\D88#O?4IN@Q;=BNRE/R/+/\GIWWG%X)KI_
M)&&`[WU*;H,6W8KLI3\CRS_)Z=]YQ>":Z?R1A@.]]2FZ#%MV*[*4_(\L_P`G
MIWWG%X)KI_)&&`[WU*;H,6W8KLI3\EJ,IV:"SF;-DO"Y5C5P@Y&:EW,=#(-*
M91)5$,Q.NH)1#.*%-4(+!$D?E49!5Y1F$90E$)@`-..'GI^2G)&;\C/_`+H.
MY)3DG/2OG9+]D>V*V$86T0"`0"`BR/2.4U9QU:Z<G%"M53*B4-D=)M3EX*)!
M.:4Q``EUJ<W0R^8`>>(2F`0"`0"`IFA4S/':NE4V-.V;N36%Z;QZ<QVS,AH\
M_F0%S(!`(!`(!`(!`(!`(!`(!`(!`:/S*?-YOC^:>X/Q94HC<\_Q(O@HMZ\3
MB6V")7@U$4NFC8T:R@4VHU[;`>>$7VD?1_!2R?\`6?#]$Y[H!SL::7XIC<:9
MW0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`
M<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8
MTTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE
M^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3`.Z`<[&FE^*8!W0#G8TTOQ3
M`1IXW$5*377A*HS;)FN#3043A=)Z:*?[ES=(!&&8_;RU-B7_`'<M3OQ_RQ-2
M>KD,NS7JUIJ]6KF_NR-6K6W1P;=O]W'#<BF5^_\`U,W[_P"ZUMS_`/R\E[GT
MA1Y%ZH@$`@$!"4&F4IK[SK%TX^4,55--$V<,RCLBG-*C$=69,$9QZ&231-^^
M']8)M`(!`(!`4I0:1;CP74J;(>VSN36!`3F`;%KZN94`#^'J8A_"@*4L_EFK
M9*=X77:&XMMU"TIIHWMO&R#*\XG22-IBS9*TK!N>[3V81NS$T[W10!<UJ%)!
M-)@8'B)X`QQ#1`;Y:G*OY.7FU%EX);P=()#<:-S7RX*1AE+7":0V[3$&&L.@
M\;H$Z9L)I11[DI9HL!>81F":;2&``(8!E<IFANAPDVBH6F7D]U-M<S34;UH*
M>LE5U6M0V<NBVA)*.XIB<B>1%?IW7!XH1A*#I$,#VG<"`G-O>4_RG7*<MC68
MV'(ZZSKS%&74G6E0ZS+69#CB5;?O!;9]ST@#5.4TG2G[9G4:8ROAM([&1P,B
M.&@`T3?3E05RT5T'>RD*U[=<J4FYK6GE)0%M?=;C;Y3KR-Y>9;\.]86.MQG/
MU4%/3Q5TU-+;.G#C-/,(\P`#E73Y0^_]J;FYA+=5<J2*_:]E;&H%Z*)ZVUVU
MAXFSM%]W&(L%BMIWMHC:#AIH*2Z1E55W`IPV`(R)--@`B(P&S[.<H,0N$]&H
MBJ;=1%]N/K+RWKSM5?L4J.*[14VN!>M1LF_&<`2-Y$6SW6BN'4PR:-"EDMBE
MVL#6&S8P&KLS'*PMS*]F=N%EU=UH5JN5;UL+:/!DW,F=!(LUWW<9^N10)SV?
M`K4(#407?UE$3*V4Q$93M,@9E`-P8#U6+Y65MWBS#TLMY^T*XQGX;S,W7LRB
MT%EUDCE!VVPMNW+I'2M]FW.4(2@>05%U6K44(RF:)R1X,1F'F!$2?+/6U;U^
M,Q%L+KVZ4V@R;#*5X4\R]T)55WFX%DS9MXL-BGB@,65FHVVJ3O47^5%+*(:D
MNFP`,#$LN.(!:5#Y37*VNW(=5H"BJ]Z-RV4U%]TN1EJ#*/DW`DJ349[:?KN8
M)\H9&78G^U&N[D\T:*&-2G*$^&T#S0UT>Y7S*P<93K<[#)W-N$M-6RMXKWFF
M4@M(:"X*/9`VXDAWMRH:-GY24S@E76D:*A*5F.@&[CS(#83\SQ.,6[E'*68L
M<LO&[.<I%5G/;ZWMRW06M)08S9;;!DN*[EBXZW(A/(^G3IR:<+E2Q8JEG1.&
MYPT@`8B''>?*9Y=K8.1^,"YX/)JW(MDV&HX'4V"+64'/,>ZZ'DT+<R)[$G1`
M$\[9"=Q'HGIF.S$MJ&;&4!@/Q/Y4+*JJ)I!:I'[D4$HNP;@W'N$<-6T<Q?N+
M,ZV#B=C&>1V]0;&,S$G3GLRE-,V>?6G$Z2F#0`Z0Y]H>4URQ7W>-M6+;`S<9
MSNNY:J]T<FCIUOUDWUK!;N1HFG*LOM7)[6AM]")4'JF"!D350!VP-&(Z`M%F
M4^;S?'\T]P?BRI1&YY_B1?S_`-I?D^2_VYO^EQ>Z0]'%2NT/6PY="0QU&H0"
M`0"`0"`0"`0"`0"`0"`0"`0"`0"`0$7=_P"3"O\`\-,_LQI[_P!%%EW/KHOH
MV_RPWS"[L_\`J[NW\6+>Q3*_/_IYSEUK87/_``,I[GT@QY=ZH@$`@$!$D6>G
M47'=3I+M=2GI**:%9,K!T#>'@<C-*6+B(`(RGO;/-#&;S<8"6P"`0"`0%*T&
MI+QW+J4N':\P]R>P/N5H]2#6S*^H>>8EZ<Y^-/<QT0&.</)U9.G:Y&0['/9-
M$7G%;TS?HPUE)04W"8KDI,SQ93*7J(&M95UCZ&\*2R8`2YD9I28ATJ%.`A;A
MY+?)N[&2S[?.=ANQPM=AEG2F-Z@H79ND"E3;;R)H!5R-`ZK$W@3/K;.4I&BE
M^Y9J:<F&Q2X2[N(3IS<GSE,=SES#.Y9M11K.?-*U&4RKVK!5R.\E7=J%;S9)
M68!<2CCDX!.ITA0L,QA-E)[9,2E$SK"`C`8!H\FSD[8B_;1VMFV1@NZK.+AU
MR6T<AI\/M26VDO+SM7WF\CJ2;.+T\TD[[7'(9X=QQ!:DFV<UK!`>MQ<GA99\
M7)N<_P!W'WO5%]WB:M_D(FT7N[[;JUO+M(=J9+++[D;CN8#@;ZW,#M8Y0O(;
M+UQ&76E'#S`W/Q6K1%@O)62B3R;3AO\`*+16+G/5`N$^D-^JQYC-U,;;2X.?
M9-QRN%"G149&EE#@\S3`-<R(ATP("&EF-R>=A[?/<BM-+KD0&L@6E;UJF8QT
M%Q.)!%N$TZ]BA?IW.,V\B:]*]%]>N3<0Z7-+PF#8[<-.8#.MM,V`;!O3D7RN
MYB3KO/WBM8FO8R]URSKG7#*@L.,L9F7K!JZDLVL6$N<DIE!0CS5/K)D1`H$D
MIP)P`R$T!^)N1?*ZD7,M5>)/M6F4+EV67+W.:W#P!4<?"S<5,P:NI+=U]764
M1D4"+I6%DP8`N9UY2<X]+!*&,!`ESDS<FKJ=KZ>[CMBHKJU<-R.QUJ]-6N#<
MDVD)CE?JRWG`^UAGMTV[YT-CG'@?:*9,J"E%B(FP)2ZP:=(2EV9`LK[U<-['
M"OL53GGS%)IM/N^BI[S=Z2VW::-D4!*-N29O([@))J<\!)M=-EX4+RR'!`G+
MIQW0AZ3R8^39&D0BE&W"P?26T7NK03$->N&^W"A[5>\HX25U7";(J[@.R\/O
M`BYE`L9-8A,,D^C`=,!L-W9'<O+\MK9FUKD0W<81LOPE.XVZD^YEQT*YK&D(
MHPMG!%NBCN,B^J<R@V/<TV(J,PG"0B$PX`&`:U)<F'DQ).UROBG:M3JKSL5"
M2PL&U"X%Q5*6JJ);[9]R1,E2IUR51#;WQ;M,4C6&`G)Z8B(C*.K`9U1Y.C*0
MJJYI1,VQ4*8K"9==`=J<GO9]I2`_V_>1Y.)_/YMO]&)N64@[D`^]7@IJ14NH
M!-*2G.S;+@&@`V+:/)]8ZR2TSW"RV^XZ[B8;:=3):J^YWP[WDJI+8>!UN'E=
M)E,.5=/#L$PL].P#=#4YXXP$]S*?-YOC^:>X/Q94HC<\_P`2+^?^TOR?)?[<
MW_2XO=(>CBI7:'K8<NA(8ZC4(!`(!`(!`(!`(!`(!`(!`(!`(!`(!`("+N_\
MF%?_`(:9_9C3W_HHLNY]=%]&W^6&^87=G_U=W;^+%O8IE?G_`-/.<NM;"Y_X
M&4]SZ08\N]40"`0"`C"3MO"[CVG@S>.$BFQ[#K<(;QP2G?UKK?NM?'5PYGF8
M0$G@$`@$`@*:(6W<=JZ7]6;)W);"X;O"6KM>9#'S=77P@+EP"`0"`0"`0"`0
M"`0"`0"`0"`T?F5^;Q?'\T]P?BTI0'Q)E^2+Y5(^7HFD9M6WHHQLMP@G4>NL
MY_5:H.V$_P#P``W(_:<V_<_(\LGGY'[E7O>*W';0:^`(^<VY[52G*N1ZXGD?
MN5>]XK<=M!KX`AFW/:J3*N1ZXGD?N5>]XK<=M!KX`AFW/:J3*N1ZXGD?N5>]
MXK<=M!KX`AFW/:J3*N1ZXORIR07*P4J=6KP#;BMO(^UR[L,C^O[@:89MSVJD
MRKD>N+T$^2'Y5\T3)FNMMA$]^+;1O)AV&"IHISML]P>9#-N>U4HRLD.MR/(_
M<J][Q6X[:#7P!#-N>U4IRKD>N)Y'[E7O>*W';0:^`(9MSVJDRKD>N)Y'[E7O
M>*W';0:^`(9MSVJDRKD>N)Y'[E7O>*W';0:^`(9MSVJDRKD>N+\\D'RL'O#;
M?ML-_`,,VY[5295R/7%PT_DBN5A/DZ)KK;8!3?@]IJ#L,E3133IP_L_AS(9M
MSVJDRKD>N+F^1^Y5[WBMQVT&O@"&;<]JI,JY'KB>1^Y5[WBMQVT&O@"&;<]J
MI,JY'KB>1^Y5[WBMQVT&O@"&;<]JI,JY'KB>1^Y5[WBMQVT&O@"&;<]JI,JY
M'KB>1^Y5[WBMQVT&O@"&;<]JI,JY'KBX*?R1?*OGZ&^]:K!)],FR^\J#L,%3
M/2IS8^8WX9MSVJE&5DAUN=Y'[E7O>*W';0:^`(9MSVJE.5<CUQ/(_<J][Q6X
M[:#7P!#-N>U4F5<CUQ/(_<J][Q6X[:#7P!#-N>U4F5<CUQ/(_<J][Q6X[:#7
MP!#-N>U4F5<CUQ>@QR/O*N&B]8J:0;;5Z5?I>M1Z[3OR?TXQ.;<]U_T1EA)/
MHYY#3*)>C)=E.?\`:V^Z2EH[R7<PUQ;@E2Z.=-J9;@)?1F>2(#M1L@3F'^II
M@#0.YYD?F%X;4XU:^U/=<-#]%L20A9$G"1Z81TNZ>.,ZY`(!`("'HE"G37G=
M5I(YA.J5E%+&NIUA#9G![CI_314.<2`!+>?+`3"`0"`0"`I8@TZ?'=NI4X-,
MA5[DM@0X8PEV4=&94-\W<,90Z#SQ@+IP"`0"`0"`0"`0"`0"`0"`0"`TMF/^
M;_>K\USX^+BA`3MC?D4S_P"Z:#_R<A`2Z`0"`0&*51E%*4=\JUJ-/8#6^U:/
MM@O+LPB,TF&/1RRXCY\!CVM4+SMM"JE3==2*U49,FHJ)X0VHV7V0)Y#9O1+T
M<X:1\T=WFP$E@$`@$`@(>R:A>JU4:H54CZP6JEM:BI*.DX:EVF<-8SSIA'1Y
MV,!,(!`(!`("&LRJ6J(]82BB?5:0+2]TT?$-IE,<,J&TD\,)<`)S@,H<_#ZD
M!,H!`(!`("&-6J7JUG0)92/J>].I4H5P4,/<LS*73AG226C'@^EB`RZ=T8"9
MP"`0"`0$-0JE"HO.^G143QNM24DW:BE<<2B7,*00FE*DQE``Z.4-:;S1^K`3
M*`0"`0"`I4@ST./#=6EP@8W[N3V`Z1^Y,-3,L.ON_P"CT7GP%U8!`(!`(!`(
M!`(!`(!`(!`(!`:6S'_-_O5^:Y\?%Q0@)VQOR*9_]TT'_DY"`ET`@$`@.`H#
M5`B<WJH7I5=G,;W5,8[+(.&`3&/WH<WZL!CD$3-1#2!-&R9TT">4WX\G![FF
MZ^R2=,DQQTDIQ'H>?H@)!`(!`(!`1IK5#=1`3:IXXFJ)L:'JQU&_JLR._P`X
M:Y3'F8!AY\!)8!`(!`("+-FJ=J$JXGC::HUN%%4`,)..Q@6%6/;,5F'6PVXG
M3PE,:/1`,!*8!`(!`(",(,YN>HN[2=3C8`X38%1(Z0*E`E):I,Z./M^73CYX
M0$G@$`@$`@(ND5#G"SCE-&TVJ7IJ1;8RQ'0:*EQ220#PIK#B$XS8C+S,,("4
M0"`0"`0%,T*H>X[5T@VM.V/N36%`*'W9J[7F0UNBQP]'A`7,@$`@$`@$`@$`
M@$`@$`@$`@$!H_,H.]9?+X5>:%IK@_7;*CA`?.2R.6FSAJ#829FYE\L"J):>
M5*H](T+BN1M$O!NJ0Q-!AHPU?UQ&/W:7_A>$Y'UGL?BV^_EOZ?;Y-*_+,YW_
M`!;+"=L=Q_21L9'?>1?&<$*GVGEF<[_BV6$[8[C^DAD=]Y$S@A4^T\LSG?\`
M%LL)VQW'])#([[R)G!"I]IY9G._XMEA.V.X_I(9'?>1,X(5/M>DQRR.=HU1J
MEJN6JP=:E5H#1K4.N6Y&Z.(8>ATAIAD=]Y$S@A4^UZ2G+%YU4PF3(D,LM@J!
M`H7+4"M$')<<`+%2\H!IZ'<EE`,/VX9'?>1,X(5/M<SRS.=_Q;+"=L=Q_20R
M.^\B9P0J?:>69SO^+983MCN/Z2&1WWD3."%3[3RS.=_Q;+"=L=Q_20R.^\B9
MP0J?:>69SO\`BV6$[8[C^DAD=]Y$S@A4^T\LSG?\6RPG;'<?TD,COO(F<$*G
MVN&E\L+G-1R5)-2\LM@BA$I+J4:%!R7'P"7'$<.AW!&&1WWD3."%3[7,\LSG
M?\6RPG;'<?TD,COO(F<$*GVGEF<[_BV6$[8[C^DAD=]Y$S@A4^T\LSG?\6RP
MG;'<?TD,COO(F<$*GVGEF<[_`(MEA.V.X_I(9'?>1,X(5/M8A<Y;7..UTA17
MU[+W8%,1DPOM)TX8<5QQ`L6P]%-HTC&MD?L__K0H,X85/M=PO)BYK%/.ED^8
M>8A:9:);Y2>K@N+0-MIMG5532"W`+[7D43Q0VKX'Q!:$EM(XAAC/^M^+6I)>
M1G/(1YGZ](ST)V3\]'I=AL:;>(!`(!`1-MT=YG<7N&*1OKC4:^`&-_X5&8J1
ME%8`1#H=OYVZ&K`2R`0"`0"`B:/0WM;=-0$7@T:JB3$5'?\`'K@`$<@`'1ET
MS2B1'I8/X,!+(!`(!`("F"%0_P#.Y=*MP-JCW)["^[/0^JAMF9`-_P"=ZA[2
MY_JD!<^`0"`0"`0"`0'JJU:=,/5*@4PY^(!^T/.@/;`>JK5ITP]4J!3#GX@'
M[0\Z`]L`@$`@$!H_,I\WF^/YI[@_%E2B-SS_`!(O@%9Q@Q1;Y/>JQBCTP;]K
M\WIV;SXO=(>CBI7:'K8<NA)N$#GWV;ZK-QU&H<('/OLWU6;@'"!S[[-]5FX!
MP@<^^S?59N`<('/OLWU6;@'"!S[[-]5FX!P@<^^S?59N`<('/OLWU6;@'"!S
M[[-]5FX!P@<^^S?59N`<('/OLWU6;@'"!S[[-]5FX!P@<^^S?59N`<('/OLW
MU6;@'"!S[[-]5FX!P@<^^S?59N`UM=PP8JV_<U&K6,UJ6R_??\'&.7/^C@V[
M/];'ET/K0_R\?_M6V-_O3>3_`+JO"*67F_,S7O\`T6]L+\1*_P"/]W=['%=<
M@$`@$!#6H!+?71L1A0KX.I3VO;\>ECFS)V^E2>C#@^0,!E\W&`F4`@$`@$!"
MV^!,5]Y[/74:IKA1,X0HG1$21:MP,3WH$L1E]`-/`9OWT!-(!`(!`("E2!L?
M'?NSZLH;=W(\O0#2^X];?LSN'U=[Q^K`75@$`@$!U`<IW;'-T^G]E.>64A2?
MR8YK'J%];PFT]`6326PKAK[98J"+/LY=,E[04$"[&^*265$Q@!([,!D-(0%(
M,NC[Y7],36(SCS#=5ODY,RJ<,H;<N.QS3R5G#<95L_<!Q"CO&Y'!QTD@71:E
MXJ:84V537-B$B&&RFMJ@/8_;C\IN_&_0S&-*QM_Z#W93F1[!M2SZLV!8"JJM
M"_\`E:MZWGS=Y8;DJG*54$VS&;8@*[PD9Q-DT*4X!;H=`AL5U/3E([-7,=UC
MK,-"^;BM5:O+.[6BR'NX+?-M]%'Q>]F6TMB<M8\$ER'"!$ZI)URKAFUTNO`J
M+AX[H-#TK@4P#:+G=^91W9<N3O6\U2.MLFY2[GFM@G9EFX62N`4E!6RSEN"+
M1;B1*C3>[]L0N.30BJ6J"`\,D!*&S(]%,$!1&U65N_UPN3S1K.O^V>8TAFG?
MEZVFQEFX2T.82V"K9U.>;F.R/J]2J[CEX%@D_B#%MV6,@5,I>Q(HGQ)@!01&
M`FM];?78LY6Y2.D51+PN:V"Q9YQN5KWMN&2NJS%IJWQ2+CVR1K%6>MP;6+@.
MAK75;RZHD14^'41$0Q`0P-B(FL!#L'SC-_,Y=[);<-G,9/N,NW9.YC[.(M-'
MKH"Q:^3K%)WAM>;?A(HKL0^+H7+12M3A,#2Z6$#YXCM6C0&`5UH,7E.LL[)N
M.Q&7<YZ730;/V>M@H,BJ1M\2?AMU.&Z-[7B8N^18KE?:BL/A]*67FSX%Y&NE
MJ9KI\=EE-<Z`B#TN#RKCO9Z:TT:C>FE(_;39L6ZVE]'M0VK=7023B2-P>+Y=
MZZ9TXWSC':;Q7$0BFE1:Q4TAGMN.E34!CUBX_*BN>:WUIK?H.9]+0UC*&K-Y
M[7/N!;1GH"^-T3>61P.-MN]'.$V^3ZTKGD;XE2J&:!34]T?:F([7`;ER@7'Y
M2M5S`V39]UBC]*V#2[/6RF7UF[-GCB6\;@&S5E-I?:P\7&VV_P`!,.Z"#?*G
MLVR&E/`ZCRX[)B:VN`[:LRGS>;X_FGN#\65*(W//\2+^?^TOR?)?[<W_`$N+
MW2'HXJ5VAZV'+H2&.HU"`0"`0"`0"`0"`0"`0"`0"`US=?\`P_<W^Y_M2QRY
M_P!'!MV?ZV/+H?6O_EX__:ML=ZKOW]J[S=%SO^JCOT;L4LO-^9FO?^BWMA?B
M)7_'^[N^CBNN0"`0"`BC?KF*DZ\-=6**^].,[0H`7$/<HOTA@D',)AEVXCK"
M(\W3`2N`0"`0"`B:37,5%=STJJN44:=)5)@53Z&&TI&*00$2AO'0(SS#M`<W
MHH"60"`0"`0%,T*I7X[5TJ7"Q4:/<EL*/!?0[3+TWF0'>]W#"?T?G2P%S(!`
M(!`(!`(!`8XZ3)'Z843Q4N9I!7+UMZKEPKX&"L\IFA/@(#+K4AEQ`>9]7"`R
M,!C3I,DHT]F.E2YRAK4*P4C!?:*`5BTX&*$V$THRB,DTN(:/,YN`ADH!`(!`
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MJ4(N(^VFJ,I>($%Y-K&JQ;U*@)OGX!I'`8T9ZU9/R3/(V3.R<Z^PC_+R_P#M
M6V-]2WG^U5Y.A_\`]5=^GS\8IS>;\S->_P#1:VPOQ$K_`(_W=WD<5UR`0"`0
M$4;]`Q3G7@KI)1(WUQG:]`2X![JE^D,%<YA*$NW'M40'FZ("5P"`0"`0$32:
M!BFKN>K52"B=3JJI,2JA0PVE7P2"`";-XZ`&28-G#F]#`2R`0"`0"`IFA4Z_
M':NE5X)*A1[DMA0X4Z':9NF\R`;YN882>@\Z:`N9`(!`(!`(!`(!`(!`(!`(
M!`(#1^92EON7N^%'UVTUPOBPH_M#`=.+?_R^W)_+J&A+*@T'/5/JR,E*QRL+
MV=X:QM3*2FC>K@X1Q`1F".EQZV:Y'L<G@=BU2#,?1W^3R[$')V[N_P"'XC$%
MLUO:[$\"L2JP/H[_`">78@Y.W=W_``_#$%LUO:[#@5B56!]'?Y/+L0<G;N[_
M`(?AB"V:WM=AP*Q*K`^CO\GEV(.3MW=_P_#$%LUO:[#@5B56#BG/\O-R>)4F
M<J=:#NPI%S=<!+OAW[2(X8Z,'#SHF%OVS'_N1[$<"L2IP>A#_P`O;R>!](2#
MW64]J.U)I4Q-(H/=W\)!,9)@&J<'KA'H@QB>/6UIT><CI^!P*Q*G!D?H[_)Y
M=B#D[=W?\/Q\X@MFM[78G@5B56!]'?Y/+L0<G;N[_A^&(+9K>UV'`K$JL#Z.
M_P`GEV(.3MW=_P`/PQ!;-;VNPX%8E5@?1W^3R[$')V[N_P"'X8@MFM[78<"L
M2JP/H[_)Y=B#D[=W?\/PQ!;-;VNPX%8E5@P;9_R^G)Y+"&FJ8LE\4-K+8[TL
M/9X"I^VQ'`Y_:#=P#]B/J-O6S".CSD>Q'`K$J<&<^CO\GEV(.3MW=_P_'SB"
MV:WM=B>!6)58'T=_D\NQ!R=N[O\`A^&(+9K>UV'`K$JL#Z._R>78@Y.W=W_#
M\,06S6]KL.!6)58'T=_D\NQ!R=N[O^'X8@MFM[78<"L2JP/H[_)Y=B#D[=W?
M\/PQ!;-;VNPX%8E5@[.\GF7>U.52Q2!9*S**L(#":2R[`32"R9-FSHFC[E43
MJH:$T<PGGE.'IYI@YWU8T]]OO.;48NINMUH]D%JXQ)(!`(!`0UJ"2WUT;$74
M*&+J4]KV_'IDYLR=OIHGIPX/G#`)?-Q@)E`==-MZ+]=UL$^Z=P<X]P;?%W0X
MWJ7`K*4R_HC92@)OIP(Z2D))MRVL-'Q$"*.`!M!N>:;$=&@8#:#;MVXGE2-&
M6AGFNBZZ9,!H&*C>#+<ME2IFL`S2RFA2K0&9))@#T(3"`\[<@,NEV@?JX5VY
M%SG7D6"6_5J&V):5ER4"N_%YQIUZ&T%+*UJ(UJ%0-6>7'6E'0(`,!D>X1=3Q
MNKZ=KN7O_P"Q\!&Y["O)N&ZZ@<SD7J3##G5DPG3$^G9?2DIY9J%1)$D\EM%H
M:0&3QS>QWNA(,U2<0PE`<("2=PBZGC=7T[7<O?\`]CX#A*-F;AHZ>?5U?.3>
M=+2DLD:45-344?+H13TY/(T9S)T\?.F;)TBQ,D3+4IJE6K4FEDIR2C-,(``C
M`0U12KGVONOEZH5\PMQ+BMJXC[<[4<+=>*%:BBE'$NC:FX#R(GR!]G6];2R4
M-DEAN%=4=I&6>4<!#"`N[`("E2!L?'?NSZBH;=W(\O0C5^X];?LSN'U=[Q^K
M`75@$`@$`@$`@$`@$`@$`@$`@$!I;,?\W^]7YKGQ\7%"`G;&_(IG_P!TT'_D
MY"`ET`@$`@,:H3[V0.U!K;(`%S([;HZ5Z6FP-_Z@ACSX#@-R<*K?1*O"?#`U
M49*FX6`-YX4$2D@RG\,<0$\(ZV'FP$A@$`@$`@(HSS&TMU*K\.=<>^E]8%K9
M]GVT-_PU]7F8".KAS<("5P"`0"`0$2:Q@#*88J<.2KWNTOT1.`5E*ZN"T>`$
ML99L`Q3?:_\`J^=`2V`0"`0"`B3;K[_4<`\-\,A0<2F7QV<:`)(A*2'@;$<=
M;8,<,1TCC`2V`^<K/]ETOAF4Y->Q32R_6Q,78>S<S'*3Y/-BBJMQ)&9`2W)>
M,D<,C5<AXFGB$IY7+X!B(@`_K^DNK:LG9%M>>GWGKU67-VM8\9"1CHVHM,<E
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M.URM=).HRLU*-]7ZCKIR9J(=972=K6EE)KJE>2F<KII8N6*T`\WW9+-P_$)!
M8"Q-<]?83R)(5%PE5MYV^0*;.IN.[]`A=!'N4E!=.Y:P]V\G67+4ZJ*4*K[C
MUS)H]-/5H5I"96)AHZ>876OG_BQE$_/8[/\`L-=Z(%GH!`4M0JO_`)WKI4N&
M-8>Y/84>!NA]2Z=S(#O6&&KTQ[>Y_J7/@+I0"`0"`0"`0"`0"`0"`0"`0"`T
MMF/^;_>K\USX^+BA`3IC3R=9;/\`5`_)1O\`-YG!!'HO/@)5OM/UVE_&E]-`
M-]I^NTOXTOIH!OM/UVE_&E]-`-]I^NTOXTOIH#@J%2;83F]`7JU`+&1I4ZX]
M+",I?6"4UACT'/\`,&`X2#-5IH:33-44XD:X.*2UB2<(@F%3`E)!$L3##VE)
M@.KY@0&;WVGZ[2_C2^F@&^T_7:7\:7TT`WVGZ[2_C2^F@&^T_7:7\:7TT!ZM
M^I^NE_U__P`T!'VI*=E04L#I%-3S0EI9JI)%FI3)1<*E89Z>Q32RC*-.:0<=
M&CZL?/U0TZ.F"="3:>=+SO0CY_.B=,$&GG2_Q9OV<,(?5`/J2?K#SL<-S=PA
MI@'U)?XLWV(:??0:8/W`>=)^L,-,!$&I7K52BE0KETXJ9(+BF4K%4D)]EH!5
M-U#I*K,$P2@)ZJ0/4:I@0Q`1GW<<0CZCLQV?9%$(PCS)E$)(!`(!`1A!D-R5
M%W:22<4`7";$J!'0!HH,I+5.'0P]OS:<?."`D\!67)Y\WED?\2N!_P!R7?`6
M:@$`@$`@$!6&^?\`BQE$_/8[/^PUWH"ST`@*9H5,]QVKI#LB=L?<FL*(5_NS
M5VO,AK=#AAZ/"`N9`(!`(!`(!`(!`(!`(!`(!`(#1^9?YO%\OS2W!^*ZC$;G
MG^)%\"S'3F.?;]$RZ*SMX4`R;+^X[A6-FZ5._P#$,=`Q=J2NY8OD/1R2H4];
MMM>=T^<G="8\"6C]>N!VP*_R@C>PY=FJ2;!QJV:Y.G`EH_7K@=L"O\H(8<NS
M5),XU;-<G3@2T?KUP.V!7^4$,.79JDF<:MFN3IP):/UZX';`K_*"&'+LU23.
M-6S7)U^];UH_7G_VPK'R@AAR[-4DSC5LUR=>BF@VDI4]ZI5'_1I4<=ZH\++&
MGG#^4`PPY=FJ29QJV:Y.O=P):/UZX';`K_*"&'+LU23.-6S7)TX$M'Z]<#M@
M5_E!##EV:I)G&K9KDZ<"6C]>N!VP*_R@AAR[-4DSC5LUR=.!+1^O7`[8%?Y0
M0PY=FJ29QJV:Y.M/WU.,MG6X7E1F]>_#NS;.2K*#B6-E*`&X<QX0YF$<JU;#
ML:3DO;)R3>D;<MJ<G=$)R=?9#R=BR14<DF4R1Q`9WTMEJLR3E,A7,RS5*!9@
MMJI3DKRC5G`9PGJ"(SXZTPCI$8JEL;C=0W.SO_IA';VXPAJ]D.?WQT++S&WO
M(S$=GZ]J&SN_;#1TZ8\T?=I]BZX5&2`CA5,AK3ZPB!@S,..`RXX!/B(X#'UX
M6SW-E\>-O._M/&6=E",\FT&\)I99!QJFP#"00'2.N.&(\W"/KPMCHW>S0CQ=
MYW]MY#59LPC,-<UK35ZIC'::W\I5I#0G$/5=73)H]%J!S)A'1$>'L_[>P0WV
MWW]O0_`F9O0X&#6MNATS7P\S2,P#N\\`F_>X:8>'L?[>Q0^O&ZHQTH\[%QKM
MU$5%@A3-*!\K2&:@6$T9"2>H,HZ:@R50'"6;3HAX>S_M[%#'XV][^U2T?R:+
MV=S^M=>M;>2B:4U(,S#^(DS!FK.9GD2B[58,I$J`3C,-,J5EGFDEET:`QQQ&
M.):&CS,80AHAH=V5C]6YAM=,79%&DV"`0"`0$,:M(O2K.@"R:?3-]=2I7KBH
M8>ZAF8NG!.K$M./!]7``ET;H0$S@.A_,E1=89(\MBDW&'<&YR8@YB'4L/!GV
MX2'*NJ2L@\+WP)B*J29X[<+?!<.E<1#1I#FP&H,F2UF'2+.9YUY+8]T+!.BY
M[WLG;^P9-XM1R%!::T\@ZQ!<;91WWMG"`-2=QRJ9L-P=ATP&^6)GJS+5U,FU
MZK01#CV67LKV8W^ZYPG;AB)+\R_HS0;5X!(GS?6W,N*-R[C.8T92A*"='82/
M2A4U`;72,Y=\;CW":+4:B:PK9(QG-64M-67'BEN0U)<NUQ5GO%_%'@S938(X
M$"-P$9*34Y$F'&:8^)O$<`E``Q.:#,?<RW%V[Y]8US:*G,U;'*:E;]$0JQ15
M9EJ7ZDTDM'5YLQ;0D3P6I*2\?=Q520E$%&G+,)&8L,ND=8/%?S\W?:T]V0.M
MNSQ=%M*ZV_9VNN.YW3-8TX;AKSOM^SR-Q3;;)**PNMZUJV?<BFJ2[06`940C
MM0&S(8A`;GL?FVN)<FZ5LV"X$)F%"CT:-Q'$*PUA6%4VK%FP\%!);;@%&/J<
MBS;=FNYKE"ZDDFE0N<X9"80E&7=`+!7S_P`6,HGY['9_V&N]`6>@$!2I!DH<
M>&ZM7@\QOW<GL!T]]R8:F98-3<_T>A\^`NK`(#K@NARE]D+2+>8],7V5>-22
M<JYADH]S74WVDW3+:!S/^5G=;31;TZ@\$A34E<Y,_$W3LTA$`F'$SB$!`ECE
M?LJ2"F6V7U!(O&"#<!(=S@45<LP2QPK;-&8E[6_EZ<9U^S%7!-B33[J.4LG>
MX4JV`!ZOZ'3`6;O]G3LSE_MVT;F*==:N`@O^[219%I4+8=;BX=5;BJYM>)R)
M$II7<+=0R4I(VVCDIF<P;EU9I,``0QP#+4LY66:BXC;'<%Z;<M&XR*U33W=-
MN'([VXFO)EH:8VR#P6*CF395$P"<*&V#@&C0X]`4'6QP#6@-7V^Y2C)[<%#<
MKMEO*R&NST:\;AL@@.QSNI$2D-_NAOI#>6%4ZSCDQ^8#Z%+(Y2P2FM$N/.@)
M^<SY9+2#RJL`_F?LB5>U)R%6A6:QBX;;E597.<6NMPLC3%!/ZTI^9:`"V'^E
MNZ-(!AKH<H!DYLYPJ#\ORQB5="N&R[7KZ>GJLJVJ-YY/YRTV<W2"NGI6VJ%'
M67?4#)C5FE*#+A,,O-#)E,[N6A4=PMEO789CEI)I:X59X.%O.YMFT!CF;9%D
MXZYDIQ3"I2*`*)+A<-8"Y:?5`,*XAS0R%LLX-F[Q736+8VT6)WK(D6<;]ZP>
MJ!,45&JJ("\]'DPP2"9HE5$Z+@(KC$-;26V?$`P#=T"&OLF/*`V?SRD+C*=H
MD5[IQ.W"XDHI@\[R".53'%,N$%`^1F1SS;7W)0I*)&DG3`II9P:2NC3B$IHM
M(,P#`1!I\I_E=<CK3$E2,OFWK&=LEQS-L[WW(:`->RUV)+3J%1)?T['>1Q2F
MJ8(L],1D%2*D-M*RB);6W("S*AFLRY([I3V2J7IMV3="HZE9C$48RXB,APR\
M43#A9M!)K2R@OT0$<2WHM`X8Z`$-8D,_>5)4,*B@EWE9"DQ$IH]=QNYJ4[FX
MJLR4!=W6AP30KDE,VL5%*53T:"VR:G[KF0&QD?-GEI<EPVW:=!OM;!6N6\$@
MJOM=D)SR1S;@<*"JMT7>E*J01+'*DQZBI-:0%(O-+CK$AU@P#3`2',I\WF^/
MYI[@_%E2B-SS_$B_G_M+\GR7^W-_TN+W2'HXJ5VAZV'+H2&.HU"`0"`0"`0"
M`0"`T5F'_P`+E[_=8XUN^C=2RO64OLSY/H1XCF5#<T9>+.2:0#<FMRUZF(\[
M5U?UM,5%W,-,KNO\H_TBM1,1_P"5O-GKV8?U6]#$!#2`#HW)0`0UMS3IPQYG
M/\R-C1!@^C6\@Q`1'6F'''0.&&GGZ`QB/I@?1K,!'1HTCH$))<?/`-`#-_\`
MA\P-V)T:('T/(0P#'"3#`1PU0`!E`<!'6TCO>/[K=QT1C^K5!\_3K0A_RA*U
ME"4`Z&649@EE#5G$1D&8))I@TC,&Z`;LT3]>I]Z6NN29"F%E;WS2#6&:?--<
MJI6WT1&4:TS2MMK#1`?0T@EPT<R;6CS,_P"IB]!)^GV7:9&DV2`0"`0$.;%>
ME6K.7>EBLKA3=2G0K#7P$4LQ(5(B*,5Q#33(!-H\\8"8P%9<GGS>61_Q*X'_
M`')=\!9J`]-2E3J8#/2EJ;T.M3QY^`;F/-@/+4D_T/V/LP'KWBAZIZE2Z8_E
M>A#U;1^ZY_UX",N%GMETBD"X41/6.`UU+<Z.!DL$VQ+R5M8)2J&F41J$0,S#
M+CB`"(Z,-$!*=[I[[K[WZIJ_RN`>=AN[OU("LU\_\6,HGY['9_V&N]`6>@$!
M2Q!J2<=ZZE+A8QOO<FL"/`VC9@T9E1WO<PZ(/5//"`NG`(#K#O#R6]@KQ%,V
MQE5.G$U]YOG#;M==EQJ;38"H[&L7MWW/3:2TV\:7VR=V]H&S]MBIDRFJ(G9!
M&:;G2P&#L[R2V6VV+_MG<1>HF[L+EJTBZ]!M)K^;;/!HI#DO#=1`N^M.QMM!
M(04IOM`45>10H)::FEI29*G/A*`3!K0&V<P^1Q+S(6A8%JWI=!<`];>^Y.^C
M?=YJW]K%XN=74E6>)](;SA8*RSS5N5Q`(DG;.4&4PF3:P2RS8@8TP&D[J<DE
M9*\DKWF?C_N!74;A/5QOAQJ2.69Z`9%?<V6-.RQS"CB4;^*>F)R$E`IEBX`,
MH'L9?:^`"$35.1\92R47:RSF)N^>=C]4;PT+J.Z5`M:6,O\`9-^$JV2/<MDB
M@$V:"`TY%"2U:4)1332LITC@.$TT!+C/)#6`JIZDF%'<]R=!13+H)$E;8V>;
M.$RES\P;.S"&]4R9;XS3"AKC%*IA7G$=W3H@,&F<C[9EM&+J'FI<!UH*T]KJ
M)-WF@Z@:S%57A;YSI5^.,+P03<JPF&YW6T#UPQ"84M3`90#]US8">JW)>V[,
M,UOMIOW=NBQUAN%\UX)KW:,S82'."MFV?Z;<5[J@G"R!)C41SZ4!4F&'M/0(
M@,!D,KW)DVMRO=T&JW;BW&7J]S+9.:V*]74#22C&B95X7.N9=175FX91DTD:
M0E.5?ND<V;":;>QEEFTB.@('DEY)>VV2*[)VZK(O#<EUTU%AF[;U[?.-*9B5
M;H$NO,W)@=!)M-M!2"2=<Y<F;1;A]>+ZM1RC+TU+C`9%$Y**TY6@3:+SNE=&
MXEG&2TK[LVQUHW.59TR!9U-S%%%)(?==(6TAN$W0ZCQ%%5S11!%5,G.!24V$
MNG`8#7Y?D9K946YEX:QS,)?-92K"FR+@4>%C;:4S5U;BE[DSW1/73>@S(0?]
M0%Q3KS%3)LL$N)+"7#$,1"7N#DD[:JC#8#*;5Y+M,*C;ZP5LLO!(VUYFX4ZX
M6+;A\+;["F[B=1!EE4NN]15QX3+!J2CSMT1"46<Y*NS%F%NUS@;[V?RBI6M>
MUE'LBUU@JVA-&C5D<M[@RW-E*/&B:%1GX./-5RF39L)1Q$X.@>;`7<S*?-YO
MC^:>X/Q94HC<\_Q(OY_[2_)\E_MS?]+B]TAZ.*E=H>MARZ$ACJ-0@$`@$`@$
M`@$`@-%9A_\`"Y>_W6.-;OHW4LKUE+[+^3ZFE'(WE1QQ`>+]9L`'#&4-6V[8
MP$9@'&7<W0P$!W!`=,5%W,=$INH_ZH_T6IW\/^5O-K_3#^JX(#+B'12<X`Q$
M-,PZ<-S`1'G8#-^ZUAC+];!I>>(8X#,'HAE#1,(C-+IGEU<-89Y0]%*'12;L
MP`$/K-+\Q#2.M+A@$P#T,P#((ZH3:0FDFIS3:`FTR3#H`1'1#Z],-!I`GEQ#
MHY0Z(!$=:<1TX`(X^C&;`/18[YS-;#1'PA"W_-+.V%(91`)`+5)@$0U1F"3'
M&75``EE";F@`:H_N@$=,!KSDGQQLQ>^4*]*O))FGN/*$LF.L7&9HVVJ;/4$?
M15)9IQF$>=,$><M#U,7H9/T^R[28TFR0"`0"`BZ%MN_+NT\&:O7";V7@K[VU
M2>'"G,X2W=?FX0$H@.O:W;G=C/R?L5<9Q)3/'J3V<-$V31TH%12,(1J[[M!6
ME*$=B.B,XD<1`<-SZ^?<:/J]K7F/V(:@YB;\E;*YBWRX6\HH#C)7D:3!L(FN
M]N`4VDB^Y+9M=LFS98)$<5L>NIS&3)G#5T`/,T1\SL(0A'1U)W'-'EU-I6AS
MAU+DJMP16+<&V>T&?;IP700G0:=B4K3.)B(3[?;*(.0XE$24@H=-V2L$TJ)H
M3!-K$M([D8F=6.S&<C,B3(M)8NY;,TLMJY;",W82%(^D$K9*S!9K0:$S\NJ<
M/MTL><Z@X$%$*K:(F(8S;&=/GIYA]KB$P!(5KE.J2&DNF8Q:$C*O(#2GN;2*
MF;K-LHV3K$!ADGSL?7=.F\']T[664U.!!*2G@F/'0$#>KAB$J6L_SJ**U%';
MV7%S.=67WR^&';\D1=I03#K5;3(Z:;NF;,RE$`Z#=2V\NJ@(90P8T'C_`$0[
M,7Z*`E:IGC,)AITEC]M`1C#5OBT[.+]!8=.EI%W@5$4-_NT4A`69)6>ZCPEB
MR69304,1.@)K9,-(;QOG_BQE$_/8[/\`L-=Z`L]`("FB%MW':NE_5FR=R6PN
M&[PEJ[7F0Q\W5U\("Y<`@$`@$`@$`@$`@$`@$`@$`@-'YF/F\7R_-+<#XL*4
M!_.-+W0?*+3X*(63O(<*DS)O>C@VS?F)L=L#0/\`9_$!BUVX_D6Q9.3UZ5:]
M_<"V9Q[>[*_^\->3P9/OY/PS-L5BRYMD[LK_`.\->3P9/OY/PS-L4RYMD[LK
M_P"\->3P9/OY/PS-L4RYMD[LK_[PUY/!D^_D_#,VQ3+FV3NRO_O#7D\&3[^3
M\,S;%,N;9.[*_P#O#7D\&3[^3\,S;%,N;9.[*_\`O#7D\&3[^3\,S;%,N;9.
M[*_^\->3P9/OY/PS-L4RYMD[LK_[PUY/!D^_D_#,VQ3+FV3NRO\`[PUY/!D^
M_D_#,VQ3+FV4$N4]+@/=I+"#W%+QDZITMC1J]S)^:=./8\(;@1AG?Y`L2<DF
M?<7'MJ3GGV!Y-[ZIK(R?Y76M627!04DBPUH""O1/HB@3JEE0M;=K[4G&"QHM
M(8+G2P"(STYY)9Y9I)I1`!`8KW*S6XV]S#<;6UHV]C1'WQC#FU:/B_=YF7W\
M-[XD-G3L[?L]T(<T?C^JQW&>2](BG*.KI$?<VN&-/#`9M%#2`B.`AN"`Z>=&
MSXNZ[T&OY?>]1QG4S2`IJD&B62:4$^N.D/Y*EAL^J,F.X`AJR;LLLHZ8>+NN
M]`\OO>H'-`DZ1$@I"`B-36%.,S#JS!J!5$9J(S#/.(ZHS"(U)I=$TTTO0P\7
M==Z!Y?>]1QGDT!Z)-4)<`PF'@VN(2U``)AD_D,=$FG&(\7=]Z!Y?>]3%*^8I
M'64LRF&"IZ60Q0GI;[L%<=[DK>@JZN\RXZTP[F(0\7=]Z!Y?>]3;7)7)BDEV
M=O324TDRD3&<S3[4"LIBAO54\0,,VVTQ=1D">GZM*8JTIZ8#CIWK$``=S@3\
M=G:F([6S[81A!VI6$=G<PV8]$7:%&DV2`0"`0$1;%&G1G<FHB54<*SI4JM3?
M1WWA682I()EH!Q'"50PT!I]#`2Z`H9:4WF7M&QR5O.+BF.B@W5IZ"0<1*];2
M22RJF*KQ7UH@<$D>09#R>(DE:7H1#$,/-@)VH/\`S"*M*A15<HB<IT:1@FH4
MJ!Z]K$,%BQDJ8V@H;E`V@",AXE.&(#+@(#N#I@,.77[T$Z)LH2R7-4H5.(99
MNG"A:[=MRQ,V@EP-@4239&5`"GP'+,I&=4L("`:TP883#`<OKRON-<I7FR;H
MPU2J;612M0;QVZ'8T,R)03244U4#H2%390Q+8``ZO.W`KP^+0*UR4YO-)9R$
M(:,T;>N('$B-5"N_:QKM!45CDQ$X<.3DD5!EUY1$H`&``)1'#=$=,!NE8J70
M7I$JFO9%F(KR(2[7<Z)15[G6J594I>,&1,FU]'E/-Z8$Y>GGFUA-2#+/CS<(
M#'4$U\%JA8R6R!6X+UDYP&7:GUBUP[1@9*.DT`@:<I$>M,-[<`C,/30"$XZ.
MBT!@&?.4;]W.NO8M6<UE2%N&O;=[+[N6UHQ=5N.DT:HG+;O%GDR9-'1DZ6>8
M9CSG#6$9L``,<0TC`75@$!2M!IR\=RZE7@*O*/<GL#[JZ/50ULROJ_GEY>D^
M?C4W<=,!=2`0"`0"`0"`0"`0"`0"`0"`0&ELQ_S?[U?FN?'Q<4("6L9-3^LM
MG^YI4/[*-\/:Q3<X)(^9NZ("5\&)?O:0ZD*^D@'!B7[VD.I"OI(!P8E^]I#J
M0KZ2`<&)?O:0ZD*^D@,4JIB5P8I;X2*T:?!YH*M:B4*[05DV4=80'#3,$H8A
M]C3`<-JIR-4;#<G+4@42PHJ8%`Z>+R;6:+[))O9@T$\H#KU)1Q$!`<,8"0\&
M)?O:0ZD*^D@'!B7[VD.I"OI(!P8E^]I#J0KZ2`<&)?O:0ZD*^D@'!B7[VD.I
M"OI("&L1-0JK61YR`3*902QD*)U7*R\)&`VRH(SFP$!QGQ#2'G0$RX,2_>TA
MU(5])`.#$OWM(=2%?20#@Q+][2'4A7TD`X,2_>TAU(5])`.#$OWM(=2%?20$
M79/!_`U;@TXH'"H+:]-OJB.\&`,\,']K+!*,LF!0E4$0EW<<,=W1`3F`0"`0
M"`AC4J%*M9T@5/GU'>W4IT#8*'1;(:E+$-\)$\)<.#Z<HAJ^:,!,X!`(!`("
M%(4Y6HX'G2HJ*@;K45)-`P2,B.R)DTR,2U94P-0,):DFF;]]]<)K`(!`(!`4
MI0:I3COW4I[6?VWN2V!$26C8];5S*B$_\+>\1_A0%UH!`(!`(!`(!`(!`(!`
M(!`(!`1ITMM(>3;7&JO4!.(;D1E-!5RVT3EYC28J%9B9V26N7'7IS3T9Q#$,
M,,?J0%=2N4QOD"]$H6O7F@I%BI8J6+T0S!/T`+ERH!++I%0Z+&4,!$<=R`Y'
M%51N_CFC_2"?OPA`=&R!RAUGC^9M]Y>5Q>S&I="WM_LQMCW`I-C/&Y7[=I!)
MY<6@HO%RW>?=B"2$376?9]>()`[(J"J3``CCIYH6`3,ZN0Y0&S4QW,QGD;TE
M[RR`X&:;=[IONV"Q1F/)U)[&M\^W=,LD2?6DPKDNE5E3D)3-8`>GYH;L!V3M
M_+\PG81JJ36S&YB7$F4JYM.JJ"!F7>"X4!1+#JG"FU%%(U*)XAAZ''6#$,0@
M)%Q54;OXYH_T@G[\(0#BJHW?QS1_I!/WX0@'%51N_CFC_2"?OPA`.*JC=_'-
M'^D$_?A"`<55&[^.:/\`2"?OPA`.*JC=_'-'^D$_?A"`<55&[^.:/]()^_"$
M`XJJ-W\<T?Z03]^$(#JKY03,I;_(._+6LEPOF]*MW2[<WDN*3<-R,_#CL@WR
MH6F!NG3311#BNAN47>_79(Y994Q,#5Q&0>9A`8BS><W+Q=&[:-:%VNG/_:9=
M=89>DYIJKHNG=0RE"Z<Q5GIKP,UB/M71R0HEM7<!0H:3`*&C?3ITD.G&`SRG
MG;R)(I5]U5C,9GG2UUB/MCVV4V8K.R]:6^U-?N:3<)QAF&XVEC89U)-7B324
MQE-8`'2,V.`X8AM@Y?C)VG7RMQEZ/9G<X)"Y%SDNWM=&I&+G7@+H*,KW=25!
M9M@T7@LG-0DU7X^B*.9F2TLR,LT^`X@`X0%]>*JC=_'-'^D$_?A"`<55&[^.
M:/\`2"?OPA`=,%ZL[UM[)YT'ME"4U?,8NJC)?^62WH<'YY7&5O(]C.9)*(+!
M)QVLR^`A"MOQ`8('<%TSPGH''SH#8%C<Y>62[[?=)I7N!GX8SQ:#<NL[C#(&
MX-['*#K:EIKPG;*.=:M8M)!$J1N8">Z`3MIE3)1V,3\H8@`#-`39KYL,C[W/
MV'1FEF9SIKR]F"F<`L]`3W_=\RNI@M5_#:]QSOI'"83S>X!?H@G&M`B`AS2N
MF`VGE[NIE*S/7/N#:&S^:7-DOO"WI9?/G)#UX;II:(ZT%KN]0MLY'&PUD[5E
M3G:WD!\)!A,-&BN(`=#F[H!=;BJHW?QS1_I!/WX0@'%51N_CFC_2"?OPA`='
M=;/[;,KFPN!E:J*.8Q26F)F0=V6\2;>SW+"[>0X9;EKPNO/=16L0"$37$"S\
MV`I@KW"@['-@/F0&Z[#YS,KE[+*J=V9;C<H`U5IMVNM+=ITVL![7M6W2#9O*
MH*:2U%ABXD"O7ZT!<Z0I)H*A4-A&8B(CAH@)W;K-5D>NV]+5LJWV:3."Z%2Z
M]MTVZ*,:3[EW?!#0&JK'7>3)&WR>FFP:,VV,]4`0-8`4$EI&4(#:>5"XV5?.
M@+O"PF9K-ROU6710E!2IK]V+JM8PKM-Y<(S,U]-N5:$I,X&([*:.:%,5"N(3
M:@CT.(``7+XJJ-W\<T?Z03]^$(!Q54;OXYH_T@G[\(0#BJHW?QS1_I!/WX0@
M.M9F9JLGSU?IZWR=>[/<G&9;A7WMBE.58>UU"C/<+^RT`[C-WF^W5@%`WOPH
M`,U2]M%Y1.!+@&.B`L87-9>:V5DCG0FS'9L:-BU.SI6^))?,7JN4653C#5&J
M#D3-1O;?*?X>.$3LH%D_`#>VS!)Z+1`36PK'M%F6L[;V^=J\P6;%78-SFR6=
M+;-G[W7'1%,*!V42APDKHAY0IJ",O(APG.7-%C`!L9V28-T!@-T<55&[^.:/
M]()^_"$!PR^4AE%JZNH4+DW]!Q+=9N3*;N[MSR%X3I[7H.DFAMT%G;1J`WJ5
M=X*!D2N`2B;GUL1PP`+9P"`0"`0"`0"`0"`0"`0"`0"`0"`T:X<QU@V?<E"L
MRZ;RVR;MV'-(4ZWK;JSU;Q!ZK&WS""8!!L&CX*=3A`91V8`D'?-&`#CA`5<L
MSE\RCTVYF?ME:RX*0[SV:A[YCKHW/5D-QM%;>28:O4YE1H7(*-Q72",TY%OM
M9T%3">5D,`=$B=E&6:80Z&`UD\.31RH..[.6@VHO!Q$7_8VQMO[2H#3,&&(I
MF[I6=L>KH2NVNN\BXVDL'ZLJ&OC)M2FB"G#T_,7U@`990#L(M19>T=BFT;9M
ME[;,BU;3.+BNYS;:8+;2&JA&'(NS@:6E@4A')E"7"*G4EQKS``8X!`25GO=H
M/]*,+K(<S==J,57'$VSBDV5<FMII=P-5:.MQQH]0V1J3R<((2VGF"QDN(:TA
MF40'#=@)K`(#I&Y7:W]ZWLNY<:UI6?<ETE$BV/**D')UA%'"8+E%5U9'[HMJ
MVQ)9!%``!07WR>*E4K'HQ.B&S]%C`=';VL#GR9K+==H;LVRS(W>MC:')IR?3
M>8;Y2V_<IXO2YUNZV>2Q]T[D6W=J*W2`G5V[MIV+(NHBZ4#IT\AD=;#3`?0G
MR9K;<Z<X\X+H;MO+JV@RL/:\+*4,L%LKN(+G9:VCI27:UN(]U'(W;;.Z:1TL
M9HNZY4I@T3+&J936`)C`2@$PA`=M4`@*T/G*[;&Y5_+49BW:3,K#QL\R;A,=
MJ(ZC*EJ+7!.N8<:)Y</'DHZGFYJBZ4F9Q0"QF6N&KIW0&`T^^<@%FGY<AW70
M65U_$EUZWSLM?U8H)2^3*I]!ZV'8:A;AFE$\94.4\20>`5*>8U(%<1F-B$P3
M2X"`A1*U?(^Y)W+;>Z:#;&_%P;I-9[F6-;A[*Q=P62N>EB:R_J+M($FRX]LM
M@LHKJ<:%(\3993-*LIU8V[IH9Y36F`LDPN27RRVOO!:.[C15+BEU:T;*M,T*
M"2OJK8>-![RV11E!NVX<3N<+I:2L^)G&AIZK.!B=-4R,AR:0OK!T(@(=J4`@
M*Q,+*O:U@9@K^9E$TH94KDYA*]LC#LKKDJ2;*H,]J&(+!;@M"8$WA9$`Z@S#
MM8;1-ODPXX!A@(4(NWR6^3UO6M09[B7DN/;!FVOM_=E@E7RL7"9[8)I:3>[,
M.T\QBP:<!Y8;\J(H5);D-@J6+E30"0.$1`H:*F\0&`QC=Y(#*"^K;V.3V]=*
MXSVMO;FX#IN\Q5A&<-K%,LK*SRN34NHHGF\\&[;^4ZTP!T2@6`RUS2(.P@);
M<W`M-E3Y.VQV3ZX=Q'_:PZY1F?E=T"1;B[39U=)995YOQ1N,Y23;4TQHI;M-
MTU%UJPS""FJ'Y@`,,1&`[`8!`5*MGD^M%:H_F456[15#BSFCNB]KL7#6E@$,
MRNIZ\_6<VF*M);95RJ"4/$6W316D4V4L9F.:DP#B(A`4.O)R;62NVMO&T:N?
M?MZV@:[6M-E<R[(3N>%Q6&@I9I`RNOMY/RVY);+.]OBTW6HKB@\%(%0H8*S$
MCQ/1LN`",!D63R-&4I*+Y9C*<Z[INUL9;TTM/;.B>7F,=!7(UG([G@6&J\45
MG%'9(@KTS]-`J$TQ2))*V4V8#-.8)!$0M-DLR`6;R+(KD0K1J;H54M=+-Y(2
MZ#L+-`3+49S0D/RMIH)1QLM)M'5!/3=NF]74A/'9Q`.CETP%[X!`(#YS;<\B
M?<9GWU4KEU+JV%1$ON^YN;XT'TP+-.Y"S%O5,S/S7,FEM!<JY!VX)QKKELD&
M:X&)DI00P$[P>5'1AC`;31>38SE.S*#9K(?>[,]9XI8:U=/+VV%%QV"MD_&#
M>)UV[L2!`\"$+E=]P'FUD]37EIL(8S&I4N80`#6(>A`0O=D9RAN')<TKLVLD
MNPX[M6U<=ZG;=>UL[[E$T_&4F7'D).%[MIQN0I*7(.;?+D5%-3+3ERA(`E/"
M`ACN!?&`0"`0"`0"`0"`0"`0"`0"`0"`0"`0'0&FD+GVBSE9I&^TF-E"O@U;
MXYS;#70=-W;FWKMQ07\ODYQ@VS;)FUCPM<=/&;C2W:3R+6J*MN2Q:0`FX:UL
M0EE$!"@Z?E,OBM$+@I;<NK;`DTUF5LTU>NR<UC&21*I%/EEG==6Y\X++==Q+
M@*2>SDYI,,CN"MXH'ML!P"9/C*-F?JLA6;]E;MM0K;XBW,[IBU]$KFO29C;D
MRY+N;:S;Y2&*BOLT[SJVA-U<M"WUI`%?VG!K3J,LIHV5F$`$/=F2LCF4?MM\
MG278-GLNRC9H+2RZ;-)_'N2GR\&J\Z.81FN&@T$1]N:YY1#=R:MVL+&,00A=
M>P')Y4L>E)I1$.YKDP64HL'+J_D156&4NUCV;C.RZZ9RWSV;K\0"Y9XYJ[L.
M0LCFUIHGE-,(NI$%0F*J:6%03J0>I5"AH`-4JD!V10"`0"`0"`0"`C+IIH%9
MLN"BZ@3NMBHB*5)Q\+F-F3`0)B=0%B8Z;G&66FG@1UM\F$90"7$1$(#K9Y*9
MC-)@V4OJ0MXMV=7;=+>=G-D[+?5+'O=C/MAD6BXKF*!I`1IE-A'E5$1%Y-)S
M:AU+&;;4^<-0T`3XA`=ID`@$`@*"\I$O7P;F5AX5LM]O+8W(O<J.!F(5ND^[
MSKMVU6HW5]9<J42+/PJ<NF<)M-0=K1GZ904R:;6.+8%0`,!F@/9R:B"T&GDH
ML.V6$C%D1MMUMKB=,4+758M[A-."@\G$#P4S]S[5G5:WCM7UAY\(FE*9,JZI
M-0GJ%AE#4P@+[0"`0"`ZVN5!)K"WE5>+3(L5J/@D\4]Q-=>X:O:SLOCG:C?5
M6,XI#3N85QGW+*UB*XB32ZRCK&B8BB3&\!$("Q^4!(<2!E3RU(#N5F$O.=%L
M+:9,7UZU)@L:MBKJ":PV^5KJ+`-%0`H<9*B$@3I,X!JSD!DFE$0$!@++0"`0
*"`0"`0"`0'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
